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Abstract 
Paracetamol is a popular antipyretic and analgesic medication. It is a known hepatotoxin in 
overdose and is the commonest cause of acute liver failure in the UK. There is significant 
variability in inter-individual susceptibility to the hepatotoxic effects of paracetamol, which is 
incompletely understood. This thesis describes work done in murine models of paracetamol-
induced acute liver failure with the aim of identifying causes of variable susceptibility and 
understanding the immune response to liver injury. 
A quantitative trait locus (QTL) mapping approach was taken using a murine strain 
susceptible to paracetamol hepatotoxicity (C3H/HeH) crossed with a relatively resistant strain 
(C57BL/6). Novel QTLs on murine chromosome 17 and 18 were identified that associated 
with response to paracetamol. Within the loci a number of candidate genes were identified. 
A survey of 10 inbred mouse strains for their response to paracetamol was conducted and 
highlighted the large variability within each strain. It was hypothesised that this variability 
might be due to differences in intestinal microbiota. A study of the role of intestinal microbiota 
in paracetamol-induced liver failure was conducted, by comparing response in germ free 
(GF) mice and conventional (CV) controls. This demonstrated that the presence of intestinal 
microbiota influenced the sulphonation:glucuronidation ratio during paracetamol metabolism. 
Although the extent of liver injury as assessed by necrosis and liver enzyme elevation was 
the same in GF and CV mice, there was evidence of a protective effect of a sterile intestine.  
Finally a reverse genetics approach was taken to study the influence of the gene Slpi in the 
secondary immune response to liver injury. It was shown that absence of SLPI protected 
mice against peak liver injury. 
The work presented in this thesis highlights some potential sources of variability in response 
to paracetamol and a number of targets that with further research could have therapeutic 
potential. 
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1 INTRODUCTION 
Acute liver failure is a rare yet devastating syndrome for which few specific therapies exist. In 
the UK, paracetamol overdose is the most common cause of acute liver failure and is a 
frequent reason for admission to hospital for unscheduled care (Bernal et al., 2010, Bateman 
et al., 2014). Having previously been thought of as a classic dose-dependent toxin, it is 
increasingly recognised that there exists significant inter-individual variation in susceptibility 
to paracetamol-induced hepatotoxicity (Watkins, 2006, Harrill et al., 2009b, Gregory et al., 
2010).  Known susceptibility factors, such as chronic alcoholism and exposure to enzyme 
inducing drugs affecting the initial metabolism of paracetamol, do not account for all the 
variation observed in clinical practice. Murine models provide a useful experimental system 
in which the development of acute liver failure, from metabolic activation of paracetamol, 
through cell death to the secondary immune response to hepatic injury, can be studied.  
This thesis describes work undertaken using murine models, with the aim of identifying novel 
susceptibility factors to the development and progression of paracetamol induced acute liver 
failure. The following introduction contextualises this work and provides a review of current 
knowledge in this field. 
 
1.1 Paracetamol: from discovery to the nation’s favorite painkiller 
Paracetamol (para-acetylaminophenol) is a widely used analgesic and anti-pyretic drug. 
Despite being first synthesised in 1878 and recognised to hold analgesic properties shortly 
after, paracetamol was not marketed until the 1950s (Bertolini et al., 2006). It quickly became 
popular and has continued to be used extensively in community and hospital settings. 
Paracetamol is available over-the-counter in the UK and is a common constituent of 
compound analgesics and popular branded multi-symptom cold and ‘flu’ remedies. The exact 
mechanism by which paracetamol exerts its analgesic effect remains incompletely 
understood, though numerous convincing targets in peripheral and central nociception 
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pathways have been described. Paracetamol displays a selective cyclooxygenase 2 (COX2) 
inhibitory effect, comparable to the non-steroidal anti-inflammatory (NSAID) class of drugs, 
however is a much weaker inhibitor of COX1 (Hinz et al., 2008). Through inhibition of COX2, 
paracetamol may reduce thromboxane and prostacyclin production, hence impacting on 
peripheral pathways that mediate pain and fever in inflammation. Within the brain and spinal 
cord paracetamol can be metabolised by sequential deacetylation and conjugation with 
arachidonic acid to form N-arachidonoylphenolamine (AM404), a potent antagonist of the 
TRPV1 nociceptor (Hogestatt et al., 2005). The same metabolite also has effects on the 
endocannabinoid system, which may modulate central pain perception. Blockade of 
cannabinoid receptors has been shown to antagonise the analgesic effects of paracetamol 
(Ottani et al., 2006). More recently a paracetamol metabolite has been shown to inhibit the 
central pain receptor TRPA1, with antagonism or genetic knockout of this receptor leading to 
a reduction in the analgesic effects of paracetamol (Andersson et al., 2011).  
In the 1960s the first case reports of hepatic failure as a result of paracetamol overdose were 
published (Davidson and Eastham, 1966, Thomson and Prescott, 1966). These early reports 
describe a clinical presentation with rapidly progressive acute liver failure and a characteristic 
histological lesion of centrilobular hepatic necrosis. This clinicopathological pattern is now 
well recognised and paracetamol toxicity has gone on to become the commonest cause of 
acute liver failure in the UK and USA (Bernal et al., 2009, Larson et al., 2005).  
 
1.2 The clinical syndrome of paracetamol-induced acute liver failure 
1.2.1 Definition 
Acute liver failure is a complex clinical syndrome that develops when a sudden and critical 
loss of hepatocellular function occurs in the context of a previously healthy liver. The 
syndrome is characterised by coagulopathy, jaundice and encephalopathy and commonly 
progresses to multi-organ failure and death. The clinical manifestations of acute liver failure 
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arise due to both the failure of homeostatic functions that accompanies the loss of viable 
hepatocytes and an overwhelming immune response to large-scale liver cell death.  
Over 40 different definitions of acute liver failure have been used in published literature on 
the subject (Wlodzimirow et al., 2012). The current American Association for the Study of the 
Liver (AASLD) guideline on acute liver failure references the following definition: 
‘evidence of a coagulation abnormality (INR >1.5) and mental alteration 
(encephalopathy) in a patient without pre-existing cirrhosis and with an illness of <26 
weeks duration’ 
A number of sub-classification systems exist, largely to differentiate the rapidly progressive 
forms of acute liver failure, termed ‘fulminant’ or ‘hyper-acute’, that are associated with 
paracetamol toxicity and hepatitis A and E, from the more indolent ‘sub-acute’ presentations 
seen in auto-immune disease and non-paracetamol drug-induced liver injury (DILI) (Bernuau 
et al., 1986, O'Grady et al., 1993, Tandon et al., 1999). These distinctions have significance 
in that the presentation and complications may vary, with paracetamol toxicity associated 
with minimal jaundice at presentation and a high risk of cerebral oedema and intracranial 
hypertension, though paradoxically a better outcome with medical therapy alone than the 
sub-acute forms. 
 
1.2.2 Epidemiology 
Paracetamol overdose is a frequent cause of presentation and admission to hospital, with 
estimates that between 82,000-90,000 patients attend with paracetamol overdose every year 
in the UK (Bateman et al., 2014). Despite this staggering number, mortality from 
paracetamol-induced acute liver failure is relatively rare, at between 199-553 deaths per 
annum in the UK in the period 2001-2011 (Handley and Flanagan, 2014). The reason for this 
differential is three fold. Firstly and most simply, many individuals take an overdose that 
causes very minimal liver toxicity. Secondly, if patients present to hospital promptly after an 
 25 
overdose, treatment with N-acetyl cysteine is effective at minimising liver cell death and can 
prevent progression to acute liver failure. Indeed, most cases that progress to acute liver 
failure are those who have a delayed presentation due to concealment, an unintentional or 
staggered overdose. The high numbers presenting with paracetamol overdose and low 
threshold for admission for N-acetyl cysteine treatment, means that the cost per life saved by 
this therapy is over £17 million (Bateman et al., 2014). Therefore, there is a need for early 
biomarkers and accurate risk stratification tools to identify those at risk of progression and 
tailor treatment accordingly.  
Finally, the mortality rate from acute liver failure has improved markedly in recent decades 
thanks to the use of emergent orthotopic liver transplantation (OLT) and improved supportive 
critical care. A recent retrospective review of cases from the UK showed an improvement in 
hospital survival in ALF patients from just 17% in the mid-1970s to 62% in the mid-2000s 
(Bernal et al., 2013).  
A further influence on the numbers presenting with paracetamol overdose, is the decision in 
1999 by the UK Medicines Control Agency (since renamed the Medicine and Healthcare 
products Regulatory Agency, MHRA) to limit the availability of paracetamol by restricting the 
size of packets that could be purchased over the counter. The subsequent decline in deaths 
from paracetamol overdose has been taken by some to be proof of success of this policy, 
however it is difficult to disentangle other effects, such as the influence of improved care as 
described above. 
 
1.2.3 Clinical progression 
The clinical syndrome of paracetamol-induced acute liver failure is initiated by direct toxicity 
to the liver, but quickly evolves into a multi-system disorder with significant extra-hepatic 
manifestations (as summarised in Figure 1.1). Some of these features are due to ‘loss of 
function’ abnormalities caused by a failure of normal liver synthetic, metabolic and 
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homeostatic functions. For example, the production of both pro and anti-coagulant factors by 
the liver is impaired leading to a balanced defect in blood clotting, that is detected in 
laboratory tests as prolongation of the prothrombin time (PT) or international normalised ratio 
(INR). Defects in hepatic glucose handling and gluconeogenesis may lead to hypoglycaemia 
and lactic acidaemia and impairments in important metabolic pathways such as the urea 
cycle and bilirubin conjugation lead to elevations in circulating ammonia and bilirubin 
respectively.  
Other extra-hepatic complications of acute liver failure are driven by the secondary immune 
response to liver injury. The overwhelming production of both pro-inflammatory and anti-
inflammatory cytokines that accompanies massive hepatocyte necrosis, cause circulatory 
dysfunction, secondary organ damage and immune defects in a syndrome comparable to 
septic shock. Cardiovascular instability and decreased systemic vascular resistance cause a 
relative hypovolaemia and hypotension, which contribute to acute renal impairment. Ascites 
may develop to further compromise renal perfusion pressures and affect ventilation by 
diaphragmatic splinting and through associated pleural effusions. 
 
Hepatic encephalopathy (HE) is one of the defining features of acute liver failure and is 
particularly prominent in paracetamol-induced acute liver failure. It may be rapidly 
progressive, leading to cerebral oedema, intracranial hypertension and death from cerebral 
herniation. Indeed, cerebral herniation accounts for approximately a quarter of deaths from 
acute liver failure (Bernal et al., 2010). The development of hepatic encephalopathy and 
cerebral oedema in acute liver failure is complex and incompletely understood. Failure of 
hepatic metabolism leads to hyperammonaemia and the induction of an alternative 
detoxification pathway in muscles and brain astrocytes in which ammonia is converted to 
glutamine. Accumulation of glutamine inside astrocytes provokes osmotic swelling and 
alterations in mitochondrial function that affect cellular oxidative metabolism and cause 
increases in brain lactate (Norenberg et al., 2007). Oxidative stress leads to an increase in 
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cerebral perfusion. The systemic inflammatory response syndrome (SIRS) correlates with the 
development of encephalopathy and is thought to contribute to its pathophysiology through 
cytokine-mediated cerebral endothelial inflammatory responses and vasodilatation (Jalan et 
al., 2004, Wright and Jalan, 2007) 
 
 
Figure 1.1 Summary of the multiorgan pathophysiology of paracetamol induced acute 
liver failure. 
Paracetamol has a direct toxic effect on the liver and may cause direct renal toxicity. 
Multiorgan involvement frequently develops due to a failure of hepatic synthetic and 
metabolic functions and the effects of massive immune activation. This figure summarises 
the major extra-hepatic manifestations of paracetamol-induced acute liver failure. 
 
Infections are common in acute liver failure and are a significant cause of mortality (Rolando 
et al., 2000). Case series have shown that rates of bacterial infection in acute liver failure 
patients are as high as 80%, with the most frequent sites of infection being the respiratory 
and urinary tracts (Rolando et al., 1996, Rolando et al., 1990). Bacteraemia is also common, 
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being documented in 20-35% of cases and correlating with worsening HE and poor clinical 
indices (Karvellas et al., 2009).  
It has been demonstrated that patients with acute liver failure have immune defects in 
monocyte and neutrophil function that may contribute to their susceptibility to infection and 
poor outcome from sepsis (Antoniades et al., 2006) (Taylor et al., 2013). These defects have 
been attributed to the immunosuppressive effects of anti-inflammatory cytokines and 
mediators produced during the immune response to liver injury (Antoniades et al., 2008). 
 
1.2.4 Treatment 
Specific treatment options for paracetamol-induced acute liver failure are limited. As 
described above, the administration of N-acetyl cysteine is effective in limiting hepatocellular 
damage if given early enough. The management of established acute liver failure relies on 
quality supportive care with a view to preventing complications or identifying and treating 
early those that cannot be prevented. For example the use of prophylactic antibiotics, fluid 
management and inotropic support to maintain renal and cerebral perfusion and the 
treatment of raised intracranial pressure. Timely identification of patients in whom liver 
transplant is both required and suitable is another key management goal.  In the UK patients 
with acute liver failure are listed for transplantation according to the King’s College Criteria 
(Neuberger et al., 2008). For paracetamol-induced liver failure the criteria use features 
associated with poor prognosis: low arterial pH post-fluid resuscitation, encephalopathy of 
grade 3 or above, Creatinine >300mmol and coagulopathy with an INR >6.5 (O'Grady et al., 
1989, Bernal et al., 2010). 
As described above the immune system is responsible for driving much of the 
pathophysiology of the clinical syndrome of acute liver failure. There is a great therapeutic 
need for agents that target aspects of immune function to limit the extra-hepatic 
 29 
manifestations of acute liver failure and promote intra-hepatic regeneration and repair 
(Possamai et al., 2014b). 
 
1.3 Hepatic metabolism of paracetamol 
When taken orally, paracetamol is held by the stomach and upon gastric emptying is rapidly 
absorbed from the proximal small intestine with a transfer half-time from lumen to systemic 
circulation of less than 7 minutes (Clements et al., 1978). These absorption properties mean 
paracetamol was formerly used in a test of gastric emptying time. Once in the portal 
circulation paracetamol undergoes first pass metabolism in the liver. 
At therapeutic doses, the majority of paracetamol is metabolised in hepatocytes by direct 
conjugation by uridine 5’-diphospho-glucuronosyltransferase (50-70%) and 
sulphotransferase (25-35%) (McGill and Jaeschke, 2013b). The remaining paracetamol is 
oxidised by members of the cytochrome P450 family of enzymes, to a reactive intermediate, 
N-acetyl-p-benzoquinone imine NAPQI (5-15%) (Hinson et al., 2004).  In standard doses, 
NAPQI is inactivated through conjugation with glutathione by glutathione S-transferase. 
However in overdose, hepatocellular glutathione is rapidly depleted allowing NAPQI, a potent 
electrophile and oxidising agent, to bind to sulphydryl groups in cysteine residues on cellular 
proteins (Hoffmann et al., 1985, Jollow et al., 1973, Mitchell et al., 1973), see Figure 1.2 
The zonal distribution of hepatocellular damage observed in paracetamol toxicity, with 
centrilobular cells most severely affected, is explained by the preferential localisation of the 
cytochrome P450 (CYP) enzymes, (in particular CYP2E1) that generate NAPQI, to zone 3 
hepatocytes (Hart et al., 1995). 
Following conjugation with sulphate or glucuronide, paracetamol metabolites either efflux 
from the basolateral hepatocyte membrane and are subsequently renally excreted, or are 
actively transported from the hepatocyte into bile.  Once in the gut, intestinal microflora can 
hydrolyse these conjugates to release paracetamol, which re-enters the circulation (Watari et 
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al., 1983). Paracetamol-glutathione conjugates are actively excreted in bile and also enter 
the enterohepatic circulation. Hydrolysis of the glutathione adduct yields cysteine and 
mercapturate conjugates, which are excreted in urine (Siegers et al., 1983).  
 
 
Figure 1.2 Summary of paracetamol metabolism showing the main urinary metabolites 
detectable by 1H-NMR. 
Within the hepatocyte at therapeutic doses, paracetamol (A) is predominantly metabolised by 
conjugation to form paracetamol-sulphate (S) or paracetamol-glucuronide (G). A small 
portion of the drug is oxidised by the CYP450 system to form the toxic metabolite NAPQI. In 
overdose saturation of the sulpho- and glucuronyltransferase enzymes leads to excess drug 
being converted to NAPQI. NAPQI may be rendered harmless by conjugation with cellular 
glutathione, and excreted from the hepatocyte. Hydrolysis in the intestine yields paracetamol- 
L-cysteinyl paracetamol (C), which can be further metabolised to mercapturate (N-acetyl-L-
cysteinyl) (M). In overdose glutathione may become depleted permitting NAPQI to bind to 
cytosolic and mitochondrial proteins. 
HNCOCH3 
OH 
HNCOCH3 
OSO3 
HNCOCH3 
O 
Glucuronide 
Sulphotransferase Glucuronyl transferase 
HNCOCH3 
O 
CYP450 
(2E1, 1A2, 3A4, 
2A6) 
NAPQI 
Glutathione S 
Dehydrogenase 
HNCOCH3 
OH 
Macromolecule 
Paracetamol (A) (G) (S) 
HEPATOCYTE 
HNCOCH3 
OH 
S 
Glutathione 
HNCOCH3 
OH 
S 
CH2-CH-NH-CO-CH3 
CO2H 
HNCOCH3 
OH 
S 
CH2-CH-NH2 
CO2H 
(M) 
(C) 
 31 
1.4 Hepatocyte injury and cell death in paracetamol toxicity 
1.4.1 Covalent bonding & protein adduct formation 
In 1973 Jollow and colleagues showed that NAPQI covalently bonds to cellular proteins and 
the degree of bonding directly correlates with the extent of hepatocellular necrosis (Jollow et 
al., 1973). This process of adduct formation was therefore thought to be central to the toxicity 
of paracetamol. Later work in murine models demonstrated that paracetamol-protein adducts 
were detectable in centrilobular hepatocytes within 15 minutes of dosing, and peaked after 
an hour (Roberts et al., 1991). The following reduction in hepatic adduct concentrations 
coincided with the appearance of cytosolic liver enzymes and hepatic-derived protein 
adducts in serum, suggesting loss of hepatocellular integrity (Pumford et al., 1990, Roberts 
et al., 1991). 
More recently however, studies using N-acetyl-cysteine ‘salvage’ to avert toxicity post-dosing 
have shown the persistence of protein adducts, despite the prevention of hepatocellular 
necrosis (James et al., 2003b). Protein adducts have also been observed without 
subsequent cellular injury in experiments using a regioisomer of paracetamol (Myers et al., 
1995). This suggests that while covalent bonding, with the formation of protein adducts is a 
detectable phenomenon in toxicity, this process is not essential to downstream cell death 
pathways. 
 
1.4.2 Oxidative stress and protein nitration 
Oxidative stress and reactive nitrogen species are now recognised to play an important role 
in paracetamol toxicity (Hinson et al., 2004, Jaeschke, 2003, Knight, 2002). A full discussion 
of this area is beyond the scope of this introduction. It is clear however, that within a cellular 
environment profoundly depleted of glutathione, a major antioxidant and substrate for 
peroxide detoxification, the generation of superoxide and peroxynitrite leads to significant 
protein nitration, oxidative damage and secondary mitochondrial dysfunction(Jaeschke, 
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2003). Peroxynitrite, a potent oxidant and nitrating species, has been shown to accumulate in 
the mitochondria of hepatocytes following paracetamol overdose. This causes nitration of 
essential mitochondrial proteins and selective oxidative stress which precipitate failure of the 
organelle via the mitochondrial permeability transition. 
 
1.4.3 The mitochondrial permeability transition 
It has long been recognised that structural and functional disturbance of mitochondria are 
early events in paracetamol toxicity (Meyers et al., 1988, Donnelly et al., 1994). There is now 
conclusive evidence that mitochondrial failure, via the process of mitochondrial permeability 
transition (MPT), is a central event in hepatocellular death from paracetamol toxicity.  
Mitochondrial permeability transition (MPT) involves a sudden increase in the permeability of 
the inner mitochondrial membrane to small ions and solutes with a molecular weight 
<1.5KDa, with associated dissipation of the mitochondrial membrane potential (Δψm) and 
uncoupling of oxidative phosphorylation. This leads to mitochondrial swelling and ultimately 
rupture of the outer mitochondrial membrane with complete failure of the organelle(Grimm 
and Brdiczka, 2007). The increase in permeability of the inner mitochondrial membrane is 
thought to be mediated by opening of a transmembrane channel known as the permeability 
transition pore (PTP).  
In experimental models of paracetamol toxicity, within 1 hour of drug administration, 
peroxynitrite concentrations within hepatocellular mitochondria are elevated (Cover, 2005). 
Loss of the mitochondrial membrane potential and inner mitochondrial membrane 
permeabilisation, are then observed(Kon et al., 2004, Reid, 2004). These changes which are 
hallmarks of MPT, are inhibited in paracetamol toxicity by cyclosporine A, a known 
permeability transition pore inhibitor, which also mitigates cell death and clinical toxicity 
measures in this condition (Masubuchi et al., 2005, Kon et al., 2004). Further evidence for 
the central role of MPT in paracetamol toxicity is provided by the observation that knockout of 
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cyclophilin D, an essential component of the transition pore, protects mice from paracetamol-
induced hepatic failure (Ramachandran et al., 2011). 
 
1.4.4 The role of apoptosis and necrosis 
Loss of mitochondrial integrity has two important consequences for cellular function. Firstly, 
mitochondrial membrane permeabilisation releases pro-apoptotic factors, such as apoptosis 
inducing factor (AIF), endonuclease G and cytochrome C, from the mitochondrial inter-
membrane space into the cell cytosol from where they can initiate caspase activation and the 
cascade towards programmed cell death(Bajt et al., 2006). Apoptotic cell death is 
characterised by cytoplasmic shrinkage, nuclear fragmentation and chromatin condensation 
with the containment of cell contents within plasma membrane blebs. These cellular particles 
are engulfed by phagocytes, upon which they exert an anti-inflammatory effect, encouraging 
the production of pre-resolution mediators.  
The second consequence of mitochondrial failure is cellular adenosine triphosphate (ATP) 
depletion. The balance of these two factors determines the outcome for the hepatocyte; with 
loss of mitochondrial integrity and profound ATP depletion preventing the energy-dependent 
execution of apoptosis and resulting in cell membrane degradation and necrotic cell death. It 
has been shown however, that if ATP concentrations can be preserved despite the 
occurrence of the MPT then apoptotic cell death will proceed (Kon et al., 2007b). In cultured 
hepatocytes paracetamol treatment provokes the MPT and death by necrosis. Administration 
of fructose, which provides a substrate for glycolysis and thus generates ATP, reduces the 
number of cells dying by necrosis, but increases apoptotic cell death (Kon et al., 2007a). 
Unlike apoptosis, necrosis is an unregulated process, with cell swelling, nuclear rupture and 
plasma membrane failure resulting in externalisation of cell contents and initiation of a pro-
inflammatory response (see section 1.5.1).  
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In paracetamol induced acute liver failure, there has been much debate on the primary mode 
of cell death and whether apoptosis or necrosis predominates (Gujral et al., 2002, Jaeschke 
et al., 2004). Early reports suggested that the occurrence of DNA laddering with positive 
staining for products of terminal deoxynucleotidal transferase-mediated dUTP nick end 
labelling (TUNEL) was proof of an apoptotic process (Ray et al., 1996, Lawson et al., 1999). 
However it has since been shown that this DNA cleavage is a result of endonuclease release 
from the mitochondrial membrane during MPT rather than caspase activation (Cover, 2005). 
Indeed, an absence of caspase activation in some studies and the failure of pan-caspase 
inhibition to protect against cell death in animal models suggests that caspase-mediated 
apoptosis does not have a significant role in hepatocyte death following paracetamol (Gujral 
et al., 2002, Williams et al., 2011). Interestingly, one study showed that caspase inhibition 
exacerbated liver damage (Antoine et al., 2009). In this case the interpretation was that 
inhibition of caspase-mediated apoptosis forced hepatocyte death via necrosis, which lead to 
greater immune activation and secondary injury. Morphological studies that examined 
hepatocyte structure after paracetamol injury showed some evidence of characteristic 
changes of apoptosis (cell shrinkage, chromatin condensation and margination and apoptotic 
bodies), but a far greater proportion of cells appeared to be necrotic (40-60% compared with 
less than 1% apoptotic) (Gujral et al., 2002). 
A recent study has suggested that the absence of apoptosis in animal models of paracetamol 
toxicity is due to the standard experimental practice of fasting mice overnight prior to the 
administration of paracetamol (Antoine et al., 2010). This practice uniformly depletes hepatic 
glutathione to standardise experimental conditions. However, it also limits cellular ATP 
reserves, which may compromise the ability of hepatocytes to complete apoptosis when 
challenged with paracetamol, tipping the balance in favour of a default to necrotic death 
through exhaustion of energy supplies. Antoine et al found evidence of procaspase 3 
processing and caspase-mediated cleavage of cytokeratin 18 in mice that had been fed prior 
to paracetamol dosing, but no evidence of these processes in fasted mice. It should be noted 
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that even in fed mice the majority of hepatocytes still underwent necrotic cell death. A later 
study replicated these results in some mouse strains, but not others, concluding the effect of 
feeding was strain dependent and overall of little significance (Williams et al., 2011).  
In summary, current experimental evidence suggests that the predominant mode of cell 
death in murine models of paracetamol hepatotoxicity is necrosis, due to sudden 
mitochondrial failure and energy depletion. Apoptosis may occur in some marginal 
hepatocytes and this process can be promoted by the maintenance of cellular ATP.  
Histological evidence of necrosis or apoptosis in the early stages of human paracetamol 
hepatotoxicity has not been demonstrated due to lack of tissue availability. However, in 
patients presenting with paracetamol induced acute liver failure, circulating biomarkers of 
apoptotic cell death have been detected. Caspase-3 mediated cleavage of cytokeratin 18 
(CK-18) exposes a neoepitope on the cytokeratin, which it is possible to detect and quantify 
by the M30 assay, providing a useful surrogate marker of epithelial cell death by apoptosis 
(Ku et al., 1997) (Leers et al., 1999). Full-length, uncleaved CK-18 when present in the 
circulation provides biomarker of necrotic cell death as measured by a M65 assay. A number 
of studies have demonstrated high concentrations of both cleaved and full-length CK-18 in 
the sera of patients with paracetamol induced acute liver failure (Antoine et al., 2012, 
Possamai et al., 2013, Craig et al., 2011). Caspase-cleaved cytokeratin fragments were 
present in high concentrations on the first day of hospital admission, in excess of matched 
critically ill controls suggesting a hepatocellular origin of the CK-18 (Possamai et al., 2013). 
Concentrations fell rapidly after the first day, though remained elevated above healthy 
controls to hospital day 10. Perhaps unsurprisingly, there was a correlation between high 
concentrations of both M30 and M65 reflecting a greater magnitude of both apoptotic and 
necrotic cell death, and poor outcome in the patient groups (Possamai et al., 2013, Antoine 
et al., 2012). By the time of transplantation, when explant tissue became available, there is 
no evidence of on-going apoptosis and the liver is characterised by regeneration with a 
paucity of pro-apoptotic mediators. 
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It is therefore apparent that there is a degree of hepatocyte death by both necrosis and 
apoptosis in patients with paracetamol-induced acute liver failure, though the balance of 
these processes remains controversial (McGill and Jaeschke, 2013a) 
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1.5 The immune response in paracetamol-induced acute liver failure 
1.5.1 Damage associated molecular pattern (DAMP) signalling 
A key consequence of hepatocyte death by necrosis, is the release of intracellular contents 
in the extracellular space, where certain molecules may function as ‘damage associated 
molecular patterns’ or DAMPs. These ‘self’ molecules are analogous to the microbial, 
pathogen associated molecular patterns (PAMPs) that are detected by the innate immune 
system and lead to the initiation of a pro-inflammatory response (Broggi and Granucci, 
2015). Indeed, the innate immune system uses many of the same pattern recognition 
receptors, including the Toll-like receptor (TLR) family, to detect the presence of molecules 
communicating the presence of uncontrolled cell death by necrosis as those that detect 
microbial products. 
The defining features of DAMPs are that they are ‘self’ molecules and they have the ability to 
trigger an inflammatory reaction when detected by cells of the innate immune system. A 
number of different molecules that have these features have been identified in paracetamol 
induced acute liver failure (see Table 1).  
High-mobility group box 1 (HMGB1) is a constitutively expressed nuclear protein that has a 
role in the regulation of transcription (Tsung et al., 2014). It is passively released from cells 
during necrosis and may act on receptors TLR2, TLR4, TLR9 and the receptor for advanced 
glycation end products (RAGE) to trigger the activation of NFκB dependent pro-inflammatory 
cytokines and to initiate inflammasome assembly (see Figure 1.3). Interestingly HMGB1 may 
be secreted from activated macrophages to amplify the immune response and thus it can act 
as both a DAMP and a cytokine. During the process of apoptosis, cellular HMGB1 is 
acetylated and in this form it is anti-inflammatory (Antoine et al., 2012). HMGB1 may 
therefore also assist the immune system is discriminating between programmed cell death 
and necrosis. 
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In animal models of paracetamol induced liver injury, HMGB1 is elevated in the serum and 
liver perfusate (Antoine et al., 2009, Martin-Murphy et al., 2010). Treatment of paracetamol-
dosed mice with HMGB1 neutralising antibodies limits the extent of liver injury, implicating 
DAMP signalling in the pathogenesis of hepatotoxicity (Antoine et al., 2010). HMGB1 has 
also been shown to be elevated in patients following a paracetamol overdose, with higher 
concentrations predictive of poor clinical outcome (Antoine et al., 2012). Uric acid may also 
function as a DAMP when present in the extracellular space in its crystal form (Shi Nature 
2003). A study using transgenic mice, with reduced basal uric acid concentrations due to 
expression of a transgenic urase construct, demonstrated attenuated inflammatory response 
to paracetamol hepatotoxicity (Kono et al., 2010).  
Cyclophilin A is a cytosolic protein that may act as a DAMP, signalling through CD147. A 
recent study has shown that mice deficient in cyclophilin A (CypA-/-) are resistant to 
paracetamol induced liver injury, and that blockade of CD147 in wild type mice can also 
confer protection from paracetamol hepatotoxicity (Dear et al., 2011). 
Mitochondrial and nuclear DNA, when aberrantly free in the extracellular space can activate 
TLR9 on immune cells and trigger a pro-inflammatory response. Nuclear DNA is released 
from necrotic hepatocytes following paracetamol induced cell death, and within 6 hours coats 
the liver sinusoids (Marques et al., 2014). Enzymatic degradation of free DNA by treatment 
with DNases is protective and similarly TLR antagonism or knockout (TLR9-/-) can also limit 
the extent of liver injury (Marques et al., 2014). A number of other experimental studies have 
also targeted DAMP signalling by antagonism of TLR receptors and shown that restricting 
signalling through TLR2, TLR3, TLR4 or TLR9 can reduce the severity of paracetamol-
induced liver injury (Cavassani et al., 2013, Moles et al., 2014, Wang et al., 2013, Cai et al., 
2014). Similarly, pharmacological antagonism of the RAGE receptor in mice results in milder 
paracetamol induced liver damage (Ekong et al., 2006). 
Elevations in the circulating level of the DAMPs, HMGB1, Hyaluronic acid, mitochondrial 
DNA and nuclear DNA fragments have been observed in patients following paracetamol 
 39 
toxicity, with concentrations of HMGB1 predictive of poor clinical outcome (Antoine et al., 
2012, McGill et al., 2012). Cyclophylin A is elevated in the urine of patients with paracetamol 
induced liver injury (Dear et al., 2011). 
In summary, a number of DAMPs are released in paracetamol induced liver injury and are 
responsible for the communication of hepatocellular damage to the innate immune system 
and the initiation of a pro-inflammatory response. Experimental manipulation of these 
molecular signals indicates non-redundant functions for a number of DAMPs and their 
corresponding receptors. This raises the possibility that targeting this early signalling event 
could have therapeutic potential in patients with paracetamol induced acute liver failure. 
 
DAMP Receptor References 
HMGB1 
 
TLR4 (and TLR2, TLR9, 
RAGE) 
Martin-Murphy et al 2009 
Antoine et al 2009, Antoine 
et al 2010 
Cyclophylin A CD147 Dear JW et al 2011 
HSP-70 TLR4, CD91, CD14 Martin-Murphy et al 2009 
Mitochondrial DNA TLR9, NLRP3 McGill et al 2012 
Marques et al 2012 
Nuclear DNA TLR9 Marques et al 2012 
Marques et al 2014 
Imaeda et al 2009 
Uric acid (crystals) Receptor independent Kono et al 2010 
ATP P2XR Hoque R et al 2012 
Hyaluronic acid TLR2, TLR4 Williams AM et al 2003 
 
Table 1 Summary of key DAMPs implicated in paracetamol induced acute liver failure 
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1.5.2 Intracellular signalling and inflammasome activation  
Binding of DAMPs to receptors on cells of the innate immune system initiates an intracellular 
signalling cascade ultimately resulting in the production of pro-inflammatory cytokines and 
chemokines that activate and recruit further immune effector cells to the site of inflammation. 
One key pathway by which this activation occurs is the canonical NFκB pathway 
(summarised in Figure 1.3). NFκB is a transcription factor that resides in the cytoplasm in 
unstimulated cells in the form of a heterodimer, bound with an inhibitory protein IκBα 
(Robinson and Mann, 2010). Ligation of cell surface receptors, for example the binding of 
HMGB1 to TLR4, triggers an intracellular cascade through the protein MyD88 (Myeloid 
differentiation primary response gene 88) that leads to the activation of IκB kinase. This 
kinase phosphorylates two residues on the IκBα protein, leading to ubiquitination and 
ultimately degradation by the proteasome. Released from its inhibitory protein, the NFκB 
heterodimer is free to travel to the nucleus. Upon binding with consensus regions, NFkB 
directs the transcription of pro-inflammatory genes including TNF-α, IL-6, IL-8 and adhesion 
molecules. 
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Figure 1.3 Pro-inflammatory signalling via NFkB and AP-1 following ligation of the 
TLR4 receptor.  
Upon ligation of TLR 4, MyD88 (Myeloid differentiation primary response gene 88) is 
recruited to the intracellular TIR domain of the receptor. MyD88 interacts with members of 
the IRAK (IL-1 Receptor-associated kinase) family, first IRAK4 is activated and this 
subsequently phosphorylates and activates IRAK1. Once IRAK 4 and IRAK1 have been 
sequentially activated they dissociate from the MyD88 complex and bind TRAF6. TRAF 6 
recruits a membrane-bound complex of TAK1/TAB1/TAB2 and following ubiquitination of 
TRAF6 and TAK1 and phosphorylation of the TAB components, the complex is released 
from the cell membrane. TAK1 proceeds to phosphorylate the α and β subunits of IKK and 
activates the MAP 3 kinase family of protein kinases. Activated IKK phosphorylates IκBα, 
targeting it for degradation by the 26S proteasome and freeing the NF-κB heterodimer, 
enabling it to translocate to the nucleus. 
 
The production of some cytokines - including interleukin (IL)-1β and IL-18 by hepatic Kupffer 
cells and other cells of the innate immune system - is dependent on two concurrent DAMP 
signals stimulating the cell to assemble a cytosolic complex known as the inflammasome 
Nucleus 
HMGB1 LPS 
AP-1 
P50 P65 
MD-2 
TLR4 
CD14 
MyD88 IRAK
4 
IRAK
1 
TRAF6 
MAP3Ks 
JNK
 
 
AP-1 
P50 P65 
P50 P65 
IκBα 
P P
P50 P65 
IκBα 
TAK1 NEMO 
IKKα IKKβ 
IκBα 
 
p38 ERK1/2 
 42 
(Kubes and Mehal, 2012). The first signal is transduced via TLR receptors (in particular 
TLR9) and via NFκB dependent transcription and results in the production of the pro-caspase 
and pro-cytokines. The second signal can come from a number of sources, including 
extracellular ATP acting via purinergic receptor (P2XR) and uric acid crystals. This signal 
results in the assembly of inflammasome complex from pro-caspase 1, an adapter protein 
ASC and the nucleotide-binding domain, leucine-rich repeat-containing family member NLR, 
which acts to cleave pro-caspase 1. Cleaved caspase 1 proceeds to activate pro-IL1β and 
pro-IL-18. Experimental manipulation of this system in animal models has shown non-
redundant functions for Caspase 1, ASC and the NACHT LRR and pyrin domain-containing 
protein 3 (Nalp3) in paracetamol induced acute liver failure (Imaeda et al., 2009). Mice 
deficient in these inflammasome signalling components were protected from liver injury.  
However, the findings of this study have been called into question by another research group 
who failed to replicate the protective effect of inflammasome disruption (Williams et al., 
2011). 
 
1.5.3 The role of monocytes and macrophages 
Macrophages are tissue resident members of the mononuclear phagocytic system. They 
have important and diverse roles in the innate inflammatory response. Macrophages display 
both pro-inflammatory effects, which are aimed at microbial elimination, but may contribute to 
tissue injury and pro-resolution effects, which are essential for tissue repair. These divergent 
roles have lead to a broad classification of macrophages as polarised to either a ‘M1’ pro-
inflammatory phenotype or a ‘M2’ pro-resolution phenotype. It is now recognised that this 
catagerisation is an over-simplification and these states represent extremes, between which 
numerous activation states exist. Moreover, the inherent plasticity of macrophages means 
they may reversibly transition through these activation states depending on 
microenvironmental cues within inflamed tissue (Stout et al., 2005). 
In the adult liver macrophages may originate from two sources. Kupffer cells (KC) are tissue 
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resident and represent a self-renewing, haematopoiesis-independent population, 
embryologically derived from the yolk sac (Davies et al., 2013). The second population are 
composed of monocyte-derived macrophages of bone marrow origin, which transiently 
infiltrate the liver and are greatly expanded in number during inflammation. 
 
1.5.3.1 Recruitment 
The significance of macrophages in paracetamol hepatotoxicity begins with Kupffer cells, 
which act as resident sensors, detecting and amplifying the inflammatory alarm signal 
initiated by hepatocyte necrosis. Their activation by DAMPs leads to the production of pro-
inflammatory cytokines and chemokines, which mobilise and recruit further immune effector 
cells. Shortly after KC activation, there is a rapid and massive expansion in hepatic 
macrophage numbers. Within 12 hours of paracetamol dosing of mice a significant increase 
in hepatic macrophages can be observed (Holt et al., 2008). The early increase in 
macrophage numbers is due to the recruitment of circulating monocytes, rather than 
proliferation of Kupffer cells (Holt et al., 2008) (Zigmond et al., 2014). In murine models these 
infiltrating monocytes are distinguished from Kupffer cells by a F4/80int CD11Bhi CX3CR1+ 
Ly6Chi phenotype compared to the KC F4/80hi CD11Bint CX3CR1-/lo Ly6Clo expression pattern 
(Holt et al., 2008, Zigmond et al., 2014). 
The recruitment of this monocyte population is dependent on the chemokine monocyte 
chemoattractant protein-1 (MCP-1), which is released from KCs and hepatic parenchymal 
cells in the paracetamol damaged liver of mice and patients alike (Dambach et al., 2002, 
Leifeld et al., 2003, Antoniades et al., 2013). MCP-1 acts on the C-C chemokine receptor 
CCR2, which is expressed by monocytes and is essential for their proliferation and egress 
from bone marrow, but not subsequent trafficking to the inflamed liver (Mitchell et al., 2009, 
Karlmark et al., 2009). The growth factor M-CSF also plays an important part in the 
proliferation, trafficking and survival of the infiltrating monocyte population. Further 
chemokine signals that are yet to be elucidated are likely to be required to guide monocyte 
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recruitment from the circulation to the precise site of liver injury. 
In parallel to the increase in infiltrating monocytes, resident Kupffer cells appear to decrease 
in absolute number in the early phases of paracetamol-induced liver injury. A number of 
studies have documented a marked reduction (75% in one study) in cells bearing the F4/80hi 
KC hallmark between 24-48 hours after injury (Dambach et al., 2002, Zigmond et al., 2014, 
Ramachandran et al., 2012). It is interesting to speculate what the fate of these disappearing 
KCs might be; whether they undergo apoptosis, migrate to lymphoid tissue or whether the 
macrophage’s enormous capacity for plasticity means that these cells persist but in an 
unrecognisable form. Recovery of the KC population by 120 hours after injury in mice is 
achieved through self-renewal of remaining KCs rather than a phenotypic switch or 
maturation process of the infiltrating monocyte-derived macrophages (Zigmond et al., 2014). 
This finding concurs with data from a human study, which showed that at the time of 
transplantation (i.e. late in the course of injury) CD68+ Kupffer cells demonstrate significant 
proliferative activity (Antoniades et al., 2012). 
 
1.5.3.2 Influence on tissue injury and repair 
There has been much debate on the role of macrophages in acute liver failure. Do they 
contribute to liver damage or assist in repair? Should therapeutic strategies aim to block or 
encourage their recruitment?  The uncertainty was fuelled in part by conflicting results from 
early research using macrophage depletion techniques. Two studies using Gadolinium 
Chloride (GdCl3) to deplete KCs prior to the induction of liver injury both suggested this 
protected mice, thus implicating KCs in the pathogenesis of paracetamol-induced acute liver 
failure (Laskin et al., 1995, Michael et al., 1999). Subsequent studies, which utilised a CCR2-
/- to prevent the recruitment of infiltrating macrophages, showed either worsening 
inflammation or delayed recovery in knockout mice (Hogaboam et al., 2000, Dambach et al., 
2002). Liposome/clodronate depletion techniques were also used and demonstrated 
macrophage inhibition to have either no effect or a detrimental effect on liver injury (Ju et al., 
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2002, Karlmark et al., 2009). With increasing understanding of the macrophage subsets 
involved in acute liver injury it is clearer that these depletion techniques targeted different 
macrophage populations, potentially explaining the conflicting results. 
In addition to KCs, and Ly6Chi infiltrating monocytes a third, phenotypically distinct population 
of macrophages can be detected in the livers of experimental mice after paracetamol injury. 
These Ly6Clo CX3CR1+ F4/80hi cells are entirely derived from the Ly6Chi infiltrating monocyte 
population, but have a distinct gene expression pattern from both infiltrating monocytes and 
the separate KC population (Zigmond et al., 2014). Ly6Chi infiltrating monocytes have a 
mixed M1/M2 phenotype, with expression of pro-inflammatory molecules such as IL-1β, 
CCL2, nitric oxide synthetase 2 and COX2 in addition to those associated with alternative 
(M2) activation, such as arginase, chitinase-like protein (Ym1) and lipocalin (Lcn2). Upon 
differentiation within the inflamed liver to Ly6Clo monocyte-derived macrophages, genetic 
reprogramming occurs with the loss of pro-inflammatory gene expression and polarisation to 
a pro-restorative phenotype with expression of further ‘M2’ genes including CD163 and 
mannose receptor 1. The local trigger for this phenotypic switch is not clear, though a 
number of molecular candidates have been proposed such as glucocorticoids, specialised 
pro-resolving mediators (SPMs), IL-10 and SLPI (Possamai et al., 2014b). It has also been 
hypothesised that the act of phagocytosis may initiate the polarisation of macrophages 
towards an M2-like state (Holt et al., 2008).  
These monocyte-derived macrophages are important in tissue repair. Selective ablation of 
this population results in impaired liver recovery, as seen in earlier studies on CCR2-/- mice, 
which effectively depleted these same cells (Zigmond et al., 2014, Holt et al., 2008). 
Monocyte-derived macrophages influence tissue recovery by the production of molecules 
involved in extracellular matrix remodelling, angiogenesis and hepatocyte regeneration. They 
also have an important role in negatively regulating neutrophils by the production of inhibitors 
of neutrophil migration (PGE2, product of TNF-stimulated gene-6), factors associated in 
neutrophil engulfment (efferocytosis) and expression of the gene Lcn6 that induces 
 46 
neutrophil death. In the absence of infiltrating monocytes and monocyte derived 
macrophages, significant increases in neutrophil numbers in addition to more severe injury 
can be observed (Holt et al., 2008, Zigmond et al., 2014). Gene expression analysis of KCs 
in the recovery stages of acute liver failure shows that they also have a pro-restorative 
phenotype, expressing a discrete yet complementary set of repair-associated genes 
compared to the monocyte-derived macrophage population (Zigmond et al., 2014).  
In conclusion, recent experimental evidence has provided an increasingly clear picture of the 
role of macrophages in acute liver injury. Resident KCs are important drivers of the initial pro-
inflammatory response to injury, before modifying their gene expression during the resolution 
phase to aid liver repair. They also decline in number during the acute phase and repopulate 
through self-renewal to eventually replenish the tissue resident population. A distinct 
population of monocytes are recruited to the liver after injury in great number and initially 
display a mixed pro/anti-inflammatory phenotype. Upon recruitment to the liver infiltrating 
monocytes differentiate and undergo a phenotypic switch, triggered by as yet unidentified 
microenvironmental cues, to adopt an ‘M2-like’ pro-resolution identity. In chronic liver 
diseases, in the presence of persistent or recurrent injury, these macrophages may 
contribute to long-term pathology through the promotion of fibrogenesis. However in acute 
disease they appear to have largely beneficial roles, including the induction of neutrophil 
apoptosis, efferocytosis of neutrophils, production of anti-inflammatory mediators and 
hepatotrophic factors. 
 
1.5.4 The role of neutrophils 
Neutrophils are large polymorphonuclear leucocytes, with important effector functions in the 
innate immune response to infection and sterile inflammation. They have a vital role to play 
in the killing and phagocytosis of microbes and have may have directly cytotoxic effects on 
host cells through the generation of reactive oxygen species (ROS) and release of 
proteases. A swift and effective neutrophil response to invading pathogens is essential to the 
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containment of infection and host survival. However, when this same response is deployed in 
sterile inflammation, deleterious host tissue damage can result. Neutrophils have been 
shown to contribute to the pathogenesis of a number of sterile inflammatory conditions of the 
liver, including bile duct ligation, alcoholic hepatitis (Jaeschke, 2002), ischaemia reperfusion 
injury and toxin mediated, halothane hepatitis (You et al., 2006), Concavalin-A hepatitis 
(Bonder et al., 2004) and α-naphthylisothiocyanate (ANIT) induced liver injury (Kodali et al., 
2006). Interestingly, the contribution of neutrophils to liver injury in paracetamol overdose 
remains controversial, as discussed below (Jaeschke et al., 2013). 
 
1.5.4.1 Recruitment 
One area that is beyond controversy is that neutrophils are recruited to the liver in great 
numbers and early in the course of paracetamol induced acute liver injury. In animal models 
a neutrophilic infiltrate can be observed within 6 hours of administration of a toxic dose of 
paracetamol (Liu et al., 2006, Williams et al., 2014) (Lawson et al., 2000). Neutrophils are 
initially recruited to the liver by a gradient of CXC chemokines produced by Kupffer cells, 
including keratinocyte chemoattractant (KC/CXCL1) and MIP-2α (CXCL2), which signal 
through the neutrophil receptor CXCR2. In sterile inflammation, neutrophils become 
sequestered in the liver sinusoids and adhere to the endothelium via a β2 integrin/ICAM-1 
interaction (Kubes and Mehal, 2012). The endothelial expression of ICAM-1 is enhanced by 
local IL-1β secretion from Kupffer cells, thus promoting neutrophil adhesion near sites of 
injury. Neutrophils are also able to respond to DAMPs directly. Mitochondrial-derived formyl 
peptides released by necrotic cells and acting on neutrophil FPR1 receptors, take over from 
the CXC chemokines to guide neutrophils to the exact site of tissue damage (McDonald et 
al., 2010). These DAMPs thus act as a key component of the hierarchy of chemotactic 
signals that recruit and localise neutrophils to necrotic centrilobular regions in paracetamol 
induced liver injury. A recent study showed that neutrophils are also directly activated by 
nuclear DNA, signalling through TLR9, and are seen to patrol ‘DNA rich’ necrotic areas 
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(Marques et al., 2014). This does not however, provide direct evidence for neutrophil 
chemotaxis or adhesion via a DNA-TLR9 mechanism.  
 
1.5.4.2 Influence on tissue injury and repair 
The contribution of neutrophils to tissue damage and/or repair once they have entered the 
liver is less clearly understood. A number of experimental strategies to probe this question 
have been reported and have shown conflicting results (Jaeschke et al., 2013). An early 
study suggested that neutrophils were not activated following paracetamol-induced liver 
injury. Lawson et al reported that circulating neutrophils in an animal model of paracetamol 
induced liver injury, did not up regulate CD11B/CD18, the β integrins essential for not only 
endothelial adhesion, but adhesion-dependent target cell killing (Lawson et al., 2000). 
Treatment with a CD18 blocking antibody or comparing the response of CD18-/- mice to 
controls was not associated with protection from liver injury (Lawson et al., 2000) (Williams et 
al., 2010a).  
A more recent and comprehensive study showed that CD11B is upregulated in both 
circulating and hepatic neutrophils between 24-48 hours after paracetamol dosing in a 
murine model (Williams et al., 2014). This finding was replicated in the circulating neutrophils 
of patients presenting with severe paracetamol overdose (Williams et al., 2014). Williams et 
al suggested that the timing of this activation, at or after peak liver injury, implies that 
activated neutrophils do not contribute to liver damage. The authors also demonstrated a 
lack of ROS priming in both hepatic and circulating neutrophils, suggesting neutrophils were 
not activated to exert cytotoxic effects. An additional finding of the study, reported elsewhere 
in 2003, was that gp91phox mice, (deficient in one the critical subunits that compose NOX2, 
the enzyme that generates neutrophil ROS) were not protected from liver injury compared to 
wild type controls (James et al., 2003a) (Williams et al., 2014). Interestingly, James et al 
noted double the number of neutrophils recruited to the liver in their gp91phox mice compared 
to controls. 
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Further evidence to support the hypothesis that neutrophils do not contribute to liver damage 
in paracetamol hepatotoxicity comes from a lack of protection of mice treated with NADPH 
oxidase inhibitors (Cover et al., 2006). Staining for hypocholrate-modified proteins, a 
histological hallmark of neutrophil-mediated oxidative stress, also failed to demonstrate 
evidence of neutrophil induced damage in liver tissue (Cover et al., 2006).  Two recent 
studies have used the administration of endotoxin and a pharmacological dose of IL-1β as 
‘second hits’ after paracetamol dosing, to enhance neutrophil recruitment to the injured liver. 
In both cases neutrophil recruitment and inflammatory cytokine production were significantly 
increased, but the extent of liver damage was not altered (Williams et al., 2010a, Williams et 
al., 2010b).   
In contrast to the experiments detailed above, which have largely come from a single 
research group, a number of other investigators have demonstrated evidence that suggests 
neutrophils do indeed exert cytotoxic effects on hepatocytes after the initial phase of 
paracetamol toxicity and thus contribute to the extent and severity of liver injury. In three 
separate studies, treatment of mice with neutropaenia-inducing antibodies prior to dosing 
with paracetamol resulted in partial protection from liver damage (Ishida et al., 2006) (Liu et 
al., 2006) (Marques et al., 2012). This effect was not however replicated when the 
neutropaenia was induced after paracetamol dosing (Cover et al., 2006). The original three 
experiments received criticism for likely off-target effects of the neutropaenia inducing 
antibodies (Jaeschke and Liu, 2007). It was suggested that the observed protection 
conferred by the antibodies was due to priming of Kupffer cells by circulating cellular debris 
from the depleted neutrophils. This priming is thought to induce the expression of protective 
genes in the liver and thus attenuate the response to the secondary inflammatory insult of 
paracetamol-induced hepatocyte necrosis (Jaeschke and Liu, 2007). Strategies that inhibit 
neutrophil recruitment to the injured liver have been demonstrated to ameliorate liver injury. 
Combined blockade of CXCR2 and formyl peptide receptor 1 (FPR1), the neutrophil 
receptors for CXCL chemokines and mitochondrial-derived formyl peptides respectively, 
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proved to be protective in an animal model of paracetamol induced liver failure (Marques et 
al., 2012). ICAM-1 deficient mice also showed reduced neutrophil recruitment following liver 
injury and a reduction in the extent of liver injury (Liu et al., 2006). However, Cover et al 
failed to replicate this finding, showing no difference in the extent of liver injury between wild 
type and ICAM deficient mice (Cover et al., 2006).  
 
Figure 1.4 Summary of the innate immune response in paracetamol-induced acute 
liver failure (adapted from (Possamai et al., 2014b) with permission) 
Hepatocyte death by necrosis leads to the release of DAMPs including HMGB-1 and DNA 
fragments, which are detected by TLRs on resident KCs. This initial alarm signal leads to 
the activation of KCs and production of pro-inflammatory chemokines and cytokines. The 
systemic inflammatory response contributes to vascular endothelial dysfunction, 
cardiovascular instability and the development of extra-hepatic complications. Monocytes 
and neutrophils are recruited to the liver from the circulation. In the early phases of injury, 
infiltrating monocytes display a mixed pro- and anti-inflammatory phenotype, and thus may 
perpetuate inflammation and encourage further cellular recruitment. Exposure to the 
inflamed hepatic microenvironment provokes a phenotypic switch to a pro-resolution 
monocyte-derived macrophage. These produce repair and regeneration mediators, 
however spill over may contribute to functional monocyte deactivation in the systemic 
circulation.  
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1.6 Animal models of paracetamol-induced acute liver failure 
Mouse models provide a tractable and relevant experimental system in which to investigate 
paracetamol-induced acute liver failure. The hepatic metabolism and toxicity of paracetamol 
is comparable in the mouse to humans. While their short intergenerational time, ease of 
maintenance and availability of murine genetic tools and resources, makes mice an ideal 
system for genetic studies. The use of mice as models of paracetamol-induced acute liver 
failure is discussed in greater detail in chapters 2 and 3. 
 
1.7 Variability in response to the hepatotoxic effects of paracetamol 
Paracetamol has long been considered a dose-dependent hepatotoxin that is non-toxic in 
therapeutic doses. However, research over the last decade has identified marked inter-
individual variability in response to paracetamol, including at therapeutic doses in which a 
significant minority of healthy individuals develop evidence of liver damage. A randomized, 
single blinded, placebo-controlled trial by Watkins et al published in 2006, demonstrated that 
31-44% of healthy adults experience elevations in their serum alanine transferase (ALT) 
concentrations over 3 times the upper limit of normal (ULN) after 8 days administration of a 
therapeutic (4g/day) dose of paracetamol (Watkins, 2006). A quarter of patients had 
elevations greater than five times the ULN and 8% experienced ALT concentrations greater 
than 8 times the ULN. No abnormalities in ALT were described in volunteers receiving 
placebo and ALT concentrations in those who had responded to paracetamol returned to 
normal within one week of discontinuing the trial. Similar findings were reported in a seven-
day double-blind placebo controlled study of a 4g/day dose of paracetamol (Harrill et al., 
2009a). In their cohort, 37% of healthy volunteers had elevations in their ALT greater than 2 
times the ULN and some individuals had peak values 6-7 times the ULN. 
The variation in susceptibility between individuals extends to those taking overdoses, 
although it is not clear whether it is those same individuals who are sensitive to toxicity at low 
 52 
doses who would also exhibit enhance susceptibility to acute liver failure on overdose. A 
report from the USA Acute Liver Failure Study Group in 2010 demonstrated that the outcome 
from paracetamol-induced acute liver failure does not correlate with the dose ingested 
(Gregory et al., 2010). It is therefore apparent that significant inter-individual variability to the 
hepatotoxic effects of paracetamol exists in the general population. Some of the genetic and 
environmental factors that influence this variation have been described in Sections 1.8 and 
1.9. 
 
1.8 Genetic susceptibility factors 
1.8.1 Metabolic phase  
Following the observation that there was a marked inter-species variation in susceptibility to 
weight-adjusted paracetamol doses, with humans and rats proving to be relatively resistant 
and mice and hamsters sensitive, studies were conducted to determine the cause of this. 
Cultured hepatocytes from resistant species exhibit a predictable resilience to the toxic 
effects of paracetamol when compared to cells from sensitive species. However, when 
NAPQI is administered directly to the hepatocytes, bypassing the CYP-dependant oxidation 
of paracetamol, the toxic effects were the same in resistant and sensitive cells (Tee et al., 
1987). An in vivo study comparing paracetamol metabolism in resistant and sensitive 
laboratory animal species was conducted by Gregus et al in 1988. It demonstrated increased 
biliary excretion of glutathione conjugates of paracetamol in sensitive species, reflecting a 
greater proportion of paracetamol being converted to NAPQI (Gregus et al., 1988). These 
experiments both suggest that the biotransformation of paracetamol into NAPQI is a major 
determinant of the inter-species variation in susceptibility to toxicity. 
Ethnic differences in the metabolism of paracetamol in human subjects also suggest the 
presence of genetic susceptibility factors that contribute at this early stage of toxicity. In one 
study, Caucasian subjects given a single 1.5g dose of paracetamol display increased urinary 
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mercapturic and cysteine conjugates in urine compared to African subjects (Critchley et al., 
1986).  Significant differences in urinary metabolites of paracetamol, that imply altered 
bioactivation of this compound, have also been demonstrated between Caucasian and Asian 
subjects (Patel et al., 1992). Interestingly, Critchley et al noted significant inter-subject 
variation (> 60 fold) in paracetamol bioactivation when compared with the relatively stable 
sulfonation:gluconuration ratio and demonstrated a sub-group of individuals with extensive 
bioactivation. More recently, Liu et al have used an “integrative genomic analysis” to 
investigate variation in response to paracetamol and have identified the gene Bhmt2 as a 
diet-dependent susceptibility factor (Liu et al., 2009). The Bhmt2 enzyme effects glutathione 
biosynthesis and therefore influences the hepatocyte’s ability to detoxify NAPQI through 
glutathione conjugation. It should be noted that though approaching the problem of 
paracetamol susceptibility with a non-hypothesis driven approach, Liu and colleagues later 
applied a ‘knowledge-based’ refinement of their results and selected only metabolic enzymes 
for further investigation. Taken together, these results suggest that genetic variation in 
enzymes involved in the initial, metabolic phase of paracetamol toxicity make a significant 
contribution to the observed variability in susceptibility to this toxin. 
 
1.8.2 Cell death & immune activation phase 
Genetic variation in cell death pathways and the immune response to hepatotoxins are also 
important in determining susceptibility. Harrill et al identified a number of genes that 
influenced the phenotypic response to paracetamol in mice (Harrill et al., 2009b). 
Interestingly, these genes, that included CD44, CD59a, Ly86 and Capn6, are all involved in 
the immune response to liver toxicity and not the initial metabolic phase. In fact, there was no 
association between genetic polymorphisms of the CYP 2E1 enzymes or glutathione-related 
metabolic enzymes and toxicity. The finding of a significant association between 
susceptibility and variation at the CD44 locus was validated in a human cohort on therapeutic 
dose paracetamol (Harrill et al., 2009b). 
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A recent study using the American Acute Liver Failure cohort, has demonstrated that 
cytokeratin-8 and -18 variants are over-represented in ALF patients compared with controls 
(Strnad et al., 2010). Within the group of patients with ALF, cytokeratin variants were also 
associated with lower transplant-free survival. The mechanisms by which cytokeratin variants 
confer susceptibility to the development and progression of ALF are postulated to include: 
increased hepatocyte fragility with K-18 variants, mitochondrial dysmorphology and 
vulnerability to oxidative damage with K-8 variants and the phosphorylation of pro-apoptotic 
substrates (Strnad et al., 2010). 
Genetic polymorphisms in the TNFβ gene have been shown to influence the development of 
severe encephalopathy in paracetamol-induced ALF (Bernal et al., 1998). In patient groups 
with non-paracetamol associated ALF, this polymorphism has also been associated with 
poor outcome, underlining the common inflammatory processes in different forms of ALF 
(Tsuchiya et al., 2004, Takakura et al., 2007). 
 
1.9 Environmental susceptibility 
A number of environmental factors are well recognised to affect susceptibility to paracetamol 
toxicity. This knowledge has been used in clinical practice to risk-stratify patients presenting 
with overdose, identifying patients that require a lower treatment threshold. These factors; 
malnutrition or acute starvation, chronic alcohol abuse and the concurrent use of enzyme-
inducing drugs, all affect the initial metabolic phase of paracetamol toxicity by either induction 
of CYP2E1 leading to enhanced NAPQI production, or by glutathione depletion. 
It has been suggested that chronic use of paracetamol may afford protection from 
hepatotoxicity in subsequent overdose. Shayiq et al used an incremental dosing protocol in 
mice to show prior paracetamol dosing lead to hepatic adaptation that mitigated the effect of 
later high doses. Cellular adaptations included selective down-regulation of CYP2E1 and 
1A2, a redistribution of CYP enzyme expression through the hepatic lobule, increased 
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cellular glutathione reserves and increased hepatocyte regenerative capacity (Shayiq et al., 
1999). 
Recent metabonomic studies of the urine of healthy volunteers taking therapeutic dose 
paracetamol have indicated that an individual’s bowel microbiota can influence the 
metabolism of paracetamol. Individuals with high bacterial-derived generation of p-cresol 
sulphate, showed low urinary excretion ratios of paracetamol-sulphate: paracetamol-
glucuronide (Clayton et al., 2009). This demonstrates the importance of intestinal microbiota-
host interactions in drug metabolism and provides another potential environmental source of 
inter-individual variability to toxin handling and response. Gut microbiota may also influence 
the progression of paracetamol hepatotoxicity through the production of LPS and other 
bacterial PAMPs.  
 
1.10 Summary and aims 
Paracetamol overdose is a common cause for presentation to hospital and though the 
development of acute liver failure is a relatively rare complication, it is one that is associated 
with great morbidity and mortality. Our understanding of the pharmaco- and immuno-
pathology of paracetamol induced acute liver failure has increased significantly in recent 
years, however this knowledge is yet to be translated into new treatments. Key questions 
have arisen from the recent observation of significant inter-individual susceptibility to 
paracetamol toxicity. What is the cause for this variation and could it hold the key to 
improved risk stratification in patients presenting with overdose or lead to novel therapeutics? 
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Figure 1.5 A model of paracetamol hepatotoxicity as a multi-stage process impacted 
upon by genetic and environmental factors. 
Paracetamol induced hepatotoxicity is an acute condition, yet it can be considered in a 
number of phases. During the initial metabolic phase paracetamol is bioconverted to the 
reactive metabolite NAPQI. A phase of hepatocyte injury and death follows. The 
consequence of uncontrolled hepatocyte death is inflammation and immune activation. This 
can lead to secondary liver injury. Liver repair and regeneration are also initiated. The model 
depicts these overlapping phases and shows that at each stage environmental and genetic 
influences can impact upon the pathogenesis of acute liver failure to influence the outcome. 
 
Paracetamol overdose represents an acute insult to the liver, yet the development of the 
clinical syndrome of acute liver failure can be considered in a number of phases. Firstly the 
metabolic stage in which paracetamol is converted to a reactive metabolite, secondly the cell 
death stage in which damages hepatocytes die of necrosis or apoptosis, thirdly a robust 
immune response to tissue injury and finally a stage of liver regeneration. At all of these 
stages genetic and environmental variability can influence the extent of progression of 
disease and ultimately impact of patient survival (Figure 1.5). Many of the known 
susceptibility factors, such as chronic alcohol use and nutritional deficiency impact on the 
Outcome(
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initial metabolism of paracetamol. As many patients present with established liver failure, it 
would be particularly useful clinically to identify factors that impact on the later ‘immune’ 
phases of liver injury, conferring susceptibility to poor outcome from acute liver failure.  
Two unmet needs in the clinical management of paracetamol induced acute liver failure are 
apparent: firstly a requirement for risk-stratification tools to identify early those at risk of 
progression to acute liver failure among the tens of thousands that present having taken an 
overdose. Secondly, treatment options are needed for those who present with established 
acute liver failure in whom the immune response to the original injury is perpetuating injury 
and contributing to the development of extra-hepatic complications.  
The aim of the research described in this thesis is to exploit naturally occurring and induced 
genetic variation in mouse models to: 
 
1) identify novel susceptibility factors in paracetamol-induced acute liver 
failure. 
2) investigate key factors which influence outcome through their impact on the 
immune response to liver injury 
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2 GENETIC SUSCEPTIBILITY FACTORS: QTL MAPPING 
FOR PARACETAMOL SUSCEPTIBILITY 
 
2.1 Background and aims 
2.1.1 Quantitative traits 
Many of the diseases and conditions seen in the human population can be considered to be 
genetically ‘complex traits’. They cannot be explained through mutations in a single gene, 
like monogenic conditions such as cystic fibrosis, however they clearly have a heritable 
component. This heritability is the result of a number of genes that each confers a small to 
medium effect on the disease trait and that may interact with environmental risk factors. A 
quantitative trait is one in which these polygenic factors and environmental influences 
combine to effect the degree or extent to which a phenotype is observed. For example, 
height is a complex, quantitative trait. The final height that an adult reaches will be due to the 
inheritance of multiple genes from both parents and the effect of environmental factors such 
as childhood nutrition. 
An individual’s response to the hepatotoxic effects of paracetamol can be considered a 
complex trait, with the degree of liver damage representing a quantitative trait. Multiple genes 
at many genetic loci are likely to influence the extent of this trait in humans. In conditions 
such as this, any genetic locus that associates with the trait may be considered and termed a 
quantitative trait locus (QTL). Identifying these QTLs, when many of them contribute and 
interact to influence the phenotype is challenging. One technique that has been utilised with 
some success is the quantitative trait locus mapping using inbred strains of mice.  
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2.1.2 Inbred strains of laboratory mice 
Mice are widely used in genetics research due to their short generational time, ease of 
breeding, ability to control environmental variables, genetic similarities to humans and 
potential for genetic manipulation (Ermann and Glimcher, 2012). Standard laboratory mice 
are derived from one of a number of well known and characterised inbred strains. These 
strains were originally developed by sibling inbreeding over more than 20 generations until 
genetic variability was eradicated and individuals in the strain were homozygous at all 
genetic loci and effectively genetically identical (Paigen, 2003). Most of the commonly used 
laboratory strains were originally bred over 100 years ago by the same establishment and so 
have significant genetic similarities and represent little of the diversity present in wild mouse 
populations. Despite this, each strain has characteristic features and differing susceptibilities 
to a number of disease conditions and traits. These naturally occurring differences in the 
phenotypes and susceptibilities of inbred mouse strains can be exploited in QTL mapping to 
identify genetic loci that are linked with a phenotype of interest.  
 
2.1.3 QTL mapping  
The initial step in QTL mapping is to identify mouse strains with differing phenotypes related 
to the trait of interest. These strains are then bred in an experimental cross and the F1 
offspring are either backcrossed into one of the parental strains or intercrossed depending on 
the mode of inheritance. This forms a recombinant inbred strain in which individuals contain 
chromosomes from each parental strain, and due to recombination events during meiosis, 
contain chromosomes that are a composite of genes from each strain (Doerge, 2002). 
Phenotyping of the offspring provides a quantitative value for the observed trait. This can be 
compared to a genetic map obtained by detecting SNP markers throughout the genome to 
identify loci that associate with the quantitative trait (Carlborg et al., 2005). 
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In paracetamol hepatotoxicity it is known that inbred strains of mice have differing responses, 
with some strains showing enhanced susceptibility to liver injury compared to other, more 
resistant strains (Harrill et al., 2009b). Previous studies by our group had shown that the 
common strain C57BL/6 was relatively resistant to liver injury following a paracetamol 
overdose compared to another strain, C3H/HeH. 
 
A QTL mapping experiment was undertaken to utilise the differences in hepatotoxicity 
between the C57BL/6 and C3H/HeH strains of laboratory mice, with the aim of 
identifying novel loci associated with paracetamol-induced liver injury. 
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2.2 Materials and methods 
2.2.1 Animal Maintenance 
All research using live animals was approved by local ethics committees (MRC Harwell) and 
was carried out under Home Office supervision in accordance with the Animal (Scientific 
Procedures) Act 1986 (UK). Procedures were performed under the authority of UK project 
licence 30/2472. All efforts were taken to minimize animal suffering. 
Mouse colonies were maintained at MRC Harwell. Mice were housed in specific pathogen 
free conditions in individually ventilated cages (Techniplast UK Ltd). The environment was 
controlled with a 12 hour light/dark cycle, ambient temperature of 21°C (+/-2°C) and humidity 
of 55% (+/-10%). Mice had access to irradiated diet (Special Diet Services UK) and water 
(25ppm chlorine) ad libitum except when food was withdrawn for defined experimental 
purposes. 
 
2.2.2 Breeding strategy for QTL mapping 
Inbred strains of mice were selected for their relative resistance (C57BL/6J) and 
susceptibility (C3H/HeH) to the effects of paracetamol hepatotoxicity. An intercross between 
these strains produced a heterozygote F1 generation, which was backcrossed into the 
resistant (C57BL/6J) strain (see Figure 2.1). The backcross was maintained to produce 310 
male F2 mice. The experiment used only male mice as there is a marked difference in 
susceptibility to paracetamol hepatotoxicity between sexes, with female mice being much 
more resistant than males. 
 
2.2.3 Phenotyping procedure for QTL mapping 
Male F2 mice (n=310) between 53-69 days of age were phenotyped. Mice were fasted 
overnight for 14 hours to uniformly deplete hepatocellular glutathione. Paracetamol (Sigma-
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Aldrich, St Loius, MO) was dissolved in 0.9% saline, warmed to 50°C for 45 minutes, to make 
a 20mg/ml solution. After weighing, mice were injected with a 300mg/kg dose of paracetamol 
via the intraperitoneal route. At 30 minutes after dosing a blood sample was taken from the 
lateral tail vein into a lithium heparin tube (Sarstedt, Nümbrecht-Rommelsdorf, Germany). 
Repeat blood sampling was performed 4 hours after paracetamol dosing.  
At exactly 24 hours after dosing, terminal anaesthesia was induced in mice by intraperitoneal 
injection of 0.15ml of a 100mg/ml solution of pentobarbitone sodium (Pentoject™ Animalcare 
Ltd, York, UK). Upon confirmation of deep anaesthesia by absence of reflexes, an 
intracardiac puncture was performed. As before blood was placed into lithium heparin tubes 
for analysis.   
Technical assistance with experimental work during the phenotyping was provided by 
members of the liver group at MRC Harwell. 
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Figure 2.1 Summary of breeding and phenotyping protocol for QTL mapping 
experiment. 
Overnight 
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2.2.4  Biochemistry analysis 
Plasma was separated from the whole blood collected in lithium heparin tubes by 
centrifugation at 5000 g for 10 minutes in a refrigerated centrifuge chilled to 8°C. Biochemical 
analysis of plasma samples was performed on a Beckman Coulter AU680 semi-automated 
clinical chemistry analyser (Beckman Coulter, Brea, CA), using the manufacturer’s 
instructions, parameter settings and reagents for measurement of Paracetamol, Alanine 
Transaminase (ALT), Bilirubin and Glucose.  
 
2.2.5 DNA extraction  
DNA was extracted from murine tail samples for genotyping purposes using a DNeasy® 
Blood & Tissue Kit (Qiagen, Dusseldorf, Germany) according to the manufacturer’s 
instructions. 
In brief, tissue was incubated overnight at 56OC in 180µl ATL buffer with 20µl of proteinase 
K. The lysed sample was vortexed and 200µl of buffer AL and 200µl of ethanol were added. 
The mixture was pipetted into a mini spin column and centrifuged at 8000rpm for 1 minute. 
The flow-through liquid was discarded and 500µl of wash buffer 1 was added the mini spin 
column before centrifugation at 8000rpm for 1 minute. Again the flow-through was discarded 
and 500µl of wash buffer 2 was added. The column was centrifuged at 14,000rpm for 3 
minutes and the flow-through discarded. The DNA adherent to the mini spin membrane was 
then eluted with 100µl of AE buffer and centrifuged at 8000rpm for 1 minute. 
The DNA concentration and quality yielded from this extraction was quantified using a 
Nanodrop spectrophotometer (Thermoscientific, Waltham, MA) according to the 
manufacturers instructions. Ultra violet (UV) light at a wavelength of 260nm is passed 
through a small volume of sample and the absorbance of light recorded. The absorbance of 
light at this wavelength correlates to the amount of DNA in the sample and hence DNA 
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concentration can be quantified. DNA purity can also be quantified by the ratio of absorbance 
of UV light at 260nm and 280nm, which is 2.00 for an uncontaminated solution of DNA. 
 
2.2.6 SNP Genotyping 
DNA samples (200µl with concentration normalised to 7ng/µl) were genotyped on a custom 
SNP panel by KBiosciences (now LGC Genomics, Middlesex, UK). The panel was 
comprised of 83 SNPs distributed across all 19 non-sex chromosomes and heterologous 
between the C57BL/6 and C3H/HeH strains. There were an average of 4 SNP markers per 
chromosome and average distance between markers of 33.9Mbp (for full details see 
Appendix A and B). 
Following initial mapping which identified an area of interest on chromosome 18, and 
potential areas of interest on chromosome 17, further genotyping against a panel of 9 
heterologous SNPs was performed (see table appendix C for details). 
SNP genotyping data was coded according to whether the individual was homozygous for 
the C57Bl/6 allele or heterozygous, with a C57Bl/6 and C3H/HeH allele at the SNP locus.  
 
2.2.7 Data 
To prevent confounding by dosing error, those individuals with a 30-minute plasma 
paracetamol level greater than or less than 2 standard deviations from the mean, or 
unrecorded, were removed from analysis. In a number of samples the ALT values were 
above the dynamic range of the biochemistry analyser despite dilutions of available sample. 
In these cases an arbitrary value of 18,000U/L, which represented the maximum value 
recordable, was ascribed. 
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Coded genotyping data was imported into R/qtl (Broman et al., 2003). Preliminary scans 
were run on the data to ensure there were no genotyping errors by comparison of 
recombination fractions between every pair of markers. 
 
2.2.8 Mapping 
Single-QTL and two-QTL mapping were performed using R/qtl software (Broman et al., 
2003). Bayesian interval mapping for multiple QTL models was performed using the R-based 
package R/qtlbim (Yandell et al., 2007).  
 
2.2.9 Single QTL genome scans 
A single-QTL model was run on 24-hour ALT values. Genotype probabilities were calculated 
by the hidden Markov model (HMM) at a step distance of 1cM and at an error level of 0.01. A 
single-QTL genome scan was then conducted by maximum likelihood using Haley-Knott 
regression (Haley and Knott, 1992). Findings were validated using the alternative single-QTL 
scanning techniques of maximum likelihood via the EM algorithm (Lander and Botstein, 
1989) and multiple imputations (Sen and Churchill, 2001). Simulations were performed in the 
multiple imputations method at a step size of 2cM, 50 imputations and at an error level of 
0.01.  Permutation testing (1000 permutations) was performed by Haley-Knott regression to 
determine the genome-wide significance threshold to levels of 0.05 and 0.01. 
Single-QTL genome scanning by Haley-Knott regression was repeated with an additional 9 
markers on chromosomes 17 and 18 and using 24-hour ALT as the phenotype. 
The expanded panel of 92 markers was also used to run single-QTL genome scans with 
glucose and bilirubin at 24 hours as the traits of interest using the mapping methodologies as 
described above. 
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2.2.10 Two-QTL scan 
A two-dimensional genome scan was performed using a two QTL model. LOD scores were 
calculated for each pair of chromosomal positions in a stepwise manner. A LOD for the full 
model (Mf) was produced, assuming the two QTLs interact and then for an additive model 
(Ma) in which the QTLs were assumed not to interact. A test of epistasis (Mi = Mf - Ma) was 
performed to compare the full and additive models to determine whether there is evidence of 
interaction between loci. Two-QTL mapping was performed using R/qtl ‘scantwo’ function. 
Genetic probabilities were first calculated at steps of 1cM at an error probability level of 0.01, 
followed by Haley-Knott regression. Recommended significance threshold values for a 
murine backcross were used as recommended by R/qtl software (http://www.rqtl.org). 
 
2.2.11 Multiple QTL analysis using Bayesian interval mapping 
Genetic probabilities were calculated at 2cM steps for the whole genome (excluding sex 
chromosomes, which were not genotyped). Markov chain Monte Carlo (MCMC) samples 
were created from the Bayesian posterior to make a multiple QTL model, using ALT as trait 
of interest and allowing epistasis (Banerjee and Yi, 2012).  
 
2.2.12 Candidate gene identification 
NCBI map viewer (Annotation release 104) was used to generate lists of genes within the 
chromosomal regions identified as containing QTL by mapping (NCBI, 2014a). Candidate 
genes were identified by consideration of gene function and potential relevance to 
paracetamol hepatotoxicity.  
Single nucleotide polymorphism (SNP) data on the two strains used in the experimental 
backcross was obtained from the Jax laboratory’s Mouse Genome Informatics (MGI) 
database (The Jackson Laboratory, 2014). The closely related C3H/HeJ was used in the 
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place of C3H/HeH as there was no SNP information available for the later strain. All 
heterologous SNPs within the regions of interest were identified. Those in coding regions that 
lead to non-synonymous changes to amino acid sequence, and those in the locus region 
(within 2Kb of 5’ end of the gene or 0.5Kb of the 3’ end of the gene) that are likely to effect 
gene regulatory elements, were considered. 
Information on the influence of coding non-synonymous SNPs within the regions of interest 
was obtained from the NCBI dbSNP (NCBI, 2014b) and NCBI protein (NCBI protein, 2014) 
databases. The ‘PredictProtein’ web-based annotation tool (Technical University of Munich, 
July 2013) was used to examine the effects of amino acid substitutions. 
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2.4 Results 
2.4.1 Phenotyping 
Plasma paracetamol concentrations 30 minutes after dosing were recorded to measure 
dosing consistency. The mean paracetamol level was 1172µmol/L with a standard deviation 
of 238µmol/L. There were 9 mice with a plasma paracetamol level greater than 2 standard 
deviations (<696 µmol/L or  >1648 µmol/L) from the mean. These animals were excluded 
from further analysis. 
The primary outcome measure was ALT 24 hours after paracetamol and secondary 
outcomes of bilirubin and glucose at 24 hours were also measured. The mean ALT was 
7572U/L with a standard deviation of 4001U/L.  The mean glucose was 9.5mmol/L (+/- 
1.8mmol/L) and bilirubin 3.9µmol/L (+/-1.3 µmol/L). 
As expected a significant inverse correlation between glucose and ALT was demonstrated 
(Spearman r=-0.27, p<00001) as was a significant positive correlation between bilirubin and 
ALT (Spearman r=0.38, p=<0.001). 
 
2.4.2 Mapping – descriptive data 
Good coverage across the genome was achieved with the 83 SNP markers with no regions 
disproportionately affected by missing data (Figure 2.2A). No genotyping errors were 
identified by pairwise comparison of recombination fraction (Figure 2.2C).  
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Figure 2.2 Descriptive data on markers and recombination within QTL mapping 
experiment during initial 83-marker mapping. 
(A) Map demonstrating areas in which there is missing genotyping data, showing a good 
coverage and no markers for which data in missing in multiple individuals. (B) Genetic map 
detailing the position of 83 SNP markers across 19 chromosomes (C) Estimated 
recombination fraction for all pairs of markers. Recombination fractions are displayed in the 
top left triangle and LOD scores for the test H0: r =1/2 are displayed in the bottom right 
corner. Blue suggests a high recombination fraction/low LOD score and red suggests a low 
recombination fraction/high LOD score. This representation of the data shows that there are 
unlikely to be genotyping errors with markers attributed to the incorrect chromosome, as an 
expected pattern of linkage according to chromosomal proximity is demonstrated.  (D) Map 
showing recombination events on chromosome 1 in thirty representative individuals. Black 
circles indicate a heterozygous genotype (B6/C3H) and white circles indicate a homozygous 
(BL6) genotype at that marker. Blue crosses are used to highlight recombinant segments. 
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2.4.3 Single-QTL scan ALT at 24 hours 
A single-QTL genome scan was performed on 83-marker genotyping data with ALT at 24 
hours as the phenotype of interest. Haley-Knott regression revealed 2 loci on chromosomes 
17 and 18 with LOD values above 2 (Figure 2.3). These loci were validated on scanning 
using the alternative methodologies of maximum likelihood via the EM algorithm and multiple 
imputations, although the locus of the peak LOD score varied between methodologies (table 
2.1, Figure 2.3). The genome wide significance threshold as set by permutation analysis was 
a LOD of 2.54 for a significance of 0.05 (5% error). The LOD score of the locus on 
chromosome 18 at approximately 40cM was just in excess of this threshold, at a LOD of 
2.55. 
 
Figure 2.3	  Single-QTL genome scanning using ALT at 24 hours as phenotype with the 
original panel of 83 markers.  
LOD values across whole genome by H-K regression (black), EM algorithm (blue) and 
multiple imputations (red). This demonstrates broad agreement between QTL mapping 
methodologies, with the strongest linkage (highest LOD scores) identified on chromosomes 
17 and 18 by all 3 methods. 
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Methodology Chromosome Position 
(cM) 
LOD Significance 
threshold (0.05) 
Haley-Knott  17 41 2.24 2.54 
18 47 2.55* 2.54 
EM algorithm 
 
17 38 2.21  
18 48 2.61 
Multiple imputations 17 35 2.19 
18 33 2.47 
 
 
Table 2.1: Single-QTL genome scanning using ALT at 24 hours as phenotype with the 
original panel of 83 markers.   
Results show only those loci identified by mapping with a LOD score of >2 
 
In order to investigate these two loci with finer mapping, further genotyping for 3 markers on 
chromosome 17 and 6 markers on chromosome 18 was performed. 
Repeat mapping was conducted with the additional markers (Figure 2.4A). Single-QTL 
genome scanning and was performed as above. These markers refined the QTL analysis, 
producing higher LOD scores and more precisely localising the position of the peak loci on 
chromosomes 17 and 18 (Figure 2.4B, table 2.2).  LOD significance thresholds of 2.56 for 
p=0.05 and 3.27 for p=0.01 were calculated by permutation analysis.  The locus on 
chromosome 17, between 42-55cM and centred on the marker 17-050794277 (at 50Mbp), 
exceeded the 0.05 significance threshold with a peak LOD of 2.96 (Figure 2.4C). On 
chromosome 18 the locus that had previously been identified at approximately 40cM, was 
narrowed down to a region between the new markers at 43 and 55cM. It achieved a peak 
LOD score of 3.30, exceeding the 0.01 significance threshold (Figure 2.4D).  
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Methodology Chromosome Position 
(cM) 
LOD Significance thresholds  
  
(0.05) (0.01) 
Haley-Knott 17 50 2.96* 2.56 3.27 
18 47 3.30** 2.56 3.27 
EM algorithm 
 
17 50 2.91   
18 49 3.46  
Multiple 
imputations 
17 49 2.97  
18 49 3.19  
 
Table 2.2: Single-QTL genome scanning using ALT at 24 hours as phenotype with the 
expanded panel of 92 markers.   
Results show loci identified by mapping with a LOD score of >2. For full table of results see 
Appendix D  
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Figure 2.4 Single-QTL genome scanning results for 24hr ALT with expanded SNP 
panel 
(A) Genetic map of chromosomes 17 and 18 showing location of all markers.  (B) Plot of 
LOD values for markers across whole genome as calculated by Haley-Knott regression. 
Significance thresholds of p=0.05 (green line) and p=0.01 (blue line) calculated by 
permutations analysis.  (C) LOD values for markers on chromosome 17 with region 42-55cM   
exceeding the p=0.05 significance threshold (green line).  (D) LOD values for markers on 
chromosome 18 with region 43-52cM exceeding the p=0.01 significance threshold (blue line). 
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2.4.4 Single-QTL scan glucose at 24 hours 
Single-QTL genome scanning using the 24-hour glucose value as a phenotype of interest 
was performed using the expanded, 92-marker panel. Data was available for 242 mice. 
Haley-Knott regression demonstrated suggestive QTL on chromosomes 11 near the marker 
at 4cM (LOD 2.11) and 18 at approximately 34-55Mbp (LOD 1.96). These loci were verified 
by alternative (EM algorithm and multiple imputations) mapping methodologies. Neither locus 
reached the significance threshold of 2.58 as set by permutation analysis (1000 
permutations).  
 
 
Methodology Chromosome Position 
(cM) 
LOD Significance 
threshold (0.05) 
Haley-Knott  11 4 2.11 2.58 
18 62 1.96 2.58 
EM algorithm 
 
11 4 2.13  
18 61 1.93 
Multiple imputations 11 4 2.15 
18 41 1.89 
 
Table 2.3: Single-QTL genome scanning using plasma glucose at 24 hours as 
phenotype. Results show only loci identified by mapping to have a LOD >1. 
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2.4.5 Single-QTL scan bilirubin at 24 hours 
Mapping was repeated with bilirubin values at 24 hours, using all 92 markers. Data was 
available for 241 individuals. Two suggestive loci were identified by Haley-Knott regression 
and verified by alternative methodologies (Figure 2.5 and table 2.4). On chromosome 10 a 
locus between 28-32 cM with a non-significant but suggestive LOD score of 2.08 was 
identified. The locus on chromosome 2 at 25-29cM had a maximal LOD score of 2.61, which 
just exceeded the 2.58 p=0.05 significance threshold. 
 
Figure 2.5 Mapping of QTL for bilirubin at 24 hours post-paracetamol. 
Single-QTL genome scanning using bilirubin 24 hours post-paracetamol as the trait of 
interest. (A) LOD values across the whole genome by H-K regression (black), EM algorithm 
(blue) and multiple imputations (red), showing agreement between methodologies. (B) LOD 
values on chromosomes 2 and 10 by H-K regression showing a region of chromosome 2 that 
exceeds the significance threshold of a LOD of 2.54 (p=0.05, green line. 
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Methodology Chromosome Position 
(cM) 
LOD Significance 
threshold (0.05) 
Haley-Knott  2 28 2.61* 2.55 
10 32 2.08 2.55 
EM algorithm 
 
2 25 2.52  
10 28 2.05 
Multiple imputations 2 25 2.57 
10 29 2.09 
 
Table 2.4: Single-QTL genome scanning using plasma bilirubin at 24 hours as 
phenotype. Results show only loci identified by mapping to have a LOD >2. 
 
 
 
 
 
2.4.6 Two dimensional QTL scanning 
Two-QTL scanning was performed on mapping data with 24 hour ALT as a phenotype to 
determine whether the QTL identified on chromosomes 17 and 18 were interacting. The LOD 
values for both the full and additive two-QTL models exceeded the significance threshold 
(LOD Mf =6.18 (threshold=6.0, p<0.05) and LOD Ma = 6.17 (threshold=4.7, p=0.05). The loci 
on chromosomes 17 and 18 that had previously been identified by single QTL scanning were 
those significant in the two-QTL model. There was no evidence of epistasis between these 
loci with the full and additive model producing similar LOD scores (LOD Mi = 0.01, threshold 
4.4). 
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2.4.7 Multiple QTL model 
Bayesian interval mapping was used to explore the possibility of greater than two QTL 
accounting for the variation in ALT 24 hours after paracetamol.  Potential epistatic 
interactions between loci anywhere in the genome could also be identified by this 
methodology. Plotting the samples in the MCMC chain (Figure 2.6, full table appendix E) 
validated the known loci on chromosomes 17 and 18 that had been identified by single-QTL 
mapping. It also identified loci on chromosomes 3 and 5 that had an epistatic interaction and 
effect on the trait. 
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Figure 2.6  Identifying the location of main and epistatic QTL in a multiple-loci model 
(A) Genome map of posterior QTL Blue lines represent the main QTL and purple lines, 
epistatic QTL. (B) A jittered plot of quantitative trait loci showing all chromosomes. Each 
marker represents a single QTL model appearing as samples in the MCMC chain. Blue 
markers represent main QTL and purple markers epistatic QTLs. The density of putative 
QTLs represents the likelihood of an actual QTL being located in this region. (C) The same 
plot, with only chromosomes 3,5,17 and 18 represented, showing likely main QTL on 
chromosomes 17 and 18 and epistatic QTLs on chromosomes 3 and 5 
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There was strong evidence for a multiple QTL model. A number of different variations on the 
multiple QTL model reached a ‘strong’ evidence level (Bayesian Factor >30) ( 
Figure 2.7 A and B). A 5-QTL model incorporating the known loci on chromosomes 17 and 
18, those on chromosomes 3 and 5 and the epistatic interaction between the loci on 
chromosomes 3 and 5, achieved the highest evidence level, with a Bayesian factor of 178 
(+/- 30.3).  Nine further multiple-loci models had a ‘strong’ evidence level with a Bayesian 
factor of greater than 30.  Many of these models incorporated the two main QTL on 
chromosomes 17 and 18 (for a summary see table 2.5). The only epistatic interaction, out of 
every possible paired interaction, that had moderate to strong evidence to support it was the 
interaction between the loci on chromosomes 3 and 5 ( 
Figure 2.7C and D, full results appendix F). 
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Figure 2.7 Summary of the models sampled by the MCMC chain. 
(A) and (B) Pattern of chromosomes involved in the model, showing the prior (blue line) and 
posterior probabilities (histogram). A number of potential multiple-QTL models have strong 
evidence to support them, including a 5 locus model with QTL on chromosomes 3,5,17 and 
18 and an epistatic interaction between chromosome 3 and 5 contributing. See appendix F 
for data. (C) and (D) Relative importance of epistatic pairs, showing the QTL on chromosome 
3 and 5 have epistatic effects. 
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Chromosomes Number 
of loci 
Posterior     Prior Bayesian 
Factor (BF) 
BF standard 
error 
3,5,17,18,3:5     5 0.01130 6.71e-06 178.00 30.300 
8,17,18           3 0.00633 4.98e-06 134.00 30.600 
11,17,18          3 0.00367 4.84e-06   79.80 24.000 
7,17,18           3 0.00300 4.02e-06   78.60 26.200 
10,17,18          3 0.00367 5.13e-06   75.20 22.600 
17,18             2 0.01730 3.12e-05   58.50   8.040 
3,17,18           3 0.00300 6.28e-06   50.30 16.700 
3,5,8,18,3:5      5 0.00333 8.70e-06   40.30 12.700 
3,5,18,3:5        4 0.01100 3.15e-05   36.80   6.370 
1,17,18           3 0.00267 7.74e-06   36.30 12.800 
 
Table 2.5: Summary of multiple-QTL models with Bayesian factors greater than 30. 
Multiple QTL models are ranked by their Bayesian Factor (BF), showing the most plausible 
combination of loci to account for the observed variability between strains 
 
Using the multiple QTL models it was possible to determine the proportion of observed 
variance that could be attributed to the multiple QTL models, and by inference the proportion 
that is ‘unexplained’ and likely to be due to environmental variation. The heritability of the trait 
can therefore be approximated. Multiple QTL modelling was able to explain a greater degree 
of variance than single-QTL analysis as shown by the incremental improvement in heritability 
and variance with each additional locus added to the model, and incremental decline in 
inferred environmental variation (Figure 2.8). However, the multiple-QTL models were 
unable to explain all the observed variation. The mean heritability for the models was 0.16, 
with the ‘best-fit’ outliers explaining no more than 0.5 of total variation.  
 
 83 
 
Figure 2.8	  Diagnostic plots of multiple-QTL models 
(A) and (B) show the effect of environmental variation (envvar) on the trait of ALT at 24 hours 
after paracetamol. The box plot (B) shows the diminishing apparent effect of environmental 
variability with the addition of more QTL to the model.  (C) and (D) show the variation (var) 
explained by the multiple-loci model, the mean of which increases as a greater number of 
loci are added to the model.  (E) and (F) show the overall heritability (herit) of the trait as a 
proportion of the total variance within the population. 
 
2.4.8 Candidate gene identification 
Quantitative trait locus mapping identified four loci that contribute to the variance in response 
to paracetamol, as defined by plasma ALT 24 hours after a hepatotoxic dose. The loci on 
chromosomes 17 and 18 had significant independent effects and those on chromosomes 3 
and 5 had an epistatic effect. The locus on chromosome 18 also appeared to contribute to 
the correlated trait of glucose level following paracetamol hepatotoxicity. A further locus on 
chromosome 2 contributes to variance in plasma bilirubin following paracetamol toxicity. 
Candidate genes within these loci were identified using the NCBI map viewer (annotation 
104) database. 
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Chromosome 18 
Within the region 43-52cM (approximately equivalent to 43-52Mbp) that contained the peak 
LOD score of 3.30 (p=0.01), there were 96 genes listed on the NCBI database (table G 
appendix). These included a number of uncharaceterised genes, pseudogenes and putative 
genes identified by RIKEN cDNA sequencing. Once these were removed, 30 characterised 
genes remained. Genes contained within the flanking 2Mb region were also considered, as 
this region also had a significant LOD score and with a low density of markers on the 
chromosome, localisation of the QTL may not have been precise. In total this gave a 
candidate gene list of 46 genes (table 2.6). 
The Mouse Genome Informatics (http://www.informatics.jax.org) database was used to 
search for SNP variation between the strains used in the backcross. Only two of the listed 
candidate genes contained heterologous coding-non-synonymous SNPs that would affect 
amino acid sequence and possibly protein structure. These genes were Commd10 ‘COMM 
domain containing 10’ and Gykl1 ‘glycerol kinase-like 1’. 
The heterologous SNP within the Commd10 gene is a thymine to cytosine substitution, which 
leads to an ATG to ACG mRNA sequence change and substitution of methionine for 
threonine at position 98 in the amino acid sequence (see appendix H for full amino acid 
sequence).  The paracetamol resistant C57BL/6 mice have the wild type SNP variant, with 
methionine in the protein amino acid sequence, and sensitive C3H mice have the 
polymorphic variant that results in a threonine substitution in the amino acid sequence. 
Protein structure predictions suggest that in the usual variant the methionine at position 98 is 
the last amino acid in a 10 amino-acid helical segment of the protein. Substitution of this 
methionine for threonine does not cause a local change in secondary protein structure, with 
the helical segment preserved. However, protein prediction software suggests that this 
substitution leads to down stream effects, with an additional protein binding domain at 
position 127 and polynucleotide binding region at position 147 being created in the variant 
protein (Appendix I). 
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Within the gene Gykl1 the heterologous SNP is a missense mutation, caused by a guanine to 
cytosine substitution that effects position 52 in the transcribed mRNA and alters a codon 
from GAG to GAC. This leads to an alteration in amino acid sequence with glutamate being 
replaced by aspartate at position 3 in the protein.  Structural predictions suggest the Gykl1 
protein has a protein binding domain composed of the first 6 amino acids and thus this amino 
acid substitution would be within this binding region. The substitution of glutamate with 
aspartate is predicted to cause a slight change in protein secondary structure, with a 
reduction in the helical content and produces a new protein binding domain at position 244. 
A number of other genes contained SNPs within the locus region, that is the un-transcribed 
region of 2Kb at the 5’ end of the gene or 0.5Kb at the 3’ end of the gene, which tend to 
contain regulatory elements that might effect gene transcription. Genes with heterologous 
SNPs in their locus regions were; Stk32a, (serine/threonine kinase 32A), Spink3 (serine 
peptidase inhibitor, Kazal type 3), Spink5 (serine peptidase inhibitor, Kazal type 5) and Dcp2,  
(DCP2 decapping enzyme homolog (S. cerevisiae)). 
Other genes within this region that were thought to be of potential mechanistic relevance to 
paracetamol toxicity include, members of the Spink family, Ticam2, toll-like receptor adapter 
molecule 2, Tnfaip8, tumour necrosis factor, alpha-induce protein 8 and Ftmt, ferritin 
mitochondrial.  
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 Symbol Gene Name 
 
Heterologous SNP 
Q
TL
 s
ig
ni
fic
an
ce
 p
=0
.0
5 
Prelid2 PRELI domain containing 2  
Grxcr2 glutaredoxin, cysteine rich 2  
Sh3rf2 SH3 domain containing ring finger 2  
Plac8l1 PLAC8-like 1  
Lars leucyl-tRNA synthetase  
Rbm27 RNA binding motif protein 27  
Pou4f3 POU domain, class 4, transcription factor 3  
Tcerg1 transcription elongation regulator 1 (CA150)  
Gpr151 G protein-coupled receptor 151  
42
-5
3M
bp
 Q
TL
 s
ig
ni
fic
an
ce
 p
=0
.0
1 
 
Ppp2r2b protein phosphatase 2, regulatory subunit B, beta  
Stk32a serine/threonine kinase 32A Locus region 
Dpysl3 dihydropyrimidinase-like 3  
Spink3 serine peptidase inhibitor, Kazal type 3 Locus region 
Scgb3a2 secretoglobin, family 3A, member 2  
Spink5 serine peptidase inhibitor, Kazal type 5 Locus region 
Spink12 serine peptidase inhibitor, Kazal type 12  
Spinkl serine protease inhibitor, Kazal type-like  
Npy6r neuropeptide Y receptor Y6  
Myot Myotilin  
Dcp2 DCP2 decapping enzyme homolog (S. cerevisiae) Locus region 
Mcc mutated in colorectal cancers  
Kcnn2 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 
 
Trim36 tripartite motif-containing 36  
Pggt1b protein geranylgeranyltransferase type I, beta subunit  
Ccdc112 coiled-coil domain containing 112  
Fem1c fem-1 homolog c (C.elegans)  
 87 
Ticam2 toll-like receptor adaptor molecule 2  
Tmed7 transmembrane emp24 protein transport domain containing 7  
Eif1a eukaryotic translation initiation factor 1A  
Cdo1 cysteine dioxygenase 1, cytosolic  
Atg12 autophagy related 12  
Ap3s1 adaptor-related protein complex 3, sigma 1 subunit  
Commd10 COMM domain containing 10 Coding-non-synon 
Sema6a sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A 
 
Dtwd2 DTW domain containing 2  
Dmxl1 Dmx-like 1  
Tnfaip8 tumor necrosis factor, alpha-induced protein 8  
Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4  
Fam170a family with sequence similarity 170, member A  
Q
TL
 s
ig
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fic
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 p
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.0
5 
Ftmt ferritin mitochondrial  
Srfbp1 serum response factor binding protein 1  
Lox lysyl oxidase  
Zfp474 zinc finger protein 474  
Gykl1 glycerol kinase-like 1 Coding-non-synon 
Sncaip synuclein, alpha interacting protein (synphilin)  
Zfp608 zinc finger protein 608  
 
Table 2.6 Summary of candidate genes on chromosome 18.  
Genes were identified within the region with a high likelihood of containing a QTL, 43-52Mb 
(LOD significant to p=0.01) and 2Mb either side. Heterologous, coding-non-synonymous 
SNPs and heterologous non-coding, locus region SNPs are highlighted. Gene symbols for 
genes with a potential functional significance in paracetamol induced liver injury are shown in 
bold.  
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Chromosome 17 
A significant QTL was identified on chromosome 17 in a region between 42-55cM, which 
approximately corresponds to 42-55Mbp. A search of the NCBI gene database revealed 181 
genes in this region (see appendix J for full table). When limited to characterised genes only, 
the list of candidate genes was reduced in number to 88.  
Two genes within the region of interest contained coding non-synonymous SNPs. 
Translocator protein 2 (Tspo2) contains a SNP, which codes for a missense mutation 
resulting in an mRNA codon change from GCC to ACC, leading to an amino acid sequence 
change from alanine to threonine at position 146 in the protein. The gene for shugoshin-like 1 
(S. pombe) (Sgol1) contains two coding non-synonymous SNPs. The first is a missense SNP 
that results in a codon change from TCA to CCA in mRNA, which causes the substitution of 
serine for proline in the amino acid sequence of the protein.  The second SNP is a produces 
a variant codon, changing from GCT to TCT and therefore an amino acid substitution of 
alanine to serine. 
A number of other genes within the QTL region had SNPs within their locus region, which 
could influence gene expression (table 2.7) and thus have an effect on protein function.  The 
gene for CYP39a1, one of the cytochrome P450 family of enzymes, is also contained within 
this region, as are a number of inflammatory genes. 
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Symbol Gene Name 
 
Heterologous SNP 
Gpr111 G protein-coupled receptor 111 Locus-region (2) 
Cd2ap CD2-associated protein Locus-region (7) 
Tnfrsf21 tumor necrosis factor receptor superfamily, member 21 Locus-region (3) 
Mep1a meprin 1 alpha Locus-region (2) 
Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1  
Rcan2 regulator of calcineurin 2 Locus-region (1) 
Enpp5 ectonucleotide pyrophosphatase/phosphodiesterase 5 Locus region (2) 
Hsp90ab1 heat shock protein 90 alpha (cytosolic), class B   
Vegfa vascular endothelial growth factor A Locus-region(2) 
Ccnd3 cyclin D3 Locus-region (1) 
Nfya nuclear transcription factor-Y alpha Locus-region(1) 
Apobec2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2 
Locus-region (4) 
Tspo2 translocator protein 2 Coding-non-synonymous 
Unc5cl unc-5 homolog C (C. elegans)-like Locus-region (1) 
Mocs1 molybdenum cofactor synthesis 1 Locus-region (2) 
Pp2d1 protein phosphatase 2C-like domain containing 1 Locus-region (1) 
Sgol1 shugoshin-like 1 (S. pombe) 
Locus-region (4) 
Coding-non-synonymous (2) 
Sult1c2 sulfotransferase family, cytosolic, 1C, member 2 Locus-region (2) 
Sult1c1 sulfotransferase family, cytosolic, 1C, member 1  
 
Table 2.7 Summary of candidate genes on chromosome 17.  
Genes were identified within the region with a high likelihood of containing a QTL, 42-55Mb 
(LOD significant to p=0.05). Heterologous, coding-non-synonymous SNPs and heterologous 
non-coding, locus region SNPs are highlighted. The numbers in brackets refer to the number 
of heterologous SNPs per gene, as some contained more than one. Gene symbols for genes 
with a potential functional significance in paracetamol induced liver injury are shown in bold. 
Only those genes with a potential significance or that contain heterologous SNPs are shown 
in the interests of space. For full list see Appendix I 
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Chromosomes 3 and 5 
On chromosome 5 the QTL identified to have epistatic effects was localised around the first 
SNP marker on that chromosome, positioned at 21Mb. Candidate genes 10Mb either side of 
the marker were considered (see appendix J for full table). Three characterised genes within 
this region contain heterologous coding non-synonymous SNP. These are reelin (Reln), 
lysine (K)-specific methyltransferase 2C (Kmt2c) and dipeptidylpeptidase 6 (Dpp6).  A further 
5 genes contained heterologous locus region SNPs. Within this region genes of potential 
mechanistic significance or interest in paracetamol hepatotoxicity include hepatocyte growth 
factor (Hgf) and Interleukin-6 (IL-6).  
The region on chromosome 3 identified by mapping to contain a locus that interacts with a 
gene on chromosome 5, was located between the markers at 43cM and 110cM, with peak at 
approximately 58cM (approximates to 58Mb). Genes between 43 and 73Mb were considered 
(see appendix K for full table). Two genes within this region contained heterologous coding-
non-synonymous SNPs: protocadherin 18 (Pcdh18) and sucrase isomaltase (alpha-
glucosidase) (Sis).  A further 11 genes have heterologous SNPs within their locus region. 
This region also contains the gene for Interleukin-12a (Il-12a) 
 
Chromosome 2 
A locus on chromosome 2 between SNP markers at 20 and 43cM (peak at 28cM) was found 
by mapping to contribute to elevated bilirubin following paracetamol toxicity. The region 
between 20cM and 40cM was searched for potential candidate genes and for heterology 
between strains (table, Appendix L). This chromosomal region shows a high degree of 
homology between the C57Bl/6 and C3H strains. Only one gene contains a coding non-
synonymous SNP; zinc finger and BTB domain containing 6 (Zbtb6). A further heterologous 
SNP lies in the locus region of two genes at approximately 38cM, these are proteasome 
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(prosome, macropain) subunit, beta type 7 (Psmb7) and zinc finger and BTB domain 
containing 6 (Nek6). 
No obvious candidate genes involved in bilirubin metabolism and transport were identified. 
However a number of genes that might contribute to the inflammatory response to injury are 
contained within this region, including heat shock protein 5 (Hspa5), TNF receptor associated 
factor 1 (Tnfraf1) and two prostaglandin E synthetase genes (Ptges and Ptges2). 
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2.6 Discussion 
Paracetamol-induced liver injury is a classic quantitative trait, in which variation in the 
response of individuals is due to the combined influence of multiple genes and their 
interaction with non-genetic, environmental factors. This QTL mapping experiment aimed to 
identify chromosomal loci and therefore genes, that contribute to the observed variability in 
paracetamol induced liver injury between inbred strains of mice. By crossing a relatively 
resistant and relatively sensitive strain of mice, phenotyping their backcrossed offspring and 
performing genotyping and mapping, we were able to identify two novel loci that contribute to 
the development of liver injury in paracetamol overdose. With the aid of Bayesian mapping 
techniques a more complex, multi-QTL model was produced which identified further loci on 
chromosomes 3 and 5, which have an epistatic effect and also contribute to variability. A 
number of putative candidate genes have been identified at each of these loci. Analysis was 
also able to demonstrate a significant degree of variance unexplained by the genetic model 
and hence hinted that environmental factors might contribute to the development of 
paracetamol-induced liver injury, even in a controlled experimental situation. 
The most significant QTL identified by this mapping experiment was one on chromosome 18 
between 43-52cM (or Mbp), which exceeded a significance threshold of p=0.01. Within this 
region lies the Commd10 gene that encodes COMM domain containing 10 protein. The two 
murine strains used in this backcross experiment have a heterologous coding SNP within the 
gene, which leads to alteration in amino acid sequence and a conformational change in the 
protein.  
Commd10 is a member of the COMM (Copper Metabolism gene MURR1) domain containing 
family of proteins that is composed of ten members, COMMD1 to COMMD10. The ten 
Commd genes are highly conserved in multi-cellular eukaryotic organisms, suggesting non-
redundant roles for each protein (Burstein et al., 2005). Each COMMD protein is formed from 
a conserved carboxyl terminal COMM domain and an N-terminal region that shows no 
homology between COMMD family members, but is well conserved across species. 
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Knockout of Commd1, 6, 9 and 10 in mice is embryonic lethal, with different lethal 
phenotypes displayed by each knockout, again suggesting non-redundant roles for each 
gene product (Bartuzi et al., 2013). The family have affinity for NFκB subunits and have been 
shown to inhibit transcription of pro-inflammatory genes through binding to promoter sites 
and influencing the duration of NFκB binding. Each member of the COMMD family has a 
different pattern of association with NFκB subunits, with COMMD10 showing affinity for RelA, 
RelB and NF-κB1/p105 (Burstein et al., 2005).   
A recent genome wide association study (GWAS) in patients with COPD and asthma found a 
significant association between polymorphisms in the human Commd10 gene locus and 
inflammatory airway disease (Smolonska et al., 2014). COMMD10 has also been implicated 
in variation in the anti-inflammatory effects of fenofibrate therapy in human populations 
(Aslibekyan et al., 2012). COMMD10 is known to be expressed in the liver at steady state but 
no research is available regarding its role in hepatic inflammation. Given the known role of 
NFκB mediated pro-inflammatory cytokine release in the pathogenesis of liver injury after 
paracetamol overdose, the Commd10 gene is a promising candidate within the chromosome 
18 locus. 
The gene Gylk1 is found just adjacent to the peak LOD region on chromosome 18. Gylk1 
also contains a polymorphism between the murine strains used in mapping, which is 
predicted to influence protein structure. This gene encodes an enzyme, glycerol-kinase, 
which is involved in phosphorylation of glycerol as the first step in its metabolism (Pan et al., 
1999). There is no obvious mechanistic significance of this gene to the development of liver 
injury in paracetamol-toxicity and it therefore presents as a poor candidate. 
The QTL on chromosome 18 contains a number of members of the Spink family (serine 
peptidase inhibitor, Kazal type), including two that contain heterologous SNPs within their 
locus region, Spink3 and Spink5. These genes encode serine protease inhibitors that have 
roles in pancreatitis and autophagy. Spink 3 is an inhibitor of pancreatic trypsin, kallikreins 
and when knocked out in mouse models, leads to pancreatic cell death and inflammation 
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(Assis et al., 2013) (Ohmuraya et al., 2012). The human form of Spink5 is mutated in 
Netherton syndrome, a rare inherited disorder characterised by defective keratinisation, 
dermatitis and susceptibility to infection (Chavanas et al., 2000). 
One of the limitations of this study is the use of SNP database information on a closely 
related, but not identical inbred strain to identify heterology and potential candidate genes. 
The C3H/HeH strain used in the phenotyping experiment will have diverged genetically from 
the C3H/HeJ strain used for the in silico assessment of heterology. It is therefore possible 
that within the locus on chromosome 18 there are further coding non-synonymous SNPs that 
are heterologous between our mated strains, but not detected by the database search. It is 
with this in mind that all genes within the locus were considered as potential candidates.   
On chromosome 18 the gene Tnfaip8 is located within the region of interest. This gene 
encodes a protein product that has roles in inflammation, apoptosis and carcinogenesis. 
Interestingly, the Tnfaip8 locus has been identified by a murine QTL mapping study to be 
associated with susceptibility to Staphylococcus aureus infection (Ahn et al., 2010). This 
study used the strains A/J and C57BL/6 with differential infection susceptibility. Mechanistic 
studies on the Tnfaip8 gene were conducted and suggested knockdown of the gene product 
in macrophages leads to an attenuated IL-1β and GM-CSF response (Ahn et al., 2010). The 
product of this gene may therefore be significant in paracetamol-induced acute liver failure, 
which is mediated in part by macrophage signalling and pro-inflammatory cytokine 
production. 
The gene Ticam2 (toll-like receptor adaptor molecule 2) is found within the QTL on 
chromosome 18. The protein product of this gene is an adapter molecule that is recruited by 
and binds directly to the intracellular domain of the TLR4 receptor (Seya et al., 2005). It acts 
as a bridge to recruit TICAM1 and facilitate downstream MyD88-independent signalling 
through interferon regulatory factor 3 (IRF3) to enhance the expression of interferon inducible 
genes (Enokizono et al., 2013). This important role in TLR4 signalling raises the possibility 
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that this gene could be involved in susceptibility to paracetamol-induced liver injury, perhaps 
through its effect on HMGB1 signalling via TLR4. 
The mapping experiment also identified a QTL on chromosome 17 that is significantly 
(p<0.05) associated with ALT 24 hours after paracetamol. The two genes in this region that 
contain heterologous, coding non-synonymous SNPs are Sgol1 (shugoshin-like 1) and 
Tspo2 (translocator protein 2). Sgol1 encodes a shugoshin like protein that may have a role 
in chromatin structure and chromosomal separation during meiosis and mitosis (Gutierrez-
Caballero et al., 2012). Tspo2 has a role in cholesterol biosynthesis. Neither of these genes 
would appear to be mechanistically directly relevant to paracetamol toxicity.   
Within the same locus is the gene Vegfa that encodes vascular endothelial growth factor. 
This growth factor is known to be upregulated within 8 hours of administration of a 
hepatotoxic dose of paracetamol and acts to promote hepatocyte regeneration following liver 
injury (Donahower et al., 2006). However studies have shown that inhibition of VEGF does 
not affect paracetamol hepatotoxicity at 24 hours after injury, but has an influence of the 
speed of hepatocyte division and regeneration in the later stages. It is therefore is unlikely 
that Vegfa is the gene responsible for the difference in 24-hour ALT values between the 
inbred strains of mice that were investigated.  
The chromosome 17 QTL also contains the gene for a member of the CYP450 family, 
Cyp39a1. This CYP450 enzyme is responsible for cholesterol synthesis from bile acids and 
is not an enzyme that is involved in paracetamol metabolism (Lorbek et al., 2012). Similarly, 
the sulfotransferase gene (Sult1c2) that is within the locus encodes a family member that has 
very low hepatic expression in adult mice (Alnouti and Klaassen, 2006). 
The loci identified on chromosomes 3 and 5 had weak effects as single QTL, but were 
significant when considered in complex model that took account of epistatic interactions 
between genes. The loci identified were large and candidate gene identification was difficult, 
particularly considering the gene-gene interaction that was implied by the modeling. Two 
members of the interleukin gene family were found, with Il-6 being present in the QTL on 
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chromosome 5 and Il-12a on chromosome 3. The presence of the hepatocyte growth factor 
gene Hgf within the chromosome 5 QTL is also of potential interest as the protein HGF has 
been demonstrated to protect against paracetamol induced liver injury in a rat model 
(Masunaga et al., 1998). 
Despite the success of this experimental strategy in identifying a number of loci that 
associate with paracetamol susceptibility, this approach has a number of limitations. QTL 
mapping lacks specificity and resolution, being unable to localise a single gene and requiring 
follow up work to identify candidate genes and prove causation. The genotyping of the mice 
in this project was done on a relatively coarse map of just 92 markers across 19 
chromosomes, limited by the genotyping costs at the time the experiment was conducted. 
This may have affected the resolution of mapping somewhat. However the main limitation on 
mapping resolution is the number of recombination events in and around the locus of 
interest, which directly correlates with the number of meiosis, or animals used in the 
experiment. Further markers on chromosome 18 would have been unlikely to narrow the 
locus further without a significant increase in the number of mice. 
One of the techniques that may be used to narrow down a QTL, is the breeding of congenics 
in which small regions of the locus of interest are isolated on the background of another 
inbred strain by sequential breeding and selection methods. This is only possible if the effect 
size of the QTL is sufficient that its influence on the phenotype will still be apparent despite 
the breeding out of other contributing loci. The ongoing identification of a small to medium 
effect size gene in the breeding of congenics also relies on low ‘background noise’ or inter-
individual variation in the phenotype of interest. Due to the modest effect size of the locus on 
chromosome 18, particularly when considered within the multiple QTL model, and the high 
variability between individuals it was decided not to attempt to fine map the chromosome 18 
QTL by the breeding of congenic strains. 
Interestingly Bayesian modeling demonstrated a significant impact of environmental 
variation, even in this tightly controlled experimental population. Experimental animals are 
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subject to little of the environmental variability of humans. The finding of unexplained 
variability in this population in which individuals were housed in identical conditions was 
intriguing and forms the basis for experimental work in chapters 3 and 4 of this thesis. 
In conclusion, this QTL mapping experiment has identified a novel locus on chromosome 18 
associated with susceptibility to paracetamol-induced liver injury in a mouse model. The QTL 
was robust to various mapping methodologies and affected the two correlated traits of ALT 
and glucose concentrations 24 hours after paracetamol. Further QTL modeling identified 
small effect size loci on chromosomes 17, 3 and 5 and a locus on chromosome 2 that 
contributed to hyperbilirubinaemia. Fine mapping was not undertaken but a number of 
potential candidate genes, which have mechanistic relevance to paracetamol toxicity and 
may warrant further investigation, were identified within these loci. 
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3 VARIABILITY IN MURINE MODELS OF PARACETAMOL-
INDUCED LIVER INJURY 
 
3.1 Background and aims 
3.1.1 Variation and reproducibility in research using inbred mouse strains 
Mouse models of human diseases are widely used in biomedical science to provide an 
experimental system in which to investigate pathogenesis and potential therapeutics. Inbred 
mouse strains were developed to provide a reliable and controlled supply of genetically 
identical animals for these purposes (Paigen, 2003). One of the underlying assumptions 
when working with inbred strains is that each mouse is an identical and therefore replaceable 
and reproducible experimental unit. Yet this assumption is continually challenged by the 
demonstration of heterogeneity within strains in both baseline characteristics such as body 
weight, and in their response to experimental manipulation (Wong et al., 2005). 
In recent years there has been an increasing recognition of the effects that very subtle 
environmental changes can have on laboratory animals and how this may lead to variability 
in experimental data. A recent study in the journal Nature Methods demonstrated that mice 
exposed to male researchers, or olfactory stimuli from men, behaved differently in 
experimental testing due to increased stress (Sorge et al., 2014). Mice may therefore react 
differently to a standardised experimental situation depending on the presence and proximity 
of male researchers. Physiological differences have also been described in genetically 
identical mice, attributable to the effects of competition for nutrition in the post-natal period, in 
the ‘crowded litter’ model (Sadagurski et al., 2014). Mice adopted into a crowded litter 
demonstrate long-term metabolic alterations compared with ‘non-crowded’ controls, including 
increased insulin sensitivity and decreased fat mass. Slight changes to the home caging of 
experimental mice has also been linked to variation in stress responses. The provision of 
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nesting material and husbandry practices such as the transfer of bedding during cage 
cleaning can effect urine cortisol concentrations, thymic weight and food and water 
consumption, which are all indicators of stress (Van Loo et al., 2004). 
It is perhaps these subtle variations in environment that underlie inter-laboratory variability 
and difficulty in replicating results achieved in one centre in a different location, despite 
adherence to the same experimental protocols. A paper in Science in 1999, described a 
study that aimed to rigorously standardise six behavioural testing protocols in mice between 
three laboratories, yet ultimately found systematic differences in the results from each 
laboratory (Crabbe et al., 1999). 
In addition to inter-laboratory variation, is also recognised that genetically identical mice 
housed together in the same laboratory vary in phenotype. Body weight is an example of a 
trait that can show differences between individuals from the same strain despite genetic 
homology and equal access to nutrition in the post-weaning period. It is well known that 
inbred strains of mice housed together will develop social hierarchies with some mice taking 
a dominant role and others a submissive role. Differential displays of behaviour that reinforce 
this hierarchy, such as barbering (excessive grooming of a cage mate’s fur, particularly 
around the face) also demonstrates that mice are not phenotypically identical (Kalueff et al., 
2006). Recent research has demonstrated the presence in inbred mice, of non-random 
behavioural correlations that are consistent across time and context (Lewejohann et al., 
2011). The authors of this study described these behavioural patterns as ‘personalities’ and 
hypothesised that these may underlie some of the inter-individual variability in animal studies 
that deified attempts at standardisation (Lewejohann et al., 2011).  
These observations would tend to suggest that rigorous standardisation of environment is the 
key to reducing variability in animal studies and improving research reproducibility. However, 
there is a movement to suggest that very tight environmental standardisation may lead to the 
production of spurious ‘false positive’ results that lack external validity. It is argued that 
heterogenisation of environment may make findings more robust and reproducible by 
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increasing within experiment variation relative to between-experiment variation (Richter et al., 
2009, Richter et al., 2011). There is clearly a tension between the drive for standardisation to 
remove confounding inter-individual variability and a move to deliberately introduce 
heterogeneity to ensure the external validity of results. 
Much of the work described above, on inter-individual and inter-laboratory variability has 
been conducted in the field of animal behaviour and neuroscience. It might be predicted that 
these responses, judged by behavioural endpoints, would be particularly sensitive to 
changes in environment and the effect of external stressors. Drug toxicity, with ‘hard’ 
biochemical and histological endpoints might be considered to be more resistant to these 
influences. However, there is substantial evidence that inter-individual variation exists in 
murine models of paracetamol toxicity. 
A study by Beyer et al, published in 2007, used the model of paracetamol toxicity to 
investigate the reproducibility of micro-array studies between laboratories.  They 
demonstrated marked differences in toxicity outcomes between their seven participating 
laboratories despite central distribution of animals, bedding and preparations, adherence to 
strict standardised experimental protocols and measurement of endpoints at a centralised 
location. In addition to the inter-laboratory variability, the authors commented ‘Despite our 
best efforts to standardize the study, a considerable degree of animal-to-animal variability in 
the extent of liver injury was observed’ (Beyer et al., 2007). 
Raw data from the supplements of this study and from the Threadgill group, published on the 
Mouse Phenome Database, reveal marked variation in response to paracetamol between 
mice from the same strain, in terms of plasma biochemistry and histologically assessed liver 
necrosis (The Jackson Laboratory, 2014, Beyer et al., 2007). These observations support my 
finding from the QTL mapping experiment (chapter 2) that unexplained, ‘non-genetic’ 
variability contributes to differential susceptibility to paracetamol hepatotoxicity. 
It is possible that the same factors that explain variation in genetically identical mice could 
influence differential susceptibility in the genetically diverse human population. Indeed a 
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recent commentary on the differing susceptibility to infection within inbred mice, suggested 
this paradigm might serve as a ‘powerful tool for biomarker discovery’ (Martin et al., 2012). 
Thorough investigation of the intriguing variation seen in genetically identical mice within a 
tightly controlled environment could potentially yield novel insights into human disease.  
 
3.1.2 The principles of metabonomics 
Metabonomics is a relatively new approach to studying biological systems and has been 
defined as ‘the quantitative measurement of the time-related, multi-parametric metabolic 
response of living systems to pathophysiological stimuli or genetic modification’ (Nicholson et 
al., 2002). In this approach, the whole metabolic profile of a tissue or biofluid is assessed and 
compared in different states of health and disease or with respect to various experimental 
manipulations. These snapshots of metabolism under different conditions may reveal 
underlying patterns and pathways involved in disease pathogenesis, yielding important 
insights and potential biomarkers of susceptibility or progression. 
Proton nuclear magnetic resonance spectroscopy (1H-NMR) is frequently the methodology of 
choice in metabonomic studies. It has the advantage over alternative technologies, such as 
mass spectroscopy, of simultaneous measurement of all metabolites within a sample without 
the need for sample separation. It is therefore relatively straightforward to prepare samples 
for 1H-NMR analysis and the sample is not destroyed or degraded by the analysis process. 
NMR spectroscopy is based on the physical property of nuclei with an odd number of protons 
(including 1H), of intrinsic magnetic moment (non-zero spin). Following polarisation in a 
constant magnetic field, if a perpendicular electromagnetic field is applied at the correct 
(resonant) frequency, energy will be absorbed by the nuclei. This energy is then emitted 
during relaxation back to a thermodynamic state and the emission can be detected and 
measured. The precise magnetic resonant frequency of each 1H in a molecule depends on 
its position within the molecule and degree of shielding it receives from nearby electrons. 
Thus the degree of ‘chemical shift’ of the NMR frequency - the exact absorbed and emitted 
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frequencies - can provide information on chemical structure of compounds within a mixture. 
One-dimensional 1H-NMR spectroscopy data is viewed as a spectrum with NMR resonant 
frequency (corrected for spectrometer frequency and expressed as parts per million (ppm)) 
displayed against NMR absorption intensity. 
The complex data generated by simultaneous measurement of multiple metabolites in a fluid 
or tissue requires the application of specific statistical techniques. Multivariate statistical 
techniques such as principal components analysis (PCA) and partial-least squares method 
by projections to latent structures (PLS) are widely applied to metabonomic data sets to 
derive meaningful comparisons from the abundant data (Trygg et al., 2007). Principle 
components analysis is an unsupervised technique in which data is orthogonally transformed 
into a set of linearly unrelated ‘components’. The first principal component is that which 
describes the greatest degree of variance in the original data. Subsequent components that 
explain as much variance as possible are added to the model under the constraint that they 
are orthogonal to the existing components. Thus variance in complex data can be described 
and visualized by a few orthogonal components and allow outlying individuals and clustering 
in experimental groups to be identified. PLS-DA and OPLS-DA are extensions of the PCA 
technique, in which experimental groups are defined (supervision of data) and models are 
constructed to identify the variables that carry the class-separating information. Once a 
model has been constructed, its predictive validity can be tested by cross validation (Trygg et 
al., 2007). 
Together these techniques, when applied to complex metabonomic data can identify whether 
there is significant variation in metabolite profiles between classes and whether the 
distinction between classes is robust enough to be able to predict class membership. It also 
enables details of the individual metabolites, which most discriminate between classes, to be 
extracted. 
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3.1.3 Pharmaco-metabonomics and the prediction of drug responses 
Pharmaco-metabonomics specifically refers to the application of a metabonomic approach to 
the prediction of an individual’s response to drugs. The term was first defined in a paper in 
Nature in 2006 as “the prediction of the outcome of a drug or xenobiotic intervention in a 
individual based on a mathematical model of pre-intervention metabolic signatures” (Clayton 
et al., 2006). This same paper used a rodent model of paracetamol hepatotoxicity to 
demonstrate the principles of pharmacometabonomics. Rats were given a single, sub-
clinically toxic dose of paracetamol and their response was assessed by liver histology after 
24 hours. As in murine models, a variation in response was seen despite isogenic animals 
being utilised. The authors then examined pre-dose urine specimens to determine whether 
the response to paracetamol could be predicted. Though no fully validated model could be 
constructed there was evidence of separation on PCA of baseline urine specimens between 
the extreme high and low responders. The metabolite taurine was identified to be present in 
higher concentration in the urine of the less susceptible animals and trimethylamine-N-oxide 
(TMAO) and betaine was more abundant in the susceptible rats. 
In a human study of healthy volunteers given standard dose paracetamol, pre-dose urinary 
metabolic profiles could not predict those individuals who would go on to develop evidence of 
hepatotoxicity as defined by transient elevations in ALT (Winnike et al., 2010). Post-dosing 
the urinary metabolic profiles of volunteers diverged depending on their response to 
paracetamol, though these changes are likely to be reflective of actual hepatotoxicity, rather 
than a metabolic state predicting susceptibility such as is sought by a true 
pharmacometabolic approach. In a different study on healthy volunteers, the ratio of post-
dose urinary paracetamol metabolites could be predicted by predose concentrations of a 
bacterially derived metabolite (Clayton et al., 2009). This study is considered in greater detail 
in chapter 4. 
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3.1.4 Hypothesis and Aims 
My previous work and that of other groups had suggested a large non-genetic contribution to 
inter-individual variability in susceptibility to paracetamol in inbred strains of mice. It was 
hypothesised that a number of environmental factors might influence susceptibility to 
paracetamol hepatotoxicity in murine models, including dosing error, litter size, body weight 
as a surrogate of nutritional status and stress. It was hypothesised that these factors would 
lead to metabolic changes that would predict susceptibility to paracetamol and be detectable 
by a pharmacometabonomic approach. The aims of this chapter were therefore to: 
 
1. Characterise the variation in susceptibility between and within inbred strains of 
mice 
2.  Identify factors that contribute to variation between genetically identical mice. 
3. Use metabolic profiling of baseline urine samples to identify metabolic patterns 
that predicted later susceptibility to paracetamol. 
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3.2  Materials and methods 
3.2.1 Animals 
Mice were maintained at MRC Harwell under standard conditions as described in chapter 2 
(section 2.2.1).  
Ten male individuals, eight to twelve weeks in age, from ten inbred strains of mice were 
used. Those from strains A/J, DBA/2M (DBA), BALB/cJ (BALBc), C57BL/6 (BL6), C3H/HeH 
(C3H/H), C3H/HeJ (C3H/J) and C57BL/10 (BL10) were derived from colonies maintained at 
MRC Harwell. The three other strains LP/J, SM/J and CBA/J (CBA), were purchased from 
Charles River (Charles River, France) and allowed a week to acclimatise prior to 
experimental work. An additional group of 10 male C3H/HeH mice were used to provide 
greater numbers for urinary metabolic profiling. 
 
3.2.2 Paracetamol dosing 
Mice were fasted overnight for 14 hours to uniformly deplete hepatic glutathione 
concentrations. Prior to dosing, mice were weighed. A 200mg/Kg dose of paracetamol 
dissolved in warmed saline (50°C) was administered via the intraperitoneal route. All mice 
were dosed between 8.30-9.30am to prevent confounding due to diurnal variations. Food 
was returned 2 hours after paracetamol administration. Mice were monitored carefully for 
health throughout the experimental procedure and any individuals seen to meet pre-
determined welfare endpoints were humanely culled. 
 
3.2.3 Sample collection 
On the morning before paracetamol dosing an unfasted baseline blood sample was taken 
from the lateral tail vein. Further blood sampling was conducted at 30 minutes post-dosing 
(fasted). Eight hours after the paracetamol was administered, mice were placed under 
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terminal anaesthesia with pentobarbital and an intracardiac blood sample collected. Plasma 
collection from whole blood as performed as per section 2.2.4. 
A necropsy was performed, during which each mouse was weighed and the liver weight was 
recorded. Livers were split, with half being fixed in formalin and the other half snap frozen in 
liquid nitrogen and stored at -80°C. 
Urine samples were collected via clean catch into a sterile eppendorf 24 hours prior to dosing 
(T-24, unfasted) at baseline, just prior to dosing (T0, fasted) and at 4 hours (T4) and 8 hours 
(T8) after paracetamol administration. On each occasion urine was kept at 4°C for no longer 
than 1 hour before being stored at -80°C until analysed. 
Technical assistance with dosing and sample collection was provided by members of 
the Liver Group at MRC Harwell. 
 
3.2.4 Biochemistry 
Biochemistry analysis was performed as per section 2.2.4 
 
3.2.5 Qualitative analysis of parental and early life characteristics 
The MRC Harwell breeding and animal husbandry database (AnonyMus) was searched for 
early life and parental factors for the home bred animals. Maternal age, paternal age, 
duration of mating partnership, number of previous litters from mating, litter size, presence of 
perinatal mortality among littermates, age at weaning and number in the cage were recorded 
and compared with outcomes.  
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3.2.6 Urine preparation for metabolic profiling 
Due to the collection methodology, many of the available urine specimens were of a low 
volume. A capillary tube system was therefore employed. Before use, validation experiments 
were conducted to compare spectral quality from the capillary with that from a standard NMR 
tube and to test stability of the sample in the capillary over time. To prepare samples, urine 
was removed from storage and thawed at room temperature then centrifuged at 8,000 rpm 
for 2 minutes to sediment any debris.  A urine volume of 10µl from each sample was mixed 
with 20µl sterile water and 30µl of 0.2M phosphate buffer. The phosphate buffer (pH7.4) was 
prepared with 0.2M Na2HPO4, 0.043M NaH2PO4, 3mM NaN3, and a mixture of 80% H2O with 
20% D2O to provide an NMR field frequency lock. The addition of 0.5mM Trimethylsilyl-
propionic acid (TSP) served as an internal chemical shift reference.  The urinary solution was 
transferred to a 1.7mm OD capillary tube, capped by a Teflon adapter and placed within a 
5mm micro NMR sample tube (New Era, Vineland, New Jersey, USA). For samples included 
in the capillary validation comparison, 80µl of urine was mixed with 160µl of sterile water and 
240µl of phosphate buffer. The sample was placed into a standard 5mm NMR tube. 
 
3.2.7 1H-NMR spectral acquisition 
Urinary NMR spectra were acquired using a JEOL 500 MHz Eclipse+ NMR spectrometer 
(JEOL, Tokyo) housed at MRC Harwell. Water presaturation was used for all data 
acquisitions. The spectral width was 15ppm, pulse angle 90o, acquisition time 4.36s and 
relaxation delay 2s. 32K data points were acquired per collect and 256 transients were 
summated. The receiver gain was constant for all samples. The resulting free induction 
decay was zero filled and multiplied by an exponential function corresponding to 0.3Hz line 
broadening prior to Fourier Transformation. The NMR spectra were manually phased using 
the JEOL Delta software before being exported. 
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3.2.8 Spectral processing and multivariate analysis 
Prior to statistical analysis all NMR spectra were baseline corrected to a 4th degree 
polynomial, zero filled by a factor of 2 and referenced with the TSP peak set to 0.00ppm 
using KIA version 8.x (Bio-Rad, Philadelphia, USA). NMR spectral resonances were 
assigned according to the literature (Wishart et al., 2007). The resonances attributable to 
residual water and urea (δ 4.6-6.4ppm) were excluded from further analysis.  NMR spectra 
were normalised to the total spectral integral in the range δ = 0.2-10 ppm (excluding 4.6-
6.4ppm). Prior to multivariate analysis spectra were bucketed using the Intelligent Bucketing 
algorithm within Know It All giving a total number of buckets of 937. The bucketed spectra 
were Pareto scaled prior to multivariate analysis. Principal Components Analysis (PCA) was 
performed on SIMCA (Umetrics, Sweden) and used as an un-supervised method for data 
visualisation and outlier identification. Supervised regression modelling was performed on 
the Pareto scaled data set using Partial Least Squares Discriminant Analysis (PLS-DA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) within SIMCA. 
Validation was performed using leave one out cross validation where each observation was 
excluded in turn and its class predicted by the developing model.  
 
3.2.9 Statistics 
Statistical analyses were performed using Prism v6 (GraphPad, San Diego CA). The data 
range of ALT and plasma paracetamol concentrations were tested for normality by the 
D’Agostino & Pearson omnibus normality test. Significance between strains was tested by 
ANOVA or Kruskal-Wallis with multiple comparisons by Tukey’s test or Dunn’s multiple 
comparisons test.   
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3.3 Results 
3.3.1 Plasma paracetamol concentrations in inbred strains 
Plasma paracetamol concentrations were measured 30 minutes after dosing to check for the 
efficacy and accuracy of dosing. Paracetamol concentrations across the whole group and 
within strains were normally distributed. There was a significant difference in plasma 
paracetamol concentrations between strains (ANOVA p<0.0001) (Figure 3.1).  Missing 
values were due to dosing injection failures (BL6 n=1, C3H/H n=1) or failure to acquire a 
blood sample (LP/J n=2, SM/J n=1) or delayed timing of bleed making paracetamol 
concentrations inaccurate (BALBc n=4) 
 
Figure 3.1 Plasma paracetamol levels 30 minutes after intraperitoneal dosing of 
200mg/kg in all ten strains.  
Results demonstrate significant differences in 30-minute paracetamol levels between strains 
(ANOVA p<0.0001). BL10 (n=10, mean 664 +/-89 µmol/ml), C3H/J (n=10, mean 601 +/- 76 
µmol/ml), DBA (n=10, mean 773 +/- 59 µmol/ml), BL6 (n=9, mean 539 +/- 59 µmol/ml), A/J 
(n=10, mean 618 +/- 142 µmol/ml), BALBc (n=6, mean 551 +/- 44 µmol/ml), LP/J (n=8, mean 
891 +/- 173 µmol/ml), SM/J (n=9 mean 826 +/- 148 µmol/ml), CBA (n=10, mean 782 +/- 84 
µmol/ml), C3H/H (n=9, mean 760 +/- 162 µmol/ml). 
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3.3.2 Liver injury in inbred strains 
Liver injury was assessed by plasma ALT 8 hours following a 200mg/Kg dose of 
paracetamol. ALT values across the whole group were normally distributed, however within 
strains there were six data sets that showed a skewed distribution due to high responding 
outliers (BL6, A/J, BALBc, LP.J, SM/J, BL10). Non-parametric statistical tests were therefore 
applied to the group for maximum rigor. There were significant differences in ALT between 
strains (Kruskal-Wallis p=0.0002).  Due to the inter-individual variability and the number of 
groups tested, few pairs of strains had significantly different responses after accounting for 
multiple comparisons. Those pairs that had significantly different responses were BL10 v 
C3H/H (p<0.05), A/J v DBA2 (p<0.01) and A/J v C3H/H (P<0.05).  
Strains that exhibited sensitivity to paracetamol, with high ALT values included the two C3H 
variants, CBA and DBA2. BL/10 and A/J were the most resistant strains.  
Two mice in the C3H/H group and one in the CBA group were culled between 6-8 hours due 
to welfare concerns. ALT values at cull were in excess of 15,000U/L and were included with 
the data. One mouse in the LP/J strain was culled early on welfare grounds however a blood 
sample was not acquired. At necropsy gross haemorrhagic necrosis of the liver was present, 
suggesting this was another high responding individual.  Other missing values were due to 
dosing injection failure/error (BL6 n=1 and C3H/H n=1) and failure to achieve blood sampling 
at cull (LP/J n=1). 
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Figure 3.2 Plasma ALT 8 hours after dosing with a 200mg/Kg dose of paracetamol in 
ten inbred mouse strains 
Significant differences between the ALT concentrations between the ten strains are 
demonstrated (Kruskal-Wallis p=0.0002). Low responding strains include BL10 and A/J, with 
DBA, CBA and both the C3H strains showing a higher response. Marked inter-individual 
variability is demonstrated in many strains with high responding outliers in BALBc, BL6 and 
LP/J and a wide range of response in the C3H strains and CBA. BL10 (n=10, median 
491U/L), C3H/J (n=10, median 6848U/L), DBA (n=10, median 6615), BL6 (n=9, median 1093 
U/L), A/J (n=10, median 171U/L), BALBc (n=10, median 489 U/L), LP/J (n=8, median 116 
U/L *mouse culled early in LP/J group without blood sampling likely to have been high 
responder), (SM/J (n=10, median 1037 U/L), CBA (n=1-, median 1473), C3H/H (n=9, median 
13470). 
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3.3.3 Correlation between plasma paracetamol and ALT 
To determine whether the difference in response to paracetamol between the strains was 
due to the significant differences in dosing, the correlation between ALT and paracetamol 
level was tested. The mean plasma paracetamol for each strain did not correlate with the 
median plasma ALT (r = 0.12, p=ns).  There was also no overall correlation between plasma 
paracetamol concentrations and ALT among all the individual mice in the experiment (r = 
0.16 p=ns). 
To determine whether the variability seen within each strain was due to dosing these 
correlations were repeated for each strain individually (Figure 3.3). Pearson’s correlations 
were calculated for strains with normally distributed ALT values, C3H/H, C3H/J, DBA and 
CBA. The Spearman correlation test is more robust for outliers and is preferred in skewed 
distributions, so this test was applied to the six strains with non-normally distributed ALT 
values. There was a significant positive correlation between 30-minute paracetamol level and 
ALT in the A/J strain (Spearman r = 0.77, p=0.013) and a negative correlation in the BL6 
strain (Spearman r = -0.75, p=0.03). The strains, BALBc and C3H/H showed a moderate 
positive correlation that did not reach statistical significance. However in the majority of 
strains there was no apparent correlation between the plasma level of paracetamol and later 
ALT values. Outliers with a very high response in strains BL10, BL6, LP/J, SM/J had plasma 
paracetamol concentrations at 30 minutes no greater than other mice in the strain that 
exhibited a much milder response. 
 113 
 
 
 
0 500 1000 1500
0
200
400
600
800
1000
A/J
ALT at 8 hours (U/L)
pl
as
m
a 
pa
ra
ce
ta
m
ol
 a
t 3
0 
m
in
 µ
m
ol
/m
l
r = 0.77*
0 2000 4000 6000 8000 10000
0
200
400
600
ALT at 8 hours (U/L)
pl
as
m
a 
pa
ra
ce
ta
m
ol
 a
t 3
0 
m
in
 µ
m
ol
/m
l
BL6
r = - 0.75 *
0 5000 10000 15000 20000
0
200
400
600
800
1000
 ALT at 8 hours (U/L)
pl
as
m
a 
pa
ra
ce
ta
m
ol
 a
t 3
0 
m
in
 µ
m
ol
/m
l
CBA
r = 0.33 ns
0 1000 2000 3000
0
200
400
600
ALT at 8 hours (U/L)
pl
as
m
a 
pa
ra
ce
ta
m
ol
 a
t 3
0 
m
in
 µ
m
ol
/m
l
BALBc
r = 0.31 ns
0 1000 2000 3000 4000
0
200
400
600
800
 ALT at 8 hours (U/L)
pl
as
m
a 
pa
ra
ce
ta
m
ol
 a
t 3
0 
m
in
 µ
m
ol
/m
l
BL10
r = -0.02 ns
0 5000 10000 15000 20000 25000
0
200
400
600
800
1000
C3H/H
ALT at 8 hours (U/L)
pl
as
m
a 
pa
ra
ce
ta
m
ol
 a
t 3
0 
m
in
 µ
m
ol
/m
l
r = 0.52 ns
A B
C D
E F
 114 
 
Figure 3.3 Correlation between 30-minute post-dosing plasma paracetamol 
concentrations and 8 hour ALT for each of the 10 inbred strains. 
Correlation coefficients between paracetamol and ALT ranged from -0.75 to 0.77. The only 
statistically significant correlations were in the A/J strain in which a positive correlation 
between 30-minute paracetamol and 8 hour ALT was demonstrated (r=0.83, P=0.0024) 
and the BL6 strain which showed a negative correlation (r=-0.75, p=0.03) Graphs show 
that in a number of strains there were outliers in ALT response in mice that had moderate 
plasma paracetamol concentrations.  
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3.3.4 Baseline ALT 
Liver function and the presence of any pre-existing liver inflammation were assessed in mice 
by measurement of the baseline plasma ALT 24 hours before dosing. The SM/J strain did not 
undergo blood sampling the day before dosing, as the low body weight of the mice would not 
have permitted adequate sampling without haemodynamic consequences. There were 
significant differences in baseline ALT between groups (ANOVA p=0.0021), but there was no 
relationship between the mean baseline ALT and the response to paracetamol between 
strains.  Looking within strains to determine whether variation in baseline ALT might correlate 
with response to paracetamol, there was a positive correlation between baseline and post-
dosing ALT in the C3H/J (r=0.65, p=0.04) and DBA (r = 0.70 p=0.02) mice.  This was not 
replicated in other strains and indeed a negative though non-significant correlation was seen 
in some strains. 
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Figure 3.4 Baseline ALT values in inbred strains 
(A) Baseline ALT values taken 24 hour before dosing with paracetamol in nine inbred strains 
of mice. (B) Positive correlation between baseline ALT and post-dosing ALT in the DBA 
strain (Pearson r= 0.70 p=0.02) (C) Positive correlation between baseline and post-dosing 
ALT in the C3H/J strain (Pearson r= 0.65, p=0.04). No significant correlations were 
demonstrated in the other 7 strains (data not shown) 
 
3.3.5 Fasting blood glucose 
Fasting blood glucose was measured in mice at 30 minutes after dosing, before food was 
returned. This was used as a simple baseline measure of stress in the mice. The mean 
fasting glucose in the group was 11.29 +/- 1.94 mmol/L. The only strain in which there was a 
correlation between fasting glucose and later response to paracetamol was BL6 in which a 
positive correlation was demonstrated (r= 0.65, p=0.04). 
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3.3.6 Body weight 
It is known that access to in utero and early life nutrition influence adult body weight and 
body composition in mice. It was hypothesised that these early nutritional and metabolic 
events might also influence drug metabolism. We therefore sought to characterise weight 
differences in the strains of mice and correlate them with response to paracetamol.  
Intra-strain variability in body weight was demonstrated in this experiment. The most marked 
variability was seen in the CBA strain, in which all ten mice were exactly 77 days old, but 
weights varied between 24.0 and 32.3g, a greater than 25% difference. There were five other 
strains in which the size of the range exceeded 20% of the mean weight, BL10, BL6, LP/J, 
SM/J and C3H/H. Least variability was seen in BALBc, with a range of 25.5 - 27.4g and 
standard deviation of 0.59g. 
There was not a significant correlation between body weight and response to paracetamol in 
any of the strains. 
 
3.3.7 Qualitative analysis of parental and early life characteristics.  
In order to look at the effects of maternal and paternal factors and litter size and health on 
the variation in response to paracetamol, data was collected from the breeding database at 
MRC Harwell. For the strains that were bred at Harwell, data was available on maternal and 
paternal age, the duration of the mating pair, number of previous litters and live births, litter 
size, presence of perinatal mortality among littermates, age at weaning and post-weaning 
caging details. Tables in appendix M show representative data from the strains C3H/J and 
BL10. 
The ten mice used in each strain were derived from 2-4 litters. The small numbers meant that 
statistical testing between litters within strains was not possible. However it was clear from 
the data that heterogeneity of response was seen within littermates, caged together.  
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Extremes of high and low response to paracetamol were observed in mice from the same 
litter that shared maternal and paternal factors and an in utero environment.  
 
3.3.8 Metabolic profiling of baseline urine samples 
It was hypothesised that urinary metabolic profiles would differ between genetically identical 
animals and that they might predict susceptibility to paracetamol induced acute liver failure. 
This was investigated among the C3H groups of mice, as in the original profiling experiment 
the C3H/H and C3H/J mice had shown a great range in response. These groups were also 
very closely related genetically, so it would be acceptable to group their samples together for 
analysis. Baseline (T0) urine specimens were also available for a further ten male mice from 
the C3H/H strain that had been through the experimental protocol. Example baseline urinary 
spectra and peak assignments are shown in Figure 3.5 
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Figure 3.5 Representative 1H-NMR spectrum from a baseline urine sample from an 
unfasted C3H/HeH mouse 
Spectrum shows peaks in the aliphatic region (A – rotated for space) between 0 and 4.5ppm 
and the aromatic region (B) 6.5 to 9.5ppm. Assigned metabolites correspond to those in table 
3.1.  
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Key Metabolite Chemical Shift (δ) 
a Trimethylsilyl propanoic acid (TSP) 0.00(s) 
b 3-methyl-2-oxovalerate 0.90(t), 1.1(d), 1.46(m), 1.7(m), 2.93(m) 
c 2-oxoisocaproate 0.94(d), 2.18(m), 2.64(d) 
d Lactate 1.34(d), 4.12(q) 
e Putrescine 1.79 (m), 3.05(m) 
f Acetate 1.92(s) 
g Succinate 2.41(s) 
h 2-Oxoglutarate 2.45(t), 3.01(t) 
i Citrate 2.53(d), 2.66(d) 
j Dimethylamine (DMA) 2.73(s) 
k Trimethylamine (TMA) 2.88(s) 
l Creatine 3.04(s), 3.93(s) 
m Creatinine 3.05(s), 4.06(s) 
n Taurine 3.43(t), 3.27(t) 
o Trimethylamine-N-oxide (TMAO) 3.27(s) 
p Glycine  3.55(s) 
q 4-hydroxyphenylpropionic acid (4-
HPPA) 
2.45(t), 2.81(t), 6.85(d), 7.18(d) 
 
r Hydroxycinnamate 6.48(d), 6.91(dd), 7.08(s), 7.16(d), 7.33(m) 
s Phenylacetylglycine (PAG) 3.68(s), 3.75(d), 7.35(m), 7.40(m),  
t Hippurate 3.97(d), 7.84(d), 7.55(t), 7.64(t) 
   
 Acetaminophen 7.25(d), 6.90(d), 2.15(s) 
    Glucuronide 7.34(d), 7.13(d), 2.16(s) 
    Sulfate 7.45(d), 7.31(d), 2.18(s) 
    L-Cysteinyl 7.26(dd), 6.99(d), 7.51(d), 2.15(s) 
    Mercapturate 7.23(dd), 6.93(d), 7.42(d), 2.14(s) 
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Table 3.1: Peak assignments for metabolites in the urinary spectra of C3H/HeH murine 
urine sample. 
Table shows the predominant urinary metabolites in the urinary specimens. Letters refer to 
peaks in figure 3.5 A and B. The chemical shift localises the metabolite on the spectrum, with 
the signal shape in brackets, s, singlet; d, doublet; dd, double doublet; t, triplet; m, multiplet. 
Paracetamol peaks are included for reference for chapter 4. 
 
 
 
3.3.9 Predicting response to paracetamol from baseline urine specimens 
Mice were divided into high or low responding groups according to their ALT concentrations 
8 hours after paracetamol. High responders were defined as having an ALT value of 
>13,000U/L and low responders with an ALT <6,000U/L. An ‘medium’ responder group of 
those mice with ALT values at 8 hours between 6,000-13,000U/L was also defined for the 
purposes of principle components analysis, to utilise maximal numbers of mice and 
determine whether an intermediate phenotype could be elucidated. 
Principal components analysis (PCA) of the baseline unfasted (T-24, Figure 3.6) and (T0, 
Figure 3.7) spectra were performed with colour coding according to later response (high, 
medium low) to identify the presence of clustering and outliers. No clear clustering according 
to later response group was evident in the T24 unfasted samples. There was some evidence 
of separation between high and low responders by the 2nd component in the T0 fasted 
specimens. 
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Figure 3.6 Principle component analysis of urinary 1H-NMR spectra from baseline 
unfasted (T-24) samples. 
Principle components analysis using either 2 components (A) or 3 components (B) and 
colour coded according to later paracetamol response of mice shows no clear clustering 
according to response. (n=18, 8 high response ALT>13,000U/L, 8 low response ALT 
<6,000U/L and 2 medium responders ALT 6,000-13,000U/L) 
 
 
 
 
A 
B 
 124 
 
Figure 3.7 Principle component analysis of urinary 1H-NMR spectra from baseline 
fasted (T0) samples. 
Principle components analysis using either 2 components (A) or 3 components (B) and 
colour coded according to later paracetamol response of mice shows some separation 
between high and low samples on the second component (t2, y axis in figure A). (n=24, 14 
high response ALT>13,000U/L, 8 low response ALT <6,000U/L and 2 medium responders 
ALT 6,000-13,000U/L) 
 
 
A 
B 
 125 
PLS-DA was performed as a supervised multivariate technique, to determine whether the 
high/low responder status of mice could be predicted by their baseline urinary metabolic 
profiles. The T24 fasted urine samples produced a very poor model under PLS-DA analysis. 
With 3 components the model had a R2X score of 0.68 and R2Y of 0.70, suggesting the 
model explained nearly 70% of the variation in the population. However the model displayed 
no predictive validity, with a Q2 of -0.01, suggesting there was no power in the model to 
discriminate between high and low responders on the basis of their baseline urine samples. 
The T0 model was similarly shown to have no predictive power with a 3-component PLS-DA 
analysis, having an R2X of 0.64, R2Y of 0,73 but a Q2 of just 0.16. 
Further metabolic profiling of response to paracetamol is described in chapter 4.  
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3.4 Discussion 
This chapter describes an attempt to characterise variability in response to paracetamol 
within genetically identical inbred strains of mice, and to identify causes for this variation.  It 
has been shown that a marked degree of variability exists between individuals from the same 
strain and that this heterogeneity is independent of plasma paracetamol concentrations at 30 
minutes after dosing. In two strains there was a significant correlation between early blood 
paracetamol concentrations and later liver injury, however one showed a positive correlation 
and the other negative, with the eight remaining strains a range of intermediate but non-
significant correlations. This suggests that these ‘significant’ results are spurious and an 
effect of the low numbers in each group and high number of groups tested. A limitation of the 
test for paracetamol level at 30 minutes is that it provides only a single, static time point on 
which to judge drug delivery. A dynamic test would be required to fully characterise the 
pharmacokinetics of paracetamol in this model. However the lack of a consistent relationship 
between dose concentrations and response in these animals suggests dosing error or 
inaccuracy is not the main variable underlying the observed heterogeneity in response to 
paracetamol. 
The variability seen in the inbred strains in their response to paracetamol was not 
consistently correlated with measures of baseline liver function or fasting glucose as a 
measure of stress. Body weight was investigated as it can vary significantly between 
individuals from the same inbred strain and may correlate with access to intrauterine and 
early life nutrition. A wide range in body weights was observed within strains, however this 
did not correlate with response to paracetamol.  
The pharmacometabonomic approach was applied to attempt to predict response to 
paracetamol from baseline urinary metabolic profiles. In this experiment, a predictive model 
could not be constructed from the baseline metabolic profiles. This may have been in part 
due to the relatively low numbers used.  
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A qualitative analysis of parental and litter characteristics was performed to determine 
whether there were any associations between these features and hepatotoxic response. This 
demonstrated quite convincingly that variation in response to paracetamol was seen within 
littermates, caged together. Indeed, the within litter variation far exceeded the between litter 
variation seen in this experiment, suggesting that parental characteristics and litter size 
contributed little to the observed heterogeneity in response to paracetamol. For a full analysis 
of between-litter variation a far greater number of mice would have been required and this 
was beyond the scope of this investigation. 
The degree of variation that was observed within the inbred strains in response to 
paracetamol has a number of possible explanations. Firstly it is possible that members of the 
inbred strains are not in fact genetically identical as assumed. There is some evidence to 
suggest that gene copy number variation exists between members of an inbred strain and 
that this can lead to differential expression of genes between individuals (Watkins-Chow and 
Pavan, 2008). This genetic diversity may underlie the differences in response to paracetamol 
that we have observed. Secondly, it is possible that gut microbial differences between 
members of an inbred strain could exist and contribute to variation in hepatotoxicity. This 
hypothesis is investigated in detail in chapter 4. Thirdly, it is possible that in a multiparous 
animal like the mouse, that differential access to intrauterine nutrition could influence 
offspring, biasing some to a greater susceptibility to hepatotoxins. Evidence has shown that 
intrauterine position with respect to other siblings can affect sex-related traits due to in-utero 
hormone exposure (Ryan and Vandenbergh, 2002).  There is a marked sex-difference in 
susceptibility to paracetamol between mice, with female mice exhibiting greater resistance to 
hepatoxicity due to gene expression differences, which may be hormonally mediated 
(Masubuchi et al., 2011). It could be hypothesised that exposure of a male foetus to female 
hormones from an adjacent foetus could programme gene expression changes which might 
lead to changes in susceptibility to paracetamol later in life.  
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Finally, having considered uncontrolled genetic and environmental factors we are left with 
variation that has previously been called ‘intangible variance’ or ‘the third component’, but is 
now largely recognised to be a result of epigenetic modifications. Klaus Gartner, who coined 
the term the ‘third component’ has played a central role in defining differences between 
genetically identical animals using rodent and cattle models (Petronis, 2010).  In experiments 
on inbred strains of rats kept under either tightly standardised or near-wild conditions he was 
able to demonstrate that environmental standardisation has very little impact on the diversity 
in body weight and kidney weights seen in these rodents (original paper published in German 
results summarised (Gartner, 1990). Gartner went on to perform experiments in isogenic 
mice comparing divided 8-cell embryos (monozygotic twins) and non-divided embryos 
(identical but dizygotic twins) implanted into surrogates (Gartner and Baunack, 1981). These 
studies, also repeated in cattle, demonstrated that the animals derived from the same zygote 
showed much greater phenotypic similarity than animals that were genetically identical but 
derived from different zygotes. This relationship held true with the use of different surrogate 
mothers and was thus independent of variability in intrauterine conditions. Therefore they 
proved that a ‘third component’ contributed to phenotypic variance in isogenic animals, that 
was independent of DNA sequence or environment and that this third component became 
effective before the 8-cell embryo stage. More recently these observations have been 
replicated in cloned animals, who might be expected to be phenotypically identical, yet as 
they are derived from different zygotes they demonstrate the same degree of inter-individual 
variation as non-cloned mice from the same strain (Tamashiro et al., 2003). 
Germ cells with markedly differing DNA methylation profiles are produced by individuals 
(Petronis, 2010). After fertilisation epigenetic reprogramming occurs, however there is 
evidence to suggest that some modifications may survive this erasure and persist in the 
developing embryo, thus providing a mechanism of inherited epigenetic heterogeneity 
(Blewitt et al., 2006). 
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In addition to inherited epigenetic variance, identical animals may diverge in phenotype due 
to acquired epigenetic modification. This can be in response to environmental stimuli, such 
as the effects of in-utero position and nutrition, or through stochastic epigenetic instability. 
During each mitosis DNA methylation patterns are copied from mother chromatids to 
daughter, however the fidelity of this transmission is lower than for the DNA code itself. Thus 
as genetically animals develop they accumulate new epigenetic modifications both randomly 
and in response to their environment. These are overlaid on the inherited epigenetic variance 
determined at the zygote stage and account for the differing and continually diverging 
phenotypic characteristics of isogenic animals (Petronis, 2010). 
Gartner hypothesises that the random epigenetic variation programmed in each zygote and 
which leads to a diversity of behavioural and physiological characteristics supports rapid 
adaptation to environmental change and is thus evolutionarily advantageous (Gartner, 2012). 
A study in a murine model of liver fibrosis, which used carbon tetrachloride hepatotoxicity to 
induce repeated liver injury, showed resistance to fibrosis could be induced and inherited via 
epigenetic mechanisms (Zeybel et al., 2012). The authors hypothesised that rapid adaptation 
to environmental toxins through epigenetic inheritance was a valuable adaptive mechanism. 
This hypothesis could be extended such that even without parental exposure, a population 
diversity of susceptibility to toxins in each generation could promote species survival in the 
case of emerging threats. 
In conclusion, I have been able to demonstrate and characterise inter-individual variation in 
response to paracetamol in a murine model. This heterogeneity in response is independent 
of plasma paracetamol concentrations and does not correlate with variation in baseline liver 
function, metabolic profile or body weight. Variation is seen between members of the same 
litter who are caged together in highly standardised conditions. It is hypothesised that this 
heterogeneity may be in part due variation in intestinal microbiota, intrauterine position 
effects or to stochastic and inherited epigenetic variation, which could be an adaptive 
mechanism to ensure population diversity of response to environmental toxins. 
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4 THE ROLE OF INTESTINAL MICROBIOTA IN 
PARACETAMOL-INDUCED ACUTE LIVER INJURY 
 
4.1 Background and aims 
4.1.1 Background 
The role of intestinal microbiota in states of health and disease has attracted huge interest in 
recent years as the profound impact that these diverse and abundant microorganisms can 
have on their host begins to be understood. The dynamic relationship between host health 
and intestinal microbiota has been implicated in susceptibility to a range of metabolic, 
infectious and immune-mediated conditions (Keeney et al., 2014) (Sommer and Backhed, 
2013). Variations in host intestinal microbiota include the mix of species, their relative 
abundance and their interplay with host genetic and metabolic factors. Intestinal microbiota 
therefore add another potential source of differential susceptibility to disease outside the 
traditional ‘genetics v environment’ paradigm. Pharmacometabonomic studies have 
demonstrated that host metabolism can be altered by intestinal microbiota and that this 
alteration may affect drug handling and toxicity (Wilson, 2009). This interaction is perhaps 
unsurprising when it is considered that the liver’s drug metabolising enzymes evolved to deal 
with products of microbial metabolism and dietary toxins.  Therefore potential exists for 
interactions between bacterial metabolites and drugs, both in terms of hepatic enzyme 
induction and competitive inhibition. 
It has been speculated that the unexplained differences in response to paracetamol induced 
liver injury between genetically identical mice might be due to variations in intestinal 
microbiota (Kubes and Mehal, 2012). There are a number of ways in which the intestinal 
microbiota might impact upon the metabolism of paracetamol and its hepatotoxicity. Bacterial 
metabolites may influence the expression of hepatic enzymes responsible for the metabolism 
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of paracetamol. For example, several enzymes from the CYP450 family, including CYP3A4, 
CYP1A2 and CYP2A6, have been shown to be upregulated in response to bacterial-derived 
metabolites (Toda et al., 2009a, Toda et al., 2009b). The regulation by bacterial metabolites 
of the enzyme CYP2E1, that is predominantly responsible for conversion of paracetamol to 
its reactive metabolite NAPQI, has not been investigated. However it is known that CYP2E1 
activity can be affected by ethanol and plant-based dietary compounds (Dai et al., 2014, 
Kessova and Cederbaum, 2003).  
In addition to changes in gene expression, bacterial metabolites may compete for hepatic 
enzyme capacity. In a study on human volunteers taking a non-toxic dose of paracetamol, 
Clayton et al proved that baseline urinary concentrations of the bacterial metabolite p-cresol 
sulphate, predicted a reduced ratio of paracetamol sulphate: paracetamol glucuronide in the 
urine after dosing (Clayton et al., 2009). The authors suggested that sulphonation of 
bacterial-derived p-cresol, competitively inhibited the sulphonation of paracetamol, leading to 
reduced metabolism of the drug by this pathway. As sulphonation is one of the primary 
pathways by which paracetamol is detoxified within the hepatocyte (chapter 1, figure 1.2), 
competitive inhibition of this enzyme by bacterial substrates could potentially lead to a 
greater proportion of drug undergoing oxidation to NAPQI by the CYP450 system. 
As described in the introduction to this thesis, after the initial toxic insult to the liver in 
paracetamol-hepatotoxicity, a phase of immune activation occurs which may perpetuate liver 
injury. During this phase there is a further potential role for intestinal microbiota in the 
pathogenesis of acute liver failure. Bacterial products such as lipopolysaccharide (LPS) are 
potent stimulators of the innate immune system, and their release from the gut into the portal 
vein contributes to a number of inflammatory conditions in the liver. In chronic alcoholic liver 
disease, non-alcoholic steatohepatitis and hepatic carcinogenesis it has been shown that 
stimulation of hepatic toll-like receptors by gut-derived bacterial products, contributes to 
disease progression (Uesugi et al., 2001, Rivera et al., 2007, Dapito et al., 2012). In acute, T-
cell mediated hepatitis induced by the toxin Concanavalin-A (Con-A), gut-derived LPS has 
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been shown to exacerbate liver injury through its interaction with TLR4 (Lin et al., 2012). It is 
possible that a similar process occurs in paracetamol-induced liver injury, whereby bacterial 
products act as an additional pro-inflammatory stimulus to promote innate immune activation 
and secondary liver damage. Indeed interventions to knock out or block TLR4 signalling in 
paracetamol induced liver injury models have shown some protection (Shah et al., 2013, 
Yohe et al., 2006). 
Germ free mice provide a useful model in which to investigate intestinal microbiota. These 
mice are born into and maintained in a completely sterile environment and have no microbial 
colonisation of their intestines. Comparing the differential response to experimental 
manipulation between germ free and conventionally raised mice allows a gross overview of 
the impact of the presence of intestinal microbiota. More refined experimental manipulations 
are also possible in which known species of bacteria are introduced to germ free mice to 
produce gnotobiotic animals, which facilitate the investigation of the role of different bacterial 
species (Smith et al., 2007). 
This chapter also utilises C3H/HeJ mice, which are derived from the same founder strain as 
C3H/HeH mice and share significant genetic homology, but are known to carry a missense 
mutation within the third exon of their TLR4 receptor gene (predicted to replace proline with 
histidine at position 712) that renders them relatively LPS-resistant (Poltorak et al., 1998).  
 
4.1.2 Hypotheses and aims 
It is hypothesised that intestinal microbiota exacerbate paracetamol-induced hepatotoxicity 
by promoting its metabolism to a toxic product and contributing to secondary inflammation 
through LPS-TLR4 signalling. Furthermore it is hypothesised that heterogeneity in response 
to paracetamol in conventional mice is partly due to variation in intestinal microbiota.  
This chapter aims to test these hypotheses by: 
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1. Investigating the differences in paracetamol metabolism in germ free and 
conventional mice. 
2. Comparing the severity of hepatotoxicity and acute liver failure in germ free, 
conventional mice and a group of LPS-resistant mice. 
3. Determining whether there is less inter-individual variability in response to 
paracetamol in germ free mice compared with conventional controls. 
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4.2 Materials and methods 
4.2.1 Animals 
Animals were maintained at MRC Harwell as described in section 2.2.1. The C3H/H and 
C3H/J groups are described in chapter 3 and are used here as control groups for the germ 
free mice. To distinguish between the conventional C3H/HeH and germ free mice of the 
same strain, the notation CV for conventional and GF for germ free is used throughout this 
chapter. The C3H/HeJ group serve as a control to investigate the role of TLR4/LPS signalling 
as they are resistant to LPS, and are therefore referred to as ‘LPSr’. 
Germ free C3H/HeH mice were maintained at the Mary Lyons Centre Quarantine Suite, MRC 
Harwell. The colony was derived from stock imported from the Centre National de la 
Recherche Scientifique/Centre de Distribution, de Typage et d’Archivage Animal (CNRS-
CDTA) Orléans, France. Mice were maintained under strict sterile conditions in a positive 
pressure isolator (Harlan Isotec). Environmental conditions were otherwise maintained as 
above, with the same diet autoclaved prior to feeding. The sterility of the germ free colony 
was checked with a regimen of monthly screening. Urine, faeces and cages swabs are taken 
and cultured in three different media: nutrient broth (for non-fastidious organisms), 
Sabouraud medium (for yeasts and moulds) and Thioglycollate medium (for anaerobes, 
aerobes and microaerophils). Bacterial 16s ribosomal RNA PCR is also performed. 
Nine GF mice from the colony were dosed with paracetamol according to the protocol in 
section 3.2.2. A further ten GF and ten conventional C3H/HeH mice were culled without 
paracetamol dosing to provide tissue for baseline glutathione and CYP2E1 measurements. 
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4.2.2 Paracetamol dosing 
Overnight fasting and paracetamol dosing was performed as in section 3.2.2. Mice were 
maintained in the isolator until the morning of the experiment when they were removed and 
kept in standard individually ventilated cages to enable access for sampling and dosing.  
 
4.2.3 Sample collection 
Samples were collected as per the schedule detailed in section 3.2.3 except for the blood 
sampling the morning before the experimental protocol, which was not possible as animals 
were still maintained within the isolator. Urine samples 2 hours (T2) after paracetamol dosing 
were also collected in addition to the baseline and T4 and T8 specimens. 
 
4.2.4 CYP2E1 expression by real time polymerase chain reaction (RT-PCR) 
RNA was extracted from snap frozen liver tissue using TRIzol® reagent (Life Technologies, 
Carlsbad, CA) according to manufacturers instructions. 1µg of RNA was reverse transcribed 
using a Quantitect RT Kit (Qiagen, Dusseldorf, Germany). Gene Expression Assay 
Mm00491127 specific to murine CYP2E1 was used and beta-2 microglobulin (B2M), 
succinate dehydrogenase subunit A (SDHA) and 18s ribosomal RNA served as reference 
genes (TaqMan® Gene Expression Assays Mm00437762, Mm01352363 and Mm03928990 
respectively) (Life Technologies, Carlsbad, CA). These reference genes were chosen as they 
have been shown to have stable expression in rodent liver during paracetamol toxicity 
(Lardizabal et al., 2012). Biological replicates of five GF and five CV mice were used and 
each reaction run in triplicate. Results were analysed using a ΔΔCT method using the 
geometric means of the reference genes. 
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4.2.5  Liver homogenates 
Frozen liver tissue weighing 100mg was placed into a microcentrifuge tube with PBS. The 
liver tissue was homogenised using a motorised pestle (VWR, Lutterworth, UK) within the 
microcentrifuge tube for 15 seconds. The resulting homogenate was frozen at -800C 
overnight, then put through two freeze/thaw cycles. The homogenate was vortexed then 
centrifuged at 5,000rpm for 5 minutes at 40C. The supernatant was used for further protein 
studies. 
 
4.2.6 Protein quantification with the Bradford Assay 
In order to normalise protein concentrations between samples a protein quantification assay 
was performed. The Bradford Reagent (Sigma Aldrich, St Louis, MO) is composed of Brilliant 
Blue G in phosphoric acid and methanol. Brilliant Blue G is a dye that forms complexes with 
proteins. When in complex, the absorption maximum shifts from 465 to 595nm and this shift 
is proportional to the amount of protein present (Bradford, 1976). The linear concentration 
range is limited to 0.1-1.4mg/ml of protein. 
A protein standard series was made by diluting 2mg/ml Bovine Serum Albumin (BSA, 
Thermoscientific, Waltham MA) to give six solutions of known protein concentration (0.1, 0.2, 
0.4, 0.8, 1.0 and 1.4mg/ml). 5µl of each standard was pipetted into two separate wells of a 
96-well plate to give a duplicate dilution series. Into the other wells, 5µl of the liver 
homogenate supernatant, of unknown concentration was placed, again using duplicate wells. 
Each well containing standard or sample was topped up with 250µl of Bradford reagent and 
incubated at room temperature for ten minutes. The absorbance of the contents of each well 
was read on a plate reader (SpectraMax Plus 384, Molecular Devices, Sunnyvale, CA) at 
595nm. 
The net absorbance at 595nm for each standard was averaged between duplicates and the 
value of the averaged ‘Blank’ well was deducted. A standard curve was constructed on 
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GraphPad Prism v6 (San Diego, CA) and the concentration of the unknown samples was 
interpolated from their averaged net absorption values. Due to the narrow linear range of the 
assay a dilution series of two representative samples was first performed to determine the 
degree of dilution of the stock homogenate supernatant that was required, prior to running all 
samples. 
 
4.2.7 CYP2E1 expression by enzyme-linked immunosorbent assay (ELISA) 
The total protein concentration of liver homogenates was normalised in all samples to 
1mg/ml.  CYP2E1 concentrations in the homogenates were measured in duplicate by ELISA 
(CSB-EL006425MO, Cusabio, Wuhan, China) according to the manufacturers instructions. 
The kit utilised a sandwich ELISA methodology, whereby an antibody specific to murine 
CYP2E1 was provided bound to wells of a 96 well plate. The sample or standards of known 
concentration are added and bind to the antibody. After thorough washing to remove non-
specifically bound protein a biotin-conjugated antibody specific to the protein is added, 
followed by an avidin-conjugated HRP-based detection system. The development of colour 
by the detection system is in proportion to the concentration of the protein in the original 
sample. The colour change in each well of the 96-well plate was read at 450nm on a plate 
reader (SpectraMax Plus 384, Molecular Devices, Sunnyvale, CA). A standard curve was 
constructed on Prism v^ (GraphPad, San Diego, CA) from the absorbance of the standards 
and values for the unknown samples were interpolated from the curve. 
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4.2.8 Glutathione Assay 
Baseline liver samples from ten GF and ten CV mice were assayed for total glutathione using 
the ApoGSH™ Glutathione Detection Kit (BioVision, Milpitas, CA) according to 
manufacturers instructions. The assay is based on the properties of monochlorobamine 
(MCB), a dye that forms an adduct with glutathione and upon formation of the adduct 
converts from almost non-fluorescent, to fluorescent blue (Ex/Em=380/461nm).  
The assay was performed according to manufacturers instructions. In brief, 10mg of frozen 
murine liver was placed into 100µl of lysis buffer and homogenised with a motorised pestle. 
Following a ten-minute incubation on ice the sample was centrifuged for ten minutes at 
13,500rpm at 40C. 2µl of the supernatant was used for the assay, topped up to 100µl in the 
well of a 96-well plate. Each sample was measured in duplicate. A dilution series of a 
glutathione standard was made in duplicate within the 96 well plate (range 0-1.0ug/well). 2µl 
of both Glutathione S-Transferase (GST) and monochlorobimane (MCB) was added to each 
well and the plate incubated at 370C for 1hour. The fluorescence value was measured in a 
FLUOstar Omega (BMG LabTech, Ortenburg, Germany) at excitation and emission 
wavelengths of 360nm and 460nm.  
The RFU values were averaged between duplicates and the blank value deducted. A 
standard curve was then constructed on GraphPad Prism using the RFU values for the 
glutathione standards. Glutathione values were interpolated from the standard curve for the 
unknown samples. 
 
4.2.9 Hepatic cytokines 
Hepatic cytokines (TNFα, IL-1β, IFNγ, IL-10, IL-12 p70, IL-2, IL-4, IL-5, IL-6 and KC/GRO) 
were measured in liver homogenates prepared and normalised as above (sections 4.2.5 and 
4.2.6). 10µg of total protein was used per sample and cytokines quantified in duplicate using 
a MSD® V-PLEXTM Multi-spot cytokine assay (Mesoscale Discovery® Rockville, MD) 
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according to the manufacturers instructions. The assay is based on a sandwich ELISA 
technique and utilises a detection antibody bound to an electrochemiluminescent label that 
produces light when a voltage is applied within the plate reader. The 96 well plates are 
designed with ten discrete ‘spots’ in each well, coated with a different capture antibody, 
allowing ten different cytokines to be measured in a single 96 well plate format. 
 
4.2.10 Biochemistry 
Biochemistry analysis was performed as per section 2.2.4 
 
4.2.11 Histological assessment of necrosis 
Formalin fixed liver tissue was paraffin embedded, sectioned at 10µm thickness and 
mounted onto glass slides. Sections were stained with haematoxylin and eosin (H&E). For 
each mouse, ten representative images were taken at x40 magnification on a microscope-
mounted digital camera. Necrosis was scored by overlaying a digital 100 square grid, onto 
the image and counting the number of squares that contained predominantly necrotic tissue. 
White space (including vessels) on the slides was also counted and deducted from the total, 
so that a percentage necrosis score could be calculated. This was repeated for each of the 
ten images per mouse and an average score calculated. Slides were labelled with coded 
numbers so that the reviewer was blind to experimental group and mouse identity until after 
the scoring of all images was complete. 
 
4.2.12 Urine preparation for metabolic profiling 
Urine was prepared for 1H-NMR analysis as per section 3.2.6 
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4.2.13  1H-NMR spectral acquisition 
1H-NMR spectra were acquired as per section 3.2.7 
 
4.2.14 Spectral processing and multivariate statistical analysis 
Spectra were processed and multivariate statistics applied as per section 3.2.8 
 
4.2.15 Integration of spectra for quantification of paracetamol-derived metabolites 
1H-NMR spectra from urine samples taken two hours post-paracetamol dosing were used to 
assign resonances to paracetamol and its principle urinary metabolites (Bales et al., 1984) 
(Figure 4.6). Resonances representing two hydrogen atoms positioned on the phenolic ring 
of paracetamol or its metabolites were integrated. The concentration of each metabolite was 
divided by the total paracetamol integral to calculate a ratio. 
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4.3 Results 
4.3.1 Baseline differences in hepatic CYP2E1 expression 
Hepatic expression of CYP2E1, the principle enzyme responsible for the oxidation of 
paracetamol to its toxic metabolite NAPQI, was measured by RT-PCR.  Expression was first 
run against a single reference gene, B2M, and a significant upregulation of CYP2E1 in GF 
mice compared with CV mice was demonstrated (Mann-Whitney U-test comparison of ΔCT 
p=0.0079). For maximal rigor, two additional reference genes, SDHA and 18s ribosomal 
RNA were run against CYP2E1.  Due to increased variability the increased mRNA 
expression of CYP2E1 in GF mice did not reach statistic significance with three reference 
genes (Mann-Whitney U-test comparison of ΔCT p=0.15) (Figure 4.1 A). 
The cellular concentrations of CYP2E1 are regulated by variation in the rate of degradation 
of the enzyme as well as its expression. In the presence of certain inducers such as ethanol, 
CYP2E1 is stabilised by association with HSP90, preventing its degradation by ubiquitin-
ligase (Morishima et al., 2005).  In the absence of substrate, the half-life of CYP2E1 is only 
6-7 hours (Song et al., 1989). It was therefore felt essential to compare protein 
concentrations of CYP2E1 between GF and CV mice, in addition to mRNA.  
The total protein concentration of liver homogenates was measured via the Bradford assay 
(for example data see appendix N) and normalised to a concentration of 1mg/ml. 
Quantification of CYP2E1 concentrations was performed by ELISA. The range of values was 
1.90-4.9ng/mg of total hepatic protein and there were no significant difference between CV 
and GF mice (Figure 4.1 B). 
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Figure 4.1 Hepatic CYP2E1 concentrations in GF and CV mice 
(A) Hepatic CYP2E1 expression in paracetamol-naïve GF and CV mice as determined by 
RT-PCR. Graph showing ΔCT values calculated by comparison of CYP2E1 expression with 
geometric mean of 3 reference genes (B2M, R18s, SDHA) (p=0.19, n=5 in each group) (B) 
Hepatic CYP2E1 concentrations in paracetamol-naïve GF and CV mice determined by 
ELISA. Adapted from (Possamai et al., 2014b) 
 
 
4.3.2 Baseline hepatic glutathione 
Glutathione is an essential intracellular anti-oxidant that has an important role in detoxifying 
NAPQI, the reactive metabolite of paracetamol. Cellular glutathione reserves can vary 
according to diet, hormonal milieu and anti-oxidant status (Lu, 1999). Total glutathione 
content in the livers of GF and CV mice was quantified after fasting but prior to paracetamol 
dosing to determine whether differences existed in the baseline concentration of this 
important antioxidant. 
Germ free mice showed a significantly reduced hepatic glutathione content (mean 7.26 +/- 
0.92 µmol/g of liver tissue) compared with CV mice (mean 8.36 +/- 0.95 µmol/g of liver 
tissue) (p=0.029 Mann Whitney U test, Figure 4.2). 
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Figure 4.2 Baseline glutathione concentrations in GF and CV mice. 
Hepatic total glutathione concentrations in paracetamol-naïve mice showing reduced 
glutathione stores in GF mice compared with CV controls (p=0.028, n=10 in each group). 
Adapted from (Possamai et al., 2014b) 
 
 
4.3.3 Biochemical outcome measures 
A terminal blood sample was taken at eight hours post-dosing with paracetamol. Biochemical 
measures of acute liver failure and multi-organ dysfunction (bilirubin, glucose and creatinine) 
were assessed in the three groups of mice. There was a significant difference between 
groups in the bilirubin, glucose and creatinine concentrations (Figure 4.3 A,B & C).  GF and 
LPSr mice showed lower bilirubin concentrations (GF (mean 5.3 +/- 0.3µmol/L), LPSr (mean 
3.1 +/- 0.3µmol/L) than CV mice (mean 7.6 +/- 0.7µmol/L) (Kruskal Wallis p=0.0001, (Dunn’s 
CVvGF p=≤0.05, CVvLPSr p=≤0.0001)).  Higher glucose concentrations were also 
demonstrated in the GF and LPSr mice (GF 8.14 +/-0.38 mmol/L, LPSr 9.03 +/-0.57 mmol/L) 
than CV mice (CV 7.06 +/-0.25 mmol/L) (Kruskal Wallis p=0.009 (Dunn’s CVvGF p=ns, 
CVvLPSr p=≤0.01)). Creatinine concentrations varied significantly between the three groups 
with the CV groups having higher concentrations (27.27 +/-1.9 µmol/L) compared to the GF 
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(18.96 +/- 2.0 µmol/L) and LPSr (14.05 +/- 1.0 µmol/L) groups (Kruskal Wallis p=0.0001 
(Dunn’s CVvGF p=≤0.05, CVvLPSr p=≤0.0001)).   
ALT values showed considerable variation within each group, but demonstrated good 
correlation with the hepatic necrosis score (Spearman r=0.78, p=<0.0001). There was a 
lower mean ALT in the GF and LPS-r groups but this did not reach statistical significance 
(CV 14656+/- 6938, GF 10747 +/- 6923, LPS-r 10052 +/- 10834, Kruskal-Wallis p=0.16) (see 
figure 2D).  
 
 145 
 
Figure 4.3 Biochemical assessment of severity of acute liver injury.  
Plasma results 8 hours after a toxic paracetamol dose in experimental groups of GF (n=9), 
CV, (n=20) and LPS-r (n=10) mice. (A) Bilirubin (p=0.0001) (B) Glucose (p=0.009) (C) 
Creatinine p=0.0001 (D) ALT p=0.16. 
 
4.3.4 Histological outcome 
Review of H&E stained hepatic sections showed the classical appearance expected in 
paracetamol toxicity of centrilobular necrosis. In some of the more severely affected mice, 
extensive hepatic haemorrhage was observed (see Figure 4.4 for representative images). 
The mean percentage hepatic necrosis was 64.2% +/- 15.2 (range 37-87%) for CV, 67.4% 
+/- 16.5 (range 44-84%) for GF and 59.8% +/- 26.0 (range 27-94%) in LPSr mice.  No 
significant difference was demonstrated between groups (Kruskal Wallis p=0.79, Figure 4.4). 
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Figure 4.4 Histological assessment of severity of acute liver injury 
(A) Representative H&E stained sections from each experimental group showing range of 
hepatic necrosis from mild/moderate to severe and haemorrhagic. Magnification (x 40). (B) 
Hepatic necrosis scores for each experimental group showing no significant differences 
between groups. 
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4.3.5 Hepatic cytokines 
Hepatic inflammatory cytokines were measured by an MSD assay to determine whether 
there was differential inflammatory signalling within the liver eight hours after paracetamol 
dosing. Liver homogenates were diluted prior to use in the assay, according to estimated 
cytokine concentrations from the literature. The concentrations of IL-2 and IL-4 were below 
the dynamic range of the assay and concentrations of many of the other cytokines were 
towards the lower end of the assay range, suggesting homogenates had been over-diluted. 
There was a trend for lower concentrations of inflammasome-associated proteins, IL-1β, IL-
6, TNFα and KC in the LPS-r group, but none of the differences reached statistical 
significance (Figure 4.5) 
 148 
 
Figure 4.5 Hepatic cytokines eight hours after hepatotoxic dose of paracetamol 
Inflammatory cytokines were measured in liver homogenates of mice eight hours after 
paracetamol. No significant differences between groups are demonstrated. 
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4.3.6 Paracetamol metabolism 
Two hours after paracetamol dosing, peaks representing paracetamol and its main 
metabolites dominated the urinary 1H-NMR spectra. These were assigned according to the 
literature (Bales et al., 1984) and are summarised in Figure 4.6. Integrals for paracetamol 
and each of its metabolites were quantified. Paracetamol-glucuronide was the most 
abundant metabolite, accounting for nearly 60% of the urinary excretion of paracetamol. Of 
the paracetamol metabolites generated by conjugation of the toxic product, NAPQI with 
glutathione (see summary diagram chapter 1), L-cysteinylparacetamol and N-acetyl L-
cyteinylparacetamol could be detected in the urine. Together with paracetamol itself, these 
metabolites accounted for approximately 30% of all urinary excretion of paracetamol.  
Comparing GF with CV mice it was clear that the overall pattern of paracetamol metabolism 
and urinary excretion was similar for both groups (Figure 4.7). Paracetamol-glucuronide 
represented the major urinary metabolite in both groups, accounting for 56.6% and 60.3% of 
the total paracetamol metabolites in GF and CV mice respectively. There was a subtle shift in 
the ratio of metabolites resulting from sulphonation:glucurinidation (S:G). In germ free 
animals a greater proportion of drug was metabolised by sulphonation and less by 
glucuronidation than conventional controls, leading to a significant difference in the S:G ratio 
(0.136 for CH mice and 0.172 for GF mice (p=0.012)) (Figure 4.7 B and C). 
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Figure 4.6 Summary of paracetamol and its main metabolites in a 1H-NMR spectrum. 
Central panel shows a 1H-NMR spectrum with the water and urea resonances removed. The 
spectrum was obtained from mouse urine two hours after a toxic dose of paracetamol and 
shows dominance of the paracetamol-related resonances over other high concentration 
urinary metabolites. Resonances representing hydrogen atoms on the phenolic ring of 
paracetamol are found in the ‘aromatic region’ between 6.90 and 7.52ppm (upper left panel). 
In the ‘aliphatic’ region of the spectrum the acetanilide N-acetyl groups produce resonances 
between 2.13 and 2.18ppm (upper right panel). Peaks are attributed to Paracetamol (A), 
paracetamol-sulphate (S), paracetamol-glucuronide (G), paracetamol-mercapturate (or N-
acetyl-L-cysteinyl) (M) and L-cysteinylparacetamol (C).  Coloured numerals (i-iv) on the 
spectrum indicate which H atom each peak corresponds to with reference to the structure of 
the phenolic and 3-position conjugates of paracetamol. Adapted from (Possamai et al., 
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2014b) 
 
 
Figure 4.7 Quantification of urinary metabolites of paracetamol.  
The ratio of paracetamol and its urinary metabolites was similar overall in GF and CV mice 
(A), with most of the paracetamol excreted as paracetamol-glucuronide. A shift in the ratio of 
the sulphate:glucuronide metabolites is seen in GF mice with a greater proportion of drug 
excreted as paracetamol-sulphate (B) (p=0.012). An overlay (C) demonstrates that germ free 
mice (black lines) had on average higher peaks of paracetamol-sulphate (i) and lower 
paracetamol-glucuronide (ii) than conventionally housed mice (red lines). Adapted from 
(Possamai et al., 2014b) 
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4.3.7 Baseline urinary metabolic profiles 
Baseline urinary metabolic profiles were compared between germ free and all conventionally 
housed mice. There was a clear separation on PCA between the urinary profiles of unfasted 
(T24) germ free and conventional mice (Figure 4.8). A PLS-DA extension produced a model 
with excellent fit and predictive power with 3 components (R2X 0.82, R2Y 0.97 and Q2 0.95). 
The sensitivity and specificity of the model was 100% (CV ANOVA 3.2x10-7). 
 
 
Figure 4.8 Principal components analysis of baseline unfasted (T-24) urine samples 
from germ free (GF) and conventional (CV) mice. 
PCA scores plots demonstrate clear separation between baseline urinary metabolic profiles 
of GF and CV mice with two (A) and three (B) components. 
 
Representative spectra from baseline unfasted urine specimens of germ free and 
conventional mice are shown in Figure 4.9. This demonstrates a relative abundance of 
trimethylamine, trimethylamine N-oxide and taurine in conventional mice and a relative 
increase in the concentrations of urinary creatine in germ free mice.  
A B 
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Figure 4.9 Representative urinary spectra (aliphatic region only) from baseline (T-24) 
unfasted urine specimens from a germ free (GF) and conventional (CV) mouse. 
Spectra demonstrate the relative increase in urinary creatine (Cr) and glycine in germ free 
mice and relative deficiency in urinary trimethylamine (TMA), Trimethylamine N-oxide 
(TMAO) and taurine (Tau). Other apparent differences between these samples (for example 
the 2-keto-leucine concentrations) were non-significant on analysis of the whole group and 
may be due to variation between individuals. 
 
Principal components analysis was repeated for fasted urine samples, taken at T0, just prior 
to paracetamol dosing. Again the PCA showed clear separation between groups (Figure 
4.10). A PLS-DA extension showed good fit and predictivity of the model (R2X 0.65, R2Y 
0.89 and Q2 0.83).  
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Figure 4.10 Principal components analysis of baseline fasted (T0) urine samples from 
germ free (GF) and conventional (CV) mice. 
PCA scores plot demonstrates a clear separation between baseline urinary metabolic profiles 
of GF and CV mice with two (A) and three (B) components. 
 
From the S-loadings plot of an O-PLS-DA model it was possible to determine the 
discriminating metabolites between germ free and conventional mice. At T0, GF mice had a 
relative deficiency of the aromatic compounds, PAG, hippurate and 4-HPPA and peaks in the 
aliphatic region representing TMA, TMAO and taurine. GF mice had a relative excess of 
urinary creatine, glycine and an unattributed peak at 9.31ppm that was present in all GF 
samples. The position of citrate in 1H-NMR spectra is sensitive to subtle changes in pH. The 
appearance of citrate resonances in the model to discriminate both GF and CV, suggests a 
differential pH dependent shift in citrate that was not completely corrected by sample 
buffering.  
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Figure 4.11 O-PLS-DA coefficients for the discrimination between the spectra of germ 
free and conventional mice on fasted baseline urine samples.  
Loading coefficients from the O-PLS DA model presented as a spectral heat map 
demonstrate those peaks that discriminate GF and CV urine samples. The colour of the 
peaks corresponds to the coefficient with reference to the coloured scale on the right. GF 
mice have a relative paucity of aromatic metabolites, including PAG, hippurate and 4-HPPA. 
An unattributed resonance at 9.31ppm was consistently seen in GF mice but not CV controls. 
It is shown as a discriminating peak by this model. Other discriminating metabolites include 
TMA< TMAO and taurine, which were more abundant in CV mice and creatine and glycine in 
GF mice.  
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4.3.8 Responses to hepatotoxicity 
To explore the response of germ free and conventional mice to paracetamol-induced 
hepatotoxicity, their urinary metabolic profiles at T8, when liver injury was established, were 
analysed. Principal components analysis of urine specimens from both T0 and T8 were 
analysed for both groups (Figure 4.12).  
 
Figure 4.12 Principal components analysis of baseline (T0) and post-dose (T8) urinary 
spectra of germ free and conventional mice. 
 
The shift between T0 and T8 in conventional mice is described by both PC1 and PC2. The 
metabolites responsible for this discrimination are related to hepatotoxicity and are described 
in section 4.3.9. In the germ free mice a much more heterogeneous response to 
hepatotoxicity is seen, with wide scattering of observations, including two outliers. The 
difference between baseline and T8 spectra in GF mice is best described by PC2.  
OPLS-DA of only the T8 samples in the two groups produces a model with good fit and 
predictive validity (R2X = 0.75, Q2 = 0.88). However the discriminating metabolites were 
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similar to those at baseline (section 4.3.7), suggesting that the germ free/conventional status 
of the mice was the overriding discriminator even after the induction of hepatotoxicity.  
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4.3.9 Common markers of hepatotoxicity 
To look for urinary markers of hepatotoxicity that were common to all groups of mice and 
might have utility in humans as an early biomarker of liver injury, the pre (T0) and post (T8) 
urine samples were first analysed. The T8 samples of high and low responders were then 
compared to determine whether any of the metabolites that increased after administration of 
the hepatotoxic dose of paracetamol could discriminate high and low responders. Finally, the 
T4 samples were assessed to determine how early these markers were evident.  
The urinary spectra of mice pre- and post paracetamol clearly separated on PCA along the 
second component (Figure 4.13) 
 
 
Figure 4.13 Principal components analysis of pre and post dose urine from all groups. 
PCA shows clear separation along the second component of urine samples from all mice at 
baseline (T0) and with established paracetamol-induced liver injury (T8). The outliers are 
mice from the GF group. 
 
The model demonstrated good fit and predictive validity on PLS-DA (R2X = 0.76, R2Y = 0.88 
and Q2 = 0.77). The metabolites that most discriminated between the pre and post dose 
samples were demonstrated on an OPLS-DA coefficient plot (Figure 4.14). 
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Figure 4.14 OPLS-DA coefficients for the discrimination between pre-dose and post-
dose samples. 
This spectral heat map shows those metabolites that are more abundant in pre-dose 
specimens (shown as negative correlations) and those that are more abundant in the post-
dose, hepatotoxic samples (above the line). The strength of the correlation is colour coded 
according to the scale on the right. The spectra from post-dose mice at 8 hours are 
characterised by a relative excess of taurine, some residual paracetamol metabolites and a 
relative paucity of creatine, lactate, glucose and 2-oxoisocaproate. 
 
The presence of a high concentration of taurine in the urine of mice eight hours after a toxic 
dose of paracetamol was a clear discriminator of these samples from the pre-dose urine.  
To investigate whether taurine concentrations correlated with response a supervised PLS-DA 
model was constructed to explore variation between the ‘high’ responders and ‘low’ 
responders at eight hours. The model demonstrated good fit but required six components to 
achieve good predictive validity (PLS-DA 6 component model R2X = 0.83, R2Y = 0.98 and 
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Q2 =0.63). Taurine was one of the metabolites that contributed to the discrimination in this 
model. Interestingly, residual urinary paracetamol metabolites also weakly correlated with 
response, with greater concentration of paracetamol metabolites in the urine in high 
responders at eight hours than low responders.  
Analysis of the T4 urine samples compared with baseline samples showed that the elevation 
in urinary taurine is an early event in paracetamol toxicity. The separation between T0 and 
T4 samples on multivariate analysis was clear and was largely due to paracetamol 
metabolites that were still present in the T4 urine samples. However, taurine did contribute to 
discrimination in this model with coefficients in OPLS-DA modelling of 0.67 and 0.61 for the 
two taurine peaks at 3.27 ppm and 3.43ppm respectively.  
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4.4 Discussion 
The first aim of this study was to determine whether the presence of intestinal microbiota 
influenced the initial metabolic phase of paracetamol-induced hepatotoxicity. It was 
hypothesised that bacterial metabolites might enhance the conversion of paracetamol to its 
toxic metabolite, NAPQI, by induction of CYP2E1 and competitive inhibition of hepatic 
sulpho-transferase enzymes. Baseline hepatic CYP2E1 mRNA and protein concentrations 
did not differ significantly between the GF mice and conventional controls. Analysis of the 
urinary metabolites of paracetamol by 1H-NMR did show evidence of greater hepatic 
sulphonation of paracetamol in germ free mice. This agrees with a previous study using 
gradient elution HPLC to investigate paracetamol metabolism in GF mice (Mikov et al., 1988) 
and with a study in human volunteers that showed a greater load of bacterial-derived p-
cresol sulphate was associated with lower hepatic sulphonation of paracetamol (Clayton et 
al., 2009). The shift in paracetamol sulphonation between germ free and conventional mice 
though significant, was subtle and partly compensated for by an increase in glucuronidation 
in the conventional mice. Therefore overall, there was not significant difference in the 
proportion of paracetamol that was bioactivated by the CYP450 system. 
Baseline hepatic glutathione concentrations were shown to be significantly lower in GF than 
CV mice. This would enhance the susceptibility of these mice to paracetamol-induced liver 
injury as hepatocellular glutathione is essential for the detoxification of NAPQI. Conditions 
such as starvation, that are associated with diminished hepatocellular glutathione 
concentrations are known to predispose to exaggerated paracetamol induced hepatotoxicity 
(Waring, 2012). The causes of reduced hepatic concentrations of glutathione in germ free 
mice are not clear. The rate limiting substrate in glutathione synthesis is L-cysteine, which 
can be derived from the diet, protein breakdown or methionine, via the cystathionine pathway 
(Lu, 2009). It is possible that the absence of intestinal microbiota limits the absorption of 
cysteine from the gut, or alters the expression or activity of one of the enzymes responsible 
for glutathione synthesis. Interestingly, taurine, which is a derivative of cysteine, was found to 
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be relatively less abundant in the urine of germ free mice at baseline compared with 
conventional controls. This again suggests there may be a relative deficiency of systemic 
cysteine in germ free animals.  
It was hypothesised that germ free mice would be protected from paracetamol induced liver 
injury due to altered paracetamol metabolism and decreased secondary inflammatory stimuli 
from bacterial products. However, it was demonstrated that the extent of hepatocellular death 
was not significantly different between germ free, conventional mice or those with impaired 
LPS/TLR4 signalling. Histological assessment of hepatocellular necrosis showed no 
significant attenuation of injury in the germ free group. The mean ALT values eight hours 
after paracetamol for the GF and LPSr groups were reduced compared to the conventional 
mice, however this trend did not reach statistical significant, possibly because of the large 
variability within each group.  
Although the extent of the initial liver injury was not altered in germ free mice, there was 
evidence of a milder acute liver failure phenotype, with reduced bilirubin and creatinine and a 
trend towards higher glucose in the GF mice compared with controls. Interestingly there was 
evidence of an even greater protective effect in the LPSr than GF mice. This suggests that 
the global impairment in TLR4 signalling in the LPSr mice has benefits in excess of reduced 
LPS stimulation. The benefit of this TLR4 inhibition is likely to be due to reduced DAMP 
signalling, in particular failure to respond to HMGB1 released into the circulation by necrotic 
hepatocytes. HMGB1 signalling has been shown to have a central role in the sterile immune 
response to paracetamol induced hepatocellular necrosis and this is largely mediated 
through TLR4 (Shah et al., 2013, Antoine et al., 2012). One of the limitations of this study is 
that in order to model acute, severe toxicity, the study duration was necessarily limited by 
animal welfare considerations. In this respect, it was not possible to explore the evolution of 
acute liver failure and development of multi-organ failure. Evidence from the eight-hour 
termination point hints that, with lower glucose concentrations, higher bilirubin and greater 
renal impairment, the conventional mice might have progressed to a worse outcome.  
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Metabolic profiling of urine samples from GF and CV mice also showed a diverging metabolic 
response to paracetamol toxicity at 8 hours. Baseline differences in metabolic profile 
between the germ free and conventional mice included a paucity of the aromatic compounds, 
PAG, hippurate and 4-HPPA in the germ-free mice. This is due to the fact that these 
compounds are produced by co-metabolism between the host and intestinal microbiota 
(Claus et al., 2008). The baseline differences in urinary metabolic profiles between GF and 
conventional mice have been extensively described elsewhere (Claus et al., 2008, Claus et 
al., 2011). Although this study replicates some of their previous findings, such as elevated 
TMA and hippurate in conventional animals, the exact pattern of metabolic variation between 
groups of mice was not consistent between studies. This emphasises the limitations in 
external validity of this form of metabolic assessment in mice, in whom the environment, age, 
diet, precise strain, timing and method of sample collection and many other factors, will 
impact on the metabolic milieu and alter urinary profiles. 
Variation in gut microbiota within inbred strains of mice was postulated to underlie some of 
the unexpected heterogeneity seen in response to paracetamol hepatotoxicity by a recent 
review (Kubes and Mehal, 2012). It was therefore hypothesised that within a germ free 
population of mice, reduced interindividual variability in response to paracetamol would be 
observed. It has been shown here that a similar degree of interindividual variation to 
paracetamol hepatotoxicity exists in germ free and conventional mice. The standard 
deviation from both the mean ALT and hepatic necrosis values was similar in the two 
populations of mice.  
Intestinal microbiota can vary substantially between experimental mice. However, host 
genetics have an important influence on the species of bacteria that colonise the intestine 
and so within an inbred strain of mice, less heterogeneity is observed (Deloris Alexander et 
al., 2006). Environmental factors are also significant, with marked variation existing between 
the types and ratios of bacteria observed to colonise mice originating from different vendors 
(Hufeldt et al., 2010). Co-housing from birth and post-weaning is a major factor that limits 
 164 
variation in bowel flora. Indeed for mice from the same inbred strain, cohoused together, 
there is little variation in bowel flora (Deloris Alexander et al., 2006). Considering the 
previous observation described in chapter 3, that extreme variation exists with co-housed 
littermates from an inbred strain, our hypothesis that interindividual variability might be 
mediated by differences in intestinal microbiota, was not confirmed. It is perhaps unsurprising 
therefore that the complete absence of bowel flora did not reduce the heterogeneity of 
response to paracetamol in isogenic mice. 
The exploration of paracetamol hepatotoxicity in this group, along with metabolic profiling at 
various stages of liver injury permitted the investigation of common urinary markers of 
hepatotoxicity. Eight hours after paracetamol hepatotoxicity, when liver injury was 
established, urinary taurine concentrations were significantly elevated compared to baseline. 
Urinary taurine also correlated with the degree of liver injury at this stage and could 
discriminate between high and low responders. Looking at earlier urine samples, just four 
hours after paracetamol dosing, urinary taurine also appears to be elevated. 
Considering the early appearance of taurine in the urine after paracetamol and its ability to 
discriminate the level of liver injury, it may act as a useful non-invasive biomarker of 
hepatotoxicity.  Urinary taurine has been shown to be elevated in hepatotoxicity due to a 
range of toxins including paracetamol, aflatoxin, alpha-naphthyl isothiocyanate (ANIT), d-(+)-
galactosamine (GalN), and butylated hydroxytoluene (BHT) (Maxuitenko et al., 1997, 
Beckwith-Hall et al., 1998, Ghandforoush-Sattari and Mashayekhi, 2008).  
In summary it has been demonstrated that intestinal microbiota may cause a subtle shift in 
the metabolism of paracetamol, by reducing the ratio of hepatic sulphonation to 
glucuronidation.  However, in this acute, severe toxicity model, there was no evidence that 
intestinal microbiota significantly enhanced the bioconversion of paracetamol to a toxic 
product. A difference in the severity of liver injury as assessed by histology and ALT was not 
demonstrated between groups, though worse indices of acute liver failure and secondary 
complications were observed in the conventional group. This suggests the possibility that 
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intestinal microbiota may impact upon the secondary response to liver injury. A group of mice 
with defective TLR4 signalling had additional protection from the secondary complications of 
hepatoxicity. TLR4 inhibition or gut cleansing strategies may therefore have a potential 
therapeutic role in clinical practice to limit the sequalae of paracetamol-induced acute liver 
failure. 
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5 CHARACTERISATION OF A MURINE ACUTE LIVER 
INJURY MODEL WITH RECOVERY FOR THE 
INVESTIGATION OF A CANDIDATE GENE: SECRETORY 
LEUCOCYTE PROTEASE INHIBITOR 
 
5.1 Background and aims 
5.1.1 Reverse genetics 
The QTL mapping experiment detailed in the first chapter of this thesis adopted a classical, 
forward genetics methodology. In a forward genetics approach the observation of a 
phenotype of interest, in this case the different susceptibility to paracetamol hepatotoxicity 
between two strains of mice, is followed by an effort to determine the underlying genetic 
cause. An alternative way to approach the phenotype-genotype relationship is by reverse 
genetics methodologies, starting with the gene of interest. In this approach, the expression of 
a candidate gene, that is hypothesised to play a role in a phenotype of interest, is disturbed 
and the resulting effect on the phenotype is observed. Perturbation of the candidate gene 
can be through a variety of genetic techniques including knockout, knockdown, over-
expression and conditional or tissue specific changes in expression. Mouse models are the 
most commonly used experimental system in which reverse genetics techniques are applied. 
They allow manipulation of the genome in a tractable whole animal, mammalian system in 
which complex disease phenotypes can be explored. Observations from human disease may 
be ‘reverse translated’ into mouse models to permit studies of mechanism and potential 
therapeutics.  
It is this approach that I have taken to the investigation of a candidate gene, Slpi. The protein 
SLPI was identified in human studies conducted by our research group, as a potentially 
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important mediator of systemic immune paresis in acute liver failure (Antoniades et al., 
2013). The intrahepatic effects of SLPI are difficult to investigate in humans, as liver samples 
are only accessible if patients are undergo liver transplantation, and then the tissue is from a 
late time point in the evolution of liver injury. Genetic manipulations are also not possible in 
human populations for obvious ethical reasons. I have therefore conducted experiments to 
determine the intrahepatic effects of SLPI on paracetamol-induced liver injury in a mouse 
model. This chapter describes the validation of a liver injury time course and expression 
patterns of SLPI in this model. 
 
5.1.2 Secretory leucocyte protease inhibitor 
5.1.2.1 SLPI gene and protein structure and homology 
SLPI is a small (11.7KDa) serine protease inhibitor that was first identified as a potent 
inhibitor of proteases at mucosal surfaces, with activity against neutrophil elastase, cathepsin 
G, trypsin, chymotrypsin, tryptase and chymase (Sallenave, 2010). The human SLPI gene is 
located on chromosome 20. Its murine counterpart Slpi, shares significant sequence 
homology and is found on chromosome 2. The genes have similar intron-exon organisation, 
being composed of four exons that span 2,222bp in the mouse, with a promoter region 
approximately 110bp upstream of the transcription start site (Kikuchi et al., 1998). The 
human SLPI gene is transcribed to a 399bp mRNA, encoding a 132 amino acid protein 
(Stetler et al., 1986). The murine equivalent has a 396bp mRNA and a protein containing 131 
amino acids (for protein sequence see appendix O) (Kikuchi et al., 1998).  
SLPI is a member of the whey-acidic protein (WAP) family, with both the murine and human 
proteins containing two of the highly conserved WAP domains within their structure. These 
domains are approximately 50 amino acid long regions that contain eight highly conserved 
cysteine residues that form four disulphide bonds (also known as a 4-disulphide core 
domain) (Possamai et al., 2014a). SLPI is a highly cationic (net charge of +11) molecule. It is 
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secreted from mucosal cells and can gain entry to target cells through its interactions with 
annexin II and phospholipid scramblase receptors 1 and 4 (Ma et al., 2004, Py et al., 2009). 
 
5.1.2.2 Multiple roles for SLPI in innate immunity 
SLPI was first discovered and named for its role as an inhibitor of proteases at mucosal 
surfaces. Anti-proteases function to protect cells from the ‘bystander effects’ of endogenous 
proteases such as neutrophil elastase, produced as part of the immune response targeted 
against invading pathogens or digestive protein-cleaving enzymes such as trypsin.  The 
COOH-terminal domain of SLPI is responsible for the anti-protease actions of this molecule 
(Eisenberg et al., 1990). 
In the last 20 years many additional, anti-protease-independent actions of SLPI have been 
discovered proving it to be a pleotropic molecule with multiple and varied roles in innate 
immunity (summarised in table 5.1). SLPI has direct anti-microbial properties and is thought 
to be an important part of host mucosal defences against pathogens in the oral cavity, 
nasopharynx, lung and vagina (Sallenave, 2010). SLPI can limit HIV infection through effects 
on viral entry to cells and viral replication. It also has direct anti-bacterial, antimycobacterial 
and anti-fungal properties, which are thought to be mediated by the NH2-terminal domain and 
cationic elements in the WAP domains (Hiemstra et al., 1996).  
It is now recognised that SLPI is secreted not only from mucosal cells, but also from 
macrophages stimulated with LPS and pro-inflammatory cytokines (Jin et al., 1997). It acts 
as an anti-inflammatory, tolerogenic molecule, limiting the pro-inflammatory response by 
inhibiting NFκB signalling at multiple levels (Figure 5.1). In the extracellular space SLPI 
interferes with LPS binding of CD14, thus inhibiting signalling through TLR4 (Ding et al., 
1999). SLPI may also bind directly to microbial pathogen-associated molecular patterns 
(PAMPs) (Gomez et al., 2009). Intra-cytoplasmic SLPI prevents IκBα degradation, leading to 
the NFκB heterodimer being held in the cytoplasm by IκBα and preventing it from migrating 
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to the nucleus to induce pro-inflammatory gene expression (Taggart et al., 2002). SLPI can 
also bind directly to the NFκB and AP-1 consensus regions, thereby competitively inhibiting 
their binding and direction of gene expression (Taggart et al., 2005).  
 
Figure 5.1 The multiple inhibitory roles of SLPI in NFκB signalling 
The anti-inflammatory effects of SLPI are partly mediated through its inhibition of NFκB 
dependent pro-inflammatory cytokine production. This occurs at multiple levels in the 
signalling pathway. In the extracellular domain, SLPI can interfere with LPS binding to CD14, 
reducing TLR4 activation (A). Within the cytoplasm, SLPI prevents IκBα degradation, thus 
preventing NFκB translocation to the nucleus (B). In the nucleus SLPI can bind directly to the 
NFκB consensus region, competitively inhibiting NFκB binding and direction of gene 
expression. SLPI may also effect binding of AP-1, another pro-inflammatory transcription 
factor, to it consensus region through a similar mechanism (C). 
 
SLPI expression by macrophages can be induced by the phagocytosis of apoptotic cells 
(Odaka et al., 2003). It is thought that SLPI may then act in an autocrine fashion to assist in 
the switch of macrophages from a pro-inflammatory ‘M1-like’ to pro-resolution ‘M2-like’ 
phenotype. This mechanism is potentially important in sterile inflammation, such as found in 
A 
B 
C 
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paracetamol-induced acute liver failure, in directing monocyte-derived macrophages towards 
a pro-resolution function once they enter tissue and come into contact with apoptotic cells. 
SLPI may also be induced by the anti-inflammatory cytokines IL-6 and IL-10 and interestingly 
SLPI itself may then induce expression of IL-10 and TGFβ, producing an anti-inflammatory, 
autocrine, positive feedback mechanism within macrophages (Sano et al., 2000, Jin et al., 
1998).  
A number of cancer cells, including ovarian and pancreatic cancers, over-express SLPI 
which is thought to aid growth and survival by dampening the local anti-tumour immune 
response (Zuo et al., 2014) (Devoogdt et al., 2009). 
More recently still a role for SLPI in the normal maturation and differentiation of bone marrow 
neutrophils has been discovered (Klimenkova et al., 2014). This is discussed in more detail 
in chapter 6. 
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Role Details  References 
Anti-protease activity Anti-protease effects protect cells against 
neutrophil elastase, cathepsin G, trypsin, 
chymotrypsin, tryptase and chymase. 
(Sallenave, 2010) 
Direct anti-bacterial 
and anti-
mycobacterial effects 
Antibacterial effects against E. coli and 
S. aureus mediated by NH2-terminal 
domain 
Antimycobacterial effects mediated by 
cationic elements in WAP domains 
SLPI may bind directly to mycobacterial 
surface, acting as a pattern recognition 
receptor 
(Hiemstra et al., 1996) 
 
 
 
(Nishimura et al., 2008) 
 
(Gomez et al., 2009) 
Anti-viral effects Inhibits HIV1 replication (Wahl et al., 1997) 
Anti-fungal effects Fungicidal activity against Candida and 
Aspergillus localised to NH2-terminal 
domain 
(Tomee et al., 1998) 
Inhibition of NFκB 
signalling 
Inhibition of NF-κB pro-inflammatory 
signalling via multiple mechanisms 
(summarised in Figure 5.) 
(Jin et al., 1997) 
(Lentsch et al., 1999) 
(Taggart et al., 2002) 
Mucosal tolerance Shown to be a regulator of mucosal 
tolerance by controlling the level of 
bacterial stimuli that lead to mucosal DC 
activation. 
(Samsom et al., 2007) 
Macrophage 
phenotype 
Macrophages produce SLPI in response 
to the phagocytosis of apoptotic cells. 
(Odaka et al., 2003) 
(Holt et al., 2008) 
Neutrophil maturation SLPI controls the proliferation, 
differentiation and cell cycle of bone 
marrow neutrophils. 
(Klimenkova et al., 2014) 
Tumorigenesis Overexpression of SLPI by pancreatic 
and ovarian cancer cells linked to 
increased cell survival by anti-
inflammatory and proliferative effects 
(Zuo et al., 2014) 
(Devoogdt et al., 2009) 
Table 5.1 A summary of the multiple functions of SLPI 
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5.1.2.3 SLPI in paracetamol-induced acute liver failure 
In a study on 73 patients with paracetamol-induced liver failure it was demonstrated by our 
group that circulating SLPI concentrations are elevated compared with healthy controls 
(Antoniades et al., 2013). Serum SLPI concentrations were highest on admission and fell on 
day 3, though remained elevated above healthy controls. Comparisons of SLPI 
concentrations between the hepatic and portal veins showed significantly higher levels in the 
PV, suggesting the liver was a source of SLPI. Explant liver tissue demonstrated SLPI 
expression in the biliary epithelium and in macrophages within the centrilobular, necrotic 
region. 
The systemic effects of SLPI on circulating monocyte function were studied. It was 
demonstrated that ex vivo treatment of healthy monocytes with SLPI reproduces the 
monocyte phenotype and defects in their function seen in ALF. Incubating monocytes with 
homogenates derived from ALF liver could also recreate this pattern of monocyte 
dysfunction, and this effect was partly blocked with a SLPI inhibitor. It therefore appears that 
SLPI is produced by the injured liver in paracetamol- induced acute liver failure and spills 
over into the systemic circulation where it may be partly responsible for the observed 
monocyte dysfunction that renders patients susceptible to sepsis.  
Before consideration of SLPI as a potential target for immune therapy, a more thorough 
understanding of its intrahepatic effects is required (Possamai et al., 2014a). The known 
roles of SLPI in mitigating neutrophil elastase-mediated tissue damage and in promoting a 
pro-resolution phenotype in monocyte-derived macrophages suggest it may have important 
intrahepatic functions in ALF. Systemic blockade of SLPI with the aim of reversing 
immunoparesis in ALF may therefore have unwanted and deleterious consequences.  
 173 
5.1.3 Aims 
This chapter and chapter 6 of the thesis describe a reverse genetics, reverse translational 
approach in which a protein of interest, SLPI, identified in human acute liver failure is further 
investigated in a murine model. Paracetamol-induced liver injury with significant hepatocyte 
death and a marked inflammatory response was required, however it needed to be 
compatible with survival in order to track hepatic resolution. It was also necessary to prove 
that hepatic expression of SLPI can be detected in the model. The aims of this chapter are 
therefore: 
 
1. To generate and describe a murine model of paracetamol-induced acute liver 
injury with significant injury and immune activation, but potential for resolution 
and recovery. 
 
2. To determine the extent of hepatic SLPI expression during the initiation, 
propagation and resolution phases of acute liver injury  
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5.2 Materials and methods 
5.2.1 Mice and Paracetamol dosing 
Mice were maintained as in section 2.2.1. under standard conditions at MRC Harwell. 
Thirty-five male C57BL/6NTac mice between 69-83 days old were each dosed with a single 
325mg/kg dose of paracetamol via the IP route, following an overnight fast. The dose was 
chosen following pilot work, including the inbred strains experiment (chapter 3) that 
suggested a dose under 350mg/kg would be required to allow survival beyond 24 hours. A 
further five mice were fasted overnight but not dosed with paracetamol to provide a baseline 
control group. 
 
5.2.2 Sample collection 
All mice had a blood sample taken 8 hours post-paracetamol, via a tail vein bleed for all 
except the 8 hour cull group. Groups of five mice were culled at each of 7 time points after 
paracetamol dosing: 8 hours, 24 hours, 32 hours, 48 hours, 72 hours, 5 days or 7 days. Mice 
were culled by injection of pentobarbital to induce deep anaesthesia and terminal 
intracardiac blood sampling. Necropsy was performed, during which the liver was split, with 
half being fixed in formalin and half snap frozen in liquid nitrogen.   
 
5.2.3 Biochemical measures of liver injury 
Plasma was separated from whole blood and analysed as in section 2.2.4 
 
5.2.4 Histology 
Formalin fixed liver tissue was paraffin embedded and sectioned. Liver was stained with 
haematoxylin and eosin.  
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5.2.5 Liver homogenates 
Liver homogenates were prepared as in section 4.2.5. The total protein content of 
homogenates was quantified using a Bradford Assay, as in section 4.2.6 and normalised to a 
total protein of 1mg/ml prior to downstream analyses. 
 
5.2.6 Pro-inflammatory cytokine expression 
Concentrations of pro-inflammatory cytokines (IL-1β, IL-1RA, IL-6, IL-18, IL-23, TGFβ, IL-
12p40, MCP-1, RANTES, TNFα, IFNγ, IL-10) were quantified in liver homogenates. Samples 
were sent to Aushon Biosystems (Billerica, MA) where a Ciraplex® immunoassay was 
performed. The assay is an ELISA-based system in which antibodies specific to the 12 
analytes are applied in discrete dots to the wells of a 96-well plate, to allow simultaneous 
detection of the cytokines. A chemiluminescent detection system is used and unknown 
samples are compared with a standard curve constructed from standards of known 
concentration. 
 
5.2.7 SLPI expression by RT-PCR 
RNA extraction from snap frozen liver tissue and reverse transcription were performed as in 
section 4.2.4. RT-PCR was performed using Taqman assays for murine SLPI 
(Mm00441530_g1) and B2M (Mm00437762_m1) as the reference gene. Expression was 
compared using a ΔΔCT method (See Appendix P). 
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5.2.8 SLPI concentrations in plasma and liver 
SLPI concentrations were measured in plasma and liver homogenates by ELISA (USCN Life 
Sciences Murine SLPI ELISA, E91312Mu).  
 
5.2.9 SLPI Immunohistochemistry 
Formalin fixed liver tissue was embedded in paraffin, sectioned at 10µM thick and mounted 
on glass slides. Sections were deparaffinised in xylene and rehydrated through graded 
alcohols before washing in water. Heat-induced antigen retrieval was performed by heating 
samples in citrate buffer pH 6.0 using a microwave. Non-specific binding was blocked using 
1.5% normal mouse serum for 1 hour at room temperature. The primary antibody was a 
rabbit anti-mouse SLPI antibody (AbD Serotec, Oxford UK), it was diluted to 1 in 800 in PBS 
applied to sections and incubated overnight at 4oC. A goat anti-rabbit biotinylated secondary 
antibody from a VECTASTAIN® ABC-AP Kit (Vector laboratories, Burlingame, CA) was 
applied in blocking serum. An avidin-biotin complex reagent was applied, followed by an 
alkaline-phosphatase substrate solution from the VECTOR® red alkaline phosphatase 
substrate Kit (Vector laboratories, Burlingame, CA). Slides were washed and counterstained 
in haematoxylin, dehydrated through alcohols and xylene and coverslipped.  
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5.3 Results 
5.3.1 Liver injury in the 7 day murine model 
The time course experiment demonstrated a nearly normally distributed range of ALT values 
at 8 hours in all mice, with a mean of 6740 +/-2960 U/L (Figure 5.2 Histogram showing 
distribution of ALT values in mice 8 hours after paracetamol.) 
 
 
Figure 5.2 Histogram showing distribution of ALT values in mice 8 hours after 
paracetamol. 
The range of ALT values in the mice (n=35) was normally distributed, with a range of 1869-
12855U/L, mean of 6740U/L and standard deviation of 2960U/L 
 
Plasma ALT was measured in groups of mice at intervals between 8 hours and 7 days after 
administration of paracetamol (Figure 5.3). Within 8 hours there was a significant elevation in 
ALT to 5263 +/- 1331U/L, suggesting hepatocellular death was established by this time point. 
The peak ALT value in this model was at 24 hours after injury, with a mean value of 8838+/-
1516U/L. The ALT value then decline until by 5 days post-paracetamol it was normal at 55 
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+/- 7.7 U/L. These ALT values suggest this model produces marked acute liver injury, but is 
compatible with resolution and long-term survival. 
 
 
Figure 5.3 Plasma ALT values at cull. 
Each time point is composed of a different set of mice with n=5 for each time point, except 
day 5 and day 7, when n=4. The results show an acute elevation in ALT within 8 hours of 
paracetamol administration, to a mean value of 5263 U/L. Peak ALT is at 24 hours, with a 
mean of 8838U/L. 
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5.3.2 Descriptive histological assessment of liver injury 
Histological assessment of haematoxylin and eosin stained liver sections from all time points 
was performed. By eight hours after liver injury there was perivenular swelling and confluent 
areas of necrotic hepatocytes were visible surrounding the central vein (Figure 5.4 A). By 24 
hours there was evidence on H&E of perivenular inflammatory infiltrate and extension of the 
centrilobular necrosis (Figure 5.4 B). In some sections the necrosis could be seen to bridge 
between two adjacent hepatic lobules. Necrotic hepatocytes made up approximately 30% of 
the liver tissue area at this time point. In sections from later time points resolution of 
inflammation could be seen in the centrilobular regions. Necrotic tissue was replaced with 
hepatocytes and frequent mitotic bodies provided evidence of hepatocyte regeneration 
(Figure 5.4 D and E). 
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5.3.3  
Figure 5.4 Representative H&E stained liver sections from time points after 
paracetamol dosing 
All images are at x40 magnification. Sections show the evolution of liver damage from 
centrilobular swelling and necrosis at 8 hours (A) and 24 hours (B) after paracetamol, to the 
clearing of necrotic tissue at 72 hours (C) and repopulation of centrilobular regions with 
hepatocytes by days 5 (D) and 7 (E) after injury. 
 
A B 
C D 
E 
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5.3.3 Inflammatory cytokine production  
In order to determine whether this murine model of paracetamol-induced acute liver injury 
was associated with immune activation, twelve key pro and anti-inflammatory cytokines and 
chemokines were measured in liver tissue at various stages of liver injury (Figure 5.5).  
There was evidence of early inflammasome activation, with concentrations of IL-1β and IL-
18, elevated significantly above baseline by 8 hours after paracetamol dosing (for control v 8 
hours, Dunn’s multiple comparisons p=<0.01 and p=<0.05 respectively). IL-1β 
concentrations were highest at 8 hours and remained significantly elevated over baseline 
until 32 hours after paracetamol.  IL-18 concentrations peaked at 24 hours post-paracetamol 
and, like IL-1β, had returned to near baseline concentrations by 48 hours. 
IL-1 receptor antagonist (IL-1RA) is a naturally occurring inhibitor of IL-1 responses through 
its binding to the IL-1 receptor without inducing intracellular signalling. It is known to be 
produced by the liver and immune cells as an acute phase protein with an anti-inflammatory, 
immune-regulatory role. In this murine model, IL-1RA was significantly elevated above 
baseline by 8 hours after injury (p<0.05), however it did not peak until 48 hours post-injury 
when hepatic regenerative responses prevailed, and Il-1β concentrations had already fallen 
to baseline concentrations.  
The concentrations of other pro-inflammatory cytokines TNFα, IFNγ, IL-6, IL-23 and IL-12p40 
were elevated significantly above baseline by 8 hours and all tended to peak between 8-32 
hours and return to baseline by 48 hours post-paracetamol. The anti-inflammatory mediators 
IL-10 and TGFβ followed a similar pattern with marked early peaks followed by rapid 
declines between 32-48 hours. 
The leukocyte chemokines MCP-1 and RANTES/CCL5 were also measured. These 
molecules showed a slightly later increase and their elevation in the liver persisted to 48 
hours after paracetamol, beyond the cytokines.  
 182 
 
 
IL-1β
pg
/m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
200
400
600
p<0.002
IL-6
pg
/m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
200
400
600
800
p<0.002
IL-23
pg
/m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
2000
4000
6000
8000
p<0.001
IL-1RA
pg
/m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
10000
20000
30000
40000
50000
p<0.001
IL-18
pg
/m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
500
1000
1500
2000
p<0.001
IL-10
pg
/m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
200
400
600
p<0.001
IL-12p40
 p
g/
m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
50
100
150
p<0.001
IFNγ
pg
/m
l
Co
ntr
ol
8 h
ou
rs
24
 ho
ur
s
32
 ho
ur
s
48
 ho
ur
s
5 d
ay
s
0
200
400
600
800
1000
p<0.001
 183 
 
Figure 5.5 Inflammatory cytokine and chemokine concentrations in the liver post-
paracetamol-induced liver injury 
Inflammatory cytokines were measured in liver homogenates at various time points after 
administration of paracetamol (n=5 all groups, except day 5 when n=4). Significant elevations 
in all 12 of the mediators were demonstrated. P values displayed on graphs are the result of 
Kruskall-Wallis one-way analysis of variance by ranks testing. Dunn’s multiple comparisons 
tests were then performed to identify which time points differed significantly from the baseline 
value, these are discussed in text. 
 
5.3.4 SLPI expression by RT-PCR 
Having established that this murine experimental work could model acute severe liver injury 
with immune activation, it was questioned whether the protein of interest, SLPI was 
expressed in murine liver during injury. RT-PCR was performed on RNA extracted from liver 
at various time points after paracetamol-induced liver injury. This demonstrated a five-fold 
upregulation of hepatic SLPI mRNA within 8 hours of liver injury (p=0.014). SLPI appears to 
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be an early response gene as mRNA levels returned to baseline 24 hours after injury at the 
time of maximal tissue injury.  
 
 
Figure 5.6 SLPI expression in liver after paracetamol-induced liver injury 
SLPI expression was determined by RT-PCR, using a ΔΔCT methodology with B2M as a 
reference gene (n=5 in each group with each sample run in triplicate). There was a five-fold 
increase in expression of SLPI at 8 hours after liver injury compared with the baseline 
control group. Kruskal Wallis testing of ΔCT values showed significant differences between 
groups (p=0.01) 
 
5.3.5 SLPI concentrations in plasma and liver homogenates 
SLPI protein concentrations were measured in plasma and liver homogenates. In plasma, 
SLPI concentrations were significantly different across the time points of the study (p=0.007). 
There was an apparent elevation in circulating SLPI at the 8-hour time point; however, after 
correcting for multiple comparison this was not statistically significant. In liver the elevation in 
SLPI was more pronounced, suggesting this was the source of circulating SLPI. Protein 
concentrations were elevated in liver at 8 and 24 hours after paracetamol dosing, and 
returned to baseline by the 48-hour time point. 
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Figure 5.7 SLPI protein concentrations in plasma and liver after liver injury  
SLPI concentration in plasma (A) and liver homogenates (B) at various time points after 
paracetamol dosing (n=5 in all groups except 5 days in which n=4). In plasma the changes in 
SLPI expression were significant overall (Kruskal-Wallis p=0.007) but after correcting for 
multiple comparisons (Dunn’s), no time points were significantly different to the control. Liver 
homogenates were normalised to 1mg of total protein /ml prior to testing, the concentration 
can therefore not be compared to serum concentrations. Differences in SLPI concentration 
between time points were significant overall (Kruskal-Wallis p=0.003) and after multiple 
comparisons (Dunn’s) testing the concentration in control v 8 hrs. (p<0.001) and control v 24 
hours (p<0.05) were also significantly different. 
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5.3.6 Immunohistochemistry 
Immunohistochemistry for SLPI was performed on sections from the 24-hour time point. 
Diffuse staining was seen within the centrilobular areas of necrosis. This was present to a 
lesser degree in the negative control tissue and may therefore be non-specific staining as a 
result of the different tissue characteristics in that region (Figure 5.8 A and B). Some more 
intense and focal staining was seen around the rim between the necrotic and viable tissue 
(Figure 5.8 A). This staining appeared to be in large irregularly shaped cells, an appearance 
that would be compatible with macrophages. 
 
 
Figure 5.8 SLPI immunohistochemistry from 24 hours after paracetamol dosing (A) 
and negative control (B) 
Immunohistochemistry, performed with a rabbit anti-mouse SLPI primary antibody, showed 
the presence of SLPI in centrilobular areas of necrosis 24 hours after paracetamol dosing. 
The staining was particularly intense around the rim of the area of necrosis, in the zone 
between viable and necrotic hepatocytes (black arrows).  
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5.4 Discussion 
The purpose of work described within this chapter was to provide preparatory data for an 
investigation into the hepatic role of SLPI in a model of acute liver failure. SLPI has been 
suggested to play a role in the resolution of inflammation through its promotion of a ‘pro-
resolution’ macrophage phenotype. It was therefore important that we would able to assess 
the resolution stages of liver injury in this murine model. It has been shown in this chapter 
that using the C57BL/6 strain of mice with a dose of 325mg/Kg of paracetamol, it was 
possible to produce a recovery model of severe, acute liver injury. At 24 hours after 
paracetamol dosing, liver injury peaked with a mean ALT of nearly 9,000U/L and marked 
hepatocyte necrosis. Although we were unable to demonstrate progression to multi-organ 
failure requiring supportive care as is seen in human patients, the degree of liver injury 
observed in this model was sufficiently severe to model human liver injury.   It has also been 
shown that this degree of hepatic injury is associated with activation of the immune system, 
with increased production of pro-inflammatory cytokines, chemokines and anti-inflammatory 
mediators. Furthermore, it was demonstrated that the protein of interest, SLPI, is expressed 
in injured liver as an early, response to tissue damage.  
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6 PARACETAMOL-INDUCED ACUTE LIVER INJURY IN 
THE SECRETORY LEUCOCYTE PROTEASE INHIBITOR 
KNOCKOUT (Slpi-/-) MOUSE.  
 
6.1 Background and aims 
6.1.1 SLPI knockout mouse 
The discovery of secretory leucocyte protease inhibitor (SLPI) as an important mediator of 
immunoparesis in human acute liver failure naturally raised the possibility that inhibition of 
this molecule could be a therapeutic target. In order to progress this idea, a greater 
understanding of the intrahepatic role of SLPI during the development and resolution of acute 
liver injury was required.  In the previous chapter I demonstrated that SLPI is expressed in 
the murine liver during acute liver failure and the early peak and later decline in SLPI 
concentrations mirrors that seen in the sera of patients.  
The known action of SLPI as an inhibitor of NF-κB pro-inflammatory signalling suggests that 
an absence of SLPI might lead to enhanced activation of the immune system with deleterious 
effects. It has also been demonstrated that SLPI is expressed in macrophages in response to 
phagocytosis and this pathway has been postulated to have a role in the ‘switch’ of infiltrating 
monocyte-derived macrophages from a pro-inflammatory to a pro-resolution phenotype 
(Odaka et al., 2003). This phenotypic switch is of particular interest as it might be a target for 
immunotherapy in sterile inflammation (Possamai et al., 2014a). If SLPI is a key mediator of 
tissue macrophage plasticity, then systemic inhibition of SLPI might cause persistence of a 
pro-inflammatory macrophage phenotype with enhanced tissue destruction and cytokine 
secretion. There are clearly a number of concerns regarding the systemic targeting of SLPI 
for the treatment of immunoparesis. 
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Using a forward genetics approach I intended to study the effect of an absence of SLPI on 
paracetamol induced liver injury in a murine recovery model. A Slpi knockout, or ‘null’ (Slpi-/-) 
mouse has previously been described in the literature. The strain was originally developed by 
Professor S. Wahl’s laboratory at the NIH National Institute of Dental and Craniofacial 
Research and described in a paper published in 2000 in Nature Medicine (Ashcroft et al., 
2000). The Slpi-/- mice were generated by insertion of a targeting vector into the Slpi 
promoter and first exon (Figure 6.1).  The null mice were shown to experience persisting 
inflammation and delayed healing of cutaneous wounds compared with wild type mice. 
 
 
Figure 6.1 Structure of the endogenous Slpi allele, targeting vector and targeted 
allele. 
Slpi-/- mice were generated by Professor S. Wahl and colleagues. A targeting vector 
containing a neomycin resistance gene was introduced into the 849bp promoter region and 
46bp of exon 1 of the Slpi gene, producing an intragenic deletion and frameshift mutation. 
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6.1.2 Hypothesis and aims 
Secretory leucocyte protease inhibitor has been shown to have an important role in innate 
immunity, acting as an anti-inflammatory mediator in a number of models.  It was therefore 
hypothesised that in the absence of SLPI, acute liver injury would be more severe due to 
enhanced NFκB activation and persistence of a pro-inflammatory macrophage phenotype. 
The aims of this study were to test this hypothesis and: 
 
1) Define the severity of acute liver injury in Slpi-/- mice compared with wild type controls 
in terms of peak injury and rate of resolution. 
2) Describe the hepatic inflammatory infiltrate, including macrophage sub-populations in 
Slpi-/- mice and wild type controls during the initiation, propagation and resolution of 
paracetamol-induced acute liver injury. 
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6.2 Materials and methods 
6.2.1 Animals 
Slpi-/- breeding stock mice were a kind gift from Dr Mathias Wenes, University of Leuven, 
Belgium. Mice were used under a Material Transfer Agreement with the originator of the 
strain, Professor Sharon M. Wahl, NIH National Institute of Dental and Craniofacial Research 
(NIDCR), Bethesda, MD, USA. 
Mice were originally bred on a C57BL/6 background as described in the original paper by 
Professor Wahl and colleagues (Ashcroft et al., 2000), but had later been crossed with the 
129/SvJ strain. Upon importation to the UK, the line was rederived onto a C57BL/6 
background. Due to the mixed background and concerns regarding inter-individual variability 
in response to paracetamol, it was decided that wildtype littermates would be required as 
controls rather than purchasing pure C57BL/6 wildtype mice. The breeding of mice was 
therefore conducted using heterozygous male and female mice to give both homozygous 
Slpi-/- and homozygous wildtype littermate (WTLM) controls for experimental purposes. 
Mice were maintained at Central Biomedical Services, St Mary’s Campus, Imperial College. 
All research using live animals was approved by local ethics committees (Imperial College 
Central Animal Welfare Ethical Review Board (AWERB)) and was carried out under Home 
Office supervision in accordance with the Animal (Scientific Procedures) Act 1986 (UK). 
Procedures were performed under the authority of UK project licence 70/7578. All efforts 
were taken to minimize animal suffering. 
Mice were housed in specific pathogen free conditions in individually ventilated cages 
(Techniplast UK Ltd). The environment was controlled with a 12 hour light/dark cycle, 
ambient temperature of 21°C (+/-2°C) and humidity of 55% (+/-10%). Mice had access to 
irradiated diet (Special Diet Services UK) and water (25ppm chlorine) ad libitum except when 
food was withdrawn for defined experimental purposes. 
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6.2.2 DNA extraction and purification 
Mice underwent ear biopsy for identification and to provide tissue for genotyping. Ear biopsy 
specimens were lysed by incubation in 90µl of 50mM NaOH for 1 hour at 950C. The lysis 
mixture was neutralised by addition of 10µl of Tris-HCL pH8. Following cooling, 100µl of 
Phenol:Chloroform:IAA (Sigma Aldrich, St Louis, MO) was added to the lysis mixture, mixed 
by agitation and centrifuged for 8 minutes at 13,000rpm. The upper, aqueous phase was 
retained and again mixed with 100µl Phenol:Chloroform:IAA and centrifuged to repeat the 
phase separation. The aqueous phase was added to chloroform:IAA, mixed and centrifuged 
for 10 minutes at 13,000rpm. The aqueous phase was transferred to a fresh tube and 1µl of 
glycogen and 200µl of 100% ethanol were added, this mixture was then cooled to -800C for 1 
hour to aid DNA precipitation. The sample was centrifuged for 30 minutes at 40C to form a 
pellet of nucleic acid. The supernatant was then discarded, the pellet washed once in cold 
70% ethanol before resuspending the DNA in 30µl nuclease free water. 
 
6.2.3 Genotyping of Slpi-/- mice by duplex PCR 
Primer pairs specific for the promoter region of the wild type allele (P) and the neo-promoter 
region (N) in the knockout allele were designed. Custom primers were ordered from 
Invitrogen™ (Life Technologies, Carlsbad, CA). Primer sequences are detailed in Figure 6.2. 
A 25µl duplex PCR reaction was prepared for each sample by adding 12.5µl of Promega Go 
Taq® Green Maser Mix (Promega, Wisconsin, USA), 1µl of each of the 4 primers, 6.5µl of 
nuclease free water and 2µl of the purified DNA from the Phenol Chloroform extraction to a 
PCR tube. A non-template control was run alongside every PCR experiment, in which the 
DNA was replaced with 2µl of nuclease free water to confirm absence of contamination of 
reagents causing false positives.  The reaction was conducted in a GeneAmp® PCR System 
9700 thermocycler (Applied Biosystems) under conditions detailed in Figure 6.2. 
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Figure 6.2 Duplex PCR for genotyping of Slpi-/- colony 
Primer pairs specific to the WT promoter and the neo-promoter found in Slpi-/- were used, 
the primer sequences are shown above.  PCR cycling conditions are detailed. 
 
 
PCR products were separated by agarose gel electrophoresis. A 2% agarose gel was made 
by heating 2g of agarose in 50ml of Tris-Acetate-EDTA (TAE) buffer for 2 minutes on full 
power in an 800W microwave. 2µl of ethidium bromide was added to the liquid agarose gel 
before pouring it into a gel tank with 16-well comb and allowing it to set for 45 minutes. The 
gel was covered with TAE buffer and 3.5µl of sample, control or DNA ladder (HyperLadder™ 
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V, Bioline, London UK) was pipetted into each well. The gel was run at 60V for 30 minutes 
and then visualised in a UV transilluminator (UVP, Upland, CA). The amplified PCR products 
from the WT and Slpi-/- alleles were visualised at approximately 490 and 340bp as defined by 
the DNA ladder. Absent amplification was confirmed in the NTC lane and genotype was 
determined as heterozygote by the presence of both bands, homozygous WT by the 
presence of only the 490bp fragment or homozygous Slpi-/- by the presence of only the 
344bp fragment (see Figure 6.3).  
 
6.2.4 Validating model by RT-PCR for SLPI expression 
To validate the knockout mice that had been gifted from another research group RT-PCR for 
the expression of SLPI in the liver of wildtype and Slpi-/- mice was conducted. RNA was 
extracted from snap-frozen liver and reverse transcribed as in section 4.2.4. SLPI mRNA 
expression was compared to reference gene B2M as described in section 5.2.7. 
 
6.2.5 Baseline Histology 
Formalin-fixed liver samples from Slpi-/- and WTLM controls were Paraffin embedded, 
sectioned and mounted on glass slides. Haematoxylin and eosin (H&E) stains were 
performed.  To assess baseline liver differences between Slpi-/- and WTLM controls an 
expert histopathologist, Professor Robert Goldin, Imperial College reviewed liver sections. 
 
6.2.6 Baseline glutathione 
Glutathione was assayed in liver homogenates from Slpi-/- and WTLM controls following an 
overnight fast but no paracetamol (baseline or T0) and two hours after paracetamol dosing 
(T2). Liver homogenates were made from snap frozen liver tissue as described in section 
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4.2.5. Protein concentrations in the homogenates were quantified by the Bradford Assay and 
normalised as described in section 4.2.6.   
Reduced glutathione (GSH) and total glutathione (GSH + GSSG) were measured using a 
GSH/GSSG Ratio Detection Assay Kit (Abcam®, Cambridge UK) according to manufacturers 
instructions.  
6.2.7 Baseline CYP2E1 
Concentrations of CYP2E1 protein were determined in liver homogenates following total 
protein normalisation. A CYP2E1 ELISA kit (CSB-EL006425MO, Cusabio, Wuhan, China) 
was performed according to the manufacturers instructions as in section 4.2.7. 
 
6.2.8 Paracetamol dosing 
A power calculation was performed to determine the number of mice needed to detect a 40% 
change in peak ALT (see appendix Q). This determined that a comparison of five Slpi-/- with 
five WTLM controls would be sufficient to detect a 40% change in peak ALT to a power of 
95% and at a significance level of 0.05.  
Male mice between 8-12 weeks in age were used. Slpi-/- and WTLM controls were housed in 
mixed cages and all experimental runs contained both Slpi-/- and control mice.  
Mice were fasted overnight for 12 hours, prior to intraperitoneal dosing with 325mg/kg of 
paracetamol dissolved in saline by warming to 50oC for 45 minutes.  One experimental group 
were culled at baseline, following the overnight fast alone. Other groups of n=5 Slpi-/- and n=5 
WTLM controls were culled at 8 hours, 24 hours, 48 hours, 72 hours and 5 days after dosing 
with paracetamol. Additional mice were dosed and culled at 2 hours for hepatic glutathione 
quantification and the 24-hour time point for further experiments. 
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6.2.9 Sample collection 
Mice were placed under terminal anaesthesia with an intraperitoneal injection of 0.15ml of 
20% pentobarbitone sodium. Following the confirmation of deep anaesthesia by the absence 
of reflexes, a terminal blood sample was collected from the right ventricle. The left ventricle 
was then catheterised with a 22G butterfly needle connected to a 50ml syringe containing 
sterile PBS. An incision was made in the right ventricle and PBS was perfused through the 
circulation at a rate of approximately 8ml/minute. Visual inspection confirmed blanching of 
the liver and adequate perfusion. The liver was excised; the median lobe and gallbladder 
were separated from the rest of the liver and divided. Half the median lobe was place in 
formalin for fixation and half was snap frozen in liquid nitrogen. The remaining liver was 
roughly minced and placed on ice. 
 
6.2.10 Biochemical measures of liver injury 
Plasma was separated from whole blood and analysed for biochemical indices of liver 
dysfunction as detailed in section 2.2.4 
 
6.2.11 Assessment of liver necrosis 
To quantify peak liver injury at 24 hours post-paracetamol, the percentage area of hepatic 
necrosis as a proportion of total hepatic area was determined in 8 representative x10 power 
images. Image J image analysis software (http://imagej.nih.gov/ij/) (Schneider et al., 2012) 
was used to quantify areas of necrosis and normal tissue using the colour thresholding 
function.  
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6.2.12 Cytokine measurement in plasma and liver 
A panel of inflammatory cytokines and the neutrophil chemokine keratinocyte 
chemoattractant (KC) were measured using a MSD Multi-Spot Assay (Mesoscale 
Discoveries, Rockville, MD) as in section 4.2.9. 
 
6.2.13 Hepatic non-parenchymal cell isolation 
Fresh liver specimens were mechanically dissociated using a gentleMACS™ dissociator 
fitted with C-tubes (Miltenyi Biotech, Cologne, Germany). The single cell suspension created 
by this dissociation was passed through a 70µm cell strainer (BD Falcon, Bedford, MA) and 
the cells pelleted by centrifugation, then resuspended in 1ml of sterile PBS. Erythrocyte lysis 
was performed using ACK lysis buffer (Lonza, Basel, Switzerland). Hepatic non-parenchymal 
cells were isolated from hepatocytes by density centrifugation. The cells were suspended in 
5ml of 40% Percoll (GE Healthcare, Chalfont St. Giles, UK) and layered on top of 5mls of 
80% Percoll. Following centrifugation at 2200rpm for 20 minutes at room temperature with no 
brake, the hepatic non-parenchymal cell fraction was isolated from the interface between the 
40% and 80% Percoll. Cells were washed and counted using a disposable Neubauer 
haemocytometer (Peqlab, Erlangen, Germany). 
 
6.2.14 Cell staining and analysis by flow cytometry 
Hepatic non-parenchymal cells were first blocked by incubating in 20% normal mouse serum 
for 20 minutes, then stained with a panel of antibodies designed to discriminate populations 
of neutrophils, macrophages and ‘other’ (B, T and NK) cells. Antibodies were purchased from 
eBioscience (San Diego, CA) and AbD Serotec (Oxford, UK) and their details are given in 
Table 6.1. A fixed viability dye was used to discriminate live from dead cells. 
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Cells (5x105) were stained with fixed viability dye and following washing the cells were then 
incubated with a cocktail of the other antibodies. In parallel to cell staining, compensation 
beads (OneComp eBeads, eBioscience, San Diego, CA) were singly stained with antibodies. 
Isotype controls and fluorescence-minus-one (FMO) controls were also run to aid gating and 
discrimination of cell populations. 
Flow cytometry analysis was performed on a BD LSRFortessa (BD, San Jose, CA). 
Compensation was performed using single-stained beads at each flow cytometry session. 
Data was collected for 50,000 events within a gated population of interest, determined by 
forward and side scatter to exclude cell debris (see Figure 6.13 for full gating strategy). 
Flow cytometry data analysis was performed using FlowLogic™ software (Inivai, Melbourne, 
Australia).  
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Table 6.1 Summary of flow cytometry antibody panel for the phenotyping of hepatic 
immune cells on a BD LSR Fortessa 
 
 
  
Laser Wavelength Fluorophore Specificity Vendor Clone Cat No 
Vi
ol
et
 
 4
05
 
405-450/50 eFluor 450 CD45.2 eBioscience 104 48-0454 
405-525/50 eFluor 506 FVD eBioscience 65-0866 
405-605/12 eFluor625NC Ly6G eBioscience RB6-8C5 94-5931 
B
lu
e 
 
48
8 
488-530/30 AF488 F4/80 AbD Serotec Cl:A3-1 MCA497A488T 
488-780/60 PE-Cy7 Ly6C eBioscience HK1.4 25-5932 
R
ed
  
64
0 
633-670/14 APC CD11B eBioscience M1/70 17-0112 
633-780/60 APC-eFluor 
780 
CD3 eBioscience 17A2 47-0032 
NK1.1 eBioscience PK136 47-5941 
B220/
CD45R 
eBioscience RA3-6B
2 
47-0452 
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6.2.15 Carbon tetrachloride dosing 
To investigate the effect of an absence of SLPI on more chronic toxin-induced liver injury, a 
carbon tetrachloride (CCL4) dosing experiment was conducted. Five homozygous Slpi-/- and 
five WTLM controls were dosed via the intraperitoneal route, twice weekly for six weeks with 
0.4µl/g CCl4 diluted 1 in 3 in olive oil. A further three Slpi-/- and three WTLM controls were 
dosed to the same regimen with the same by weight volume of olive oil vehicle only. 
Mice were culled 72 hours after the 12th carbon tetrachloride injection. Cull was by terminal 
anaesthesia with pentobarbital, exsanguination via cardiac puncture and perfusion with PBS 
as described above (6.2.9). Measurement of liver function tests from plasma and fresh 
phenotyping of intra-hepatic leucocytes was performed as described above (6.2.13). 
 
6.2.16 Histological assessment of fibrosis 
To determine the degree of fibrosis associated with liver injury in the CCl4 model, Sirius Red 
staining was performed (by the Department of Pathology, St Mary’s Hospital Imperial College 
London). Sirius Red is a strong anionic dye that selectively binds to collagen in tissues.  
The degree of collagen as a proportion of the total tissue area (collagen proportionate area) 
was assessed by image analysis. Eight representative images were taken with a 
microscope-mounted digital camera at x 10 magnification. Images were imported into image 
J and using the colour-based thresholding function, the background (white) areas of the slide 
were subtracted and the proportion of the image stained red for collagen was calculated as a 
proportion of the total tissue (yellow) area. This was repeated for each of the eight images 
per mouse and averaged. 
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6.3 Results 
6.3.1 Genotyping results in Slpi-/- mouse colony 
Genotyping of the Slpi-/- colony is summarised in Figure 6.1.  Overall genotyping results for 
the colony approximately conformed to the ratio of 2:1:1 heterozygote: homozygote WT: 
homozygote KO that would be expected from a heterozygote breeding colony. 
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Figure 6.3 Slpi-/- colony genotyping 
Breeding was conducted between heterozygote pairs to provide homozygous Slpi-/- mice 
and homozygous wild type littermates to be used as controls. Genotyping was performed 
using duplex PCR with primer pairs for both the WT allele and neo-allele found in the Slpi-/-, 
yielding PCR products of 490bp and 344bp long respectively. These products could be 
separated and identified by agarose gel electrophoresis (A). Heterozygotes (M1 and M4) 
displayed two bands at 490bp and 344bp as defined by a DNA ladder, homozygous WT 
mice (M3, M5 and wild type positive control (WTPC mouse)) had only the upper band of 
larger fragment size and homozygote Slpi-/- mice (M2) displayed a single band at 344bp. 
Genotyping results for the whole colony are displayed (B).  
 
6.3.2 SLPI expression validation 
The intragenic deletion produced by the targeting vector in this strain of Slpi-/- mice should 
prevent transcription of SLPI mRNA. To validate this, and ensure that the knockout strain 
under investigation did not express SLPI mRNA, PCR expression studies in the liver were 
A 
B 
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46% 
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25% 
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performed. These demonstrated that no SLPI mRNA was detected in the liver of Slpi-/- mice 
as expected. 
 
 
Figure 6.4 Agarose gel electrophoresis of PCR products from Slpi-/- and wild type 
littermate controls 
PCR was run for the expression of SLPI mRNA in Slpi-/- and controls, using B2M as a 
positive control. SLPI expression was demonstrated in 3/3 of the wild type (WT) mice but 0/3 
of the Slpi-/-  mice, proving effective knockout of the gene in the mice. 
 
6.3.3 Baseline anatomy and histology of Slpi-/- mouse liver 
Experimental validation of the Slpi-/- mouse for the investigation of liver phenotypes has not 
previously been published. In order to exclude the presence of underlying liver dysfunction in 
the Slpi-/- mouse that could affect its subsequent response to experimentally induced acute 
liver injury, a number of baseline investigations were performed.  
At necropsy the gross liver anatomy of Slpi-/- mice was reviewed. The hepatic blood supply, 
anatomical divisions into lobes, biliary anatomy and gallbladder structure all appeared 
normal.  Baseline liver histology of sections from the Slpi-/- mouse were reviewed in 
comparison with wild type tissue from littermate controls by an expert Histopathologist 
(Professor Robert Goldin, Imperial College). The gross tissue architecture of the Slpi-/- mouse 
was normal, with liver lobules apparent and normal portal tracts. The cellular morphology 
KO1   KO2    KO3   WT1   WT2   WT3   NTC     
SLPI 
 
LAD   KO1   KO2   KO3   
B2M 
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was also normal. In two of five Slpi-/- mice reviewed occasional small inflammatory foci were 
apparent (Figure 6.5). 
 
 
 
Figure 6.5 Representative liver histology from a Slpi-/- mouse  
(A) Low power H&E stained section shows grossly normal liver architecture, with 
preservation of the usual hepatic structure. (B) A x100 view shows the cellular morphology is 
grossly normal. (C) Occasional foci of inflammation were seen in the liver of some Slpi-/- 
mice. 
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6.3.4 Baseline liver function tests in Slpi-/- 
A panel of standard liver function tests were assayed in five Slpi-/- mice and five WTLM 
controls. No significant differences in baseline liver function were apparent between the 
knockout mice and their wild type littermates. 
 
Figure 6.6 Baseline liver function tests in Slpi-/- and wild type littermate controls. 
Liver function tests were performed on mice at baseline to ensure Slpi-/- mice did not have 
underlying liver dysfunction. Figure shows the values for Ammonia, ALP, ALT, Bilirubin and 
Glucose with n=5 in each. No significant differences were demonstrated between wild type 
and Slpi-/-mice. 
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6.3.5 Baseline glutathione  
Oxidised and reduced glutathione concentrations were assayed in Slpi-/- and WTLM control 
mice to determine whether alterations in glutathione metabolism were present that would 
affect their response to paracetamol hepatotoxicity. Glutathione concentrations were 
assayed after the overnight fast but before paracetamol dosing (T0) and in separate mice 
two hours after paracetamol dosing (T2). As expected the ratio of reduced to oxidised 
glutathione (GSH/GSSG) fell significantly following administration of paracetamol in both 
groups (T-test of T0 v T2 for WTLM p=0.042 and for Slpi-/- p=0.039). However there were no 
significant differences between the two experimental groups, either at baseline or following 
paracetamol administration (Figure 6.7). 
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Figure 6.7 Ratio of reduced glutathione (GSH) to oxidised glutathione (GSSG) in liver 
homogenates at fasted baseline (T0) and two hours post-paracetamol (T2) in Slpi-/- 
and wild type littermate controls. 
Liver homogenates from mice culled following an overnight fast (T0) and following an 
overnight fast and 2 hours post-paracetamol (T2) were assayed for GSH and GSSG 
content. The values are expressed as a ratio of GSH/GSSG. No significant differences in 
hepatic glutathione were demonstrated between Slpi-/- and wild type littermate controls at 
either time point. The ratio of GSH/GSSG fell significantly following paracetamol 
administration in both groups (WTLM T0vT2 p=0.042, Slpi-/- T0vT2 p=0.039) 
 
6.3.6 Baseline CYP2E1 
As previously discussed in this thesis, the enzyme CYP2E1 is the predominant enzyme 
responsible for metabolising paracetamol to its toxic metabolite NAPQI.  To ensure that 
baseline enzyme concentrations were not different in wild type and knockout mice, the 
protein concentrations of CYP2E1 were assayed in liver homogenates by ELISA. No 
significant differences were revealed between the two experimental groups. 
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Figure 6.8 Baseline hepatic CYP2E1 concentrations in Slpi-/- and wild type littermate 
controls. 
The concentration of CYP2E1 was measured by ELISA in liver homogenates from Slpi-/- and 
wild type littermate controls. No significant difference in protein concentrations between the 
genotypes was demonstrated. 
 
6.3.7 Paracetamol induced liver injury in Slpi-/- and WTLM control mice 
Having established that the Slpi-/- mice did not have evidence of a baseline liver phenotype 
that would confound interpretation of liver injury experiments, a paracetamol-induced liver 
injury time course study was conducted. 
ALT values were compared between Slpi-/- and WTLM control mice at five time points after 
paracetamol dosing, using multiple T-tests with a Holm-Sidak correction for multiple 
comparisons (Prism V6, San Diego CA). Results are summarised in Figure 6.9. 
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Figure 6.9 ALT values post-paracetamol in Slpi-/- and WTLM control mice  
(A) ALT values in groups of mice culled at baseline, 8 hours, 24 hours, 72 hours and 5 days 
post-paracetamol. n=5 in each group except T24 and T72 where additional numbers added. 
The difference in ALT between Slpi-/- and WTLM control mice was significant at T24 hours 
(p<0.0001).  (B) 24 hour ALT values alone with n=10 in the WTLM control group and n=7 in 
the Slpi-/- group. 
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Peak ALT values in the Slpi-/- group, 24 hours after liver injury were significantly reduced 
compared with WTLM controls. The initial study of n=5 mice in each group showed a 
borderline significant level but due to analysis failure of some blood samples, inadequate 
numbers were available. A further 5 mice were therefore added to the 24 hour and 72 hour 
time points to further investigate this relationship. In the larger cohorts of Slpi-/- mice the 
mean ALT 24 hours after paracetamol was 6241 +/- 2923 U/L (n=7), however in the WTLM 
control group the mean was 11,926+/- 1520 U/L (n=10) (p<0.0001).  At no other time point 
was there a significant difference between the Slpi-/- and WTLM controls. 
 
6.3.8 Histological assessment of necrosis 
In view of the observed differences in ALT between Slpi-/- and WTLM controls at 24 hours 
post-paracetamol, a histological assessment of necrosis was performed to determine 
whether there was also a difference in the extent of liver injury. Indeed, the histological 
scores of necrosis confirmed the difference in the extent of liver injury between the two 
groups of mice.  In WTLM controls the mean percentage area of necrosis was 30.9 +/- 6.3%, 
however in Slpi-/- mice necrosis was limited to 19.5 +/- 6.3% of the total tissue area (Figure 
6.10) (p=0.0016). 
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Figure 6.10 Histological assessment of liver necrosis at peak liver injury in Slpi-/- and 
WTLM control mice 
Representative H&E stained liver sections from (A) WTLM controls and (B) Slpi-/- mice 24 
hours after paracetamol dosing are shown at x10 magnification. These demonstrate a 
typical pattern of centrilobular hepatocyte necrosis, with more extensive necrosis evident in 
the WTLM control. (C) Quantification of hepatic necrosis showed a significant difference 
between the Slpi-/- and WTLMs (p=0.0016). 
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6.3.9 Inflammatory cytokine production 
Inflammatory cytokines and KC, a neutrophil chemokine, were measured in liver 
homogenates and plasma from Slpi-/- and littermate controls at baseline and at various time 
points post-paracetamol dosing. The results showed the expected patterns of increase in 
inflammatory markers following paracetamol hepatotoxicity. The high degree of variability 
within each group meant that none of the differences between groups were significant apart 
from baseline IL-1β concentrations in plasma, which were higher in Slpi-/- than controls. It 
was interesting to note that although the severity of liver injury was greater in wild-type mice 
than Slpi-/- mice at 24 hours, the concentrations of pro-inflammatory cytokines were not any 
higher in the liver. In fact there was a trend for increased TNFα and IL-1β concentrations in 
the liver 24 hours post paracetamol in the Slpi-/- mice. 
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Figure 6.11 Comparative concentrations of hepatic cytokines and the chemokine KC in 
Slpi-/- and WTLM control mice. 
Cytokine concentrations were measured by MSD multisport assay in liver homogenates of 
Slpi null mice and littermate controls at various timepoints after administration of 
paracetamol. 
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Figure 6.12 Comparative concentrations of plasma cytokines and the chemokine KC in 
Slpi-/- and WTLM control mice. 
Inflammatory cytokines TNFα, IL-1β, IL-5, IL-6, IL-10 and the chemokine KC were measured 
in plasma of Slpi-/- and WTLM control mice at baseline and various time points after 
paracetamol dosing. A significant increase in baseline IL-1β in Slpi-/- mice was demonstrated. 
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6.3.10 Immunophenotyping of inflammatory cells 
Flow cytometry was utilised to investigate the cellular innate immune response to 
paracetamol-induced liver injury.  Hepatic non-parenchymal cells were separated from 
perfused murine livers in Slpi null and wild type control mice at various stages of injury. The 
total non-parenchymal cell fraction was stained with antibodies to cell-specific markers, 
which enabled cell types to be discriminated and quantified. The gating strategy used to 
define hepatic neutrophils and macrophages is shown in Figure 6.13. Hepatic neutrophils 
were characterised as CD45+, CD11B+, Ly6G+ cells. Macrophages were identified as CD45+, 
CD11B+, Ly6G-, F4/80+ cells. Exclusion markers for B cells, T cells and Natural Killer cells 
were also used, however back gating of these cells showed them to be CD11B negative or 
intermediate (NK cells), and thus discrimination of neutrophils and macrophages on the basis 
of their CD11B expression could be accurately performed in a more simplified gating 
strategy. 
Further definition of macrophages by their expression of Ly6C was also possible (Figure 
6.14). This enabled a population of Ly6C high macrophages to be identified, that were 
phenotypically less mature, with low granularity (side scatter area), relatively low expression 
of the tissue macrophage marker F4/80 and relatively high expression of the adhesion 
molecule CD11B. This population represent infiltrating monocytes or monocyte-derived 
macrophages. A distinct population of macrophages that express intermediate levels of Ly6C 
are more granular and express high levels of F4/80 but relatively lower levels of CD11B 
could be identified. These markers suggest a more ‘mature’ macrophage population however 
do not allow the origin of the cells to be determined. They could represent the resident 
Kupffer cell population or infiltrating monocyte-derived macrophages at a different state of 
maturity, for example a ‘post-phagocytic’ infiltrating macrophage. A stable, small population 
of Ly6C low macrophages were also apparent. These cells had variable side scatter 
properties and intermediate F4/80 and CD11B expression. 
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Figure 6.13 Gating strategy for hepatic immune cells  
Leucocyte population was gated on side and forward scatter properties to exclude debris (A). 
Doublets were excluded based on forward scatter width (B). Live cells, as defined by fixed 
viability dye, made up >95% of total gated cells (C). All CD45+ cells were selected (D). 
Neutrophils were defined as CD45+, CD11B+, Ly6G+ (E) and gated out of further analysis. 
Macrophages were defined from the non-neutrophil population as CD11B+, F4/80+ (F). 
Analysis of the macrophage gated cells revealed distinct populations based on Ly6C 
expression and side scatter (G) (also see Figure 6.14) 
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Figure 6.14 Flow cytometry analysis of hepatic macrophages defining distinct 
populations based on Ly6C expression 
Analysis of the hepatic macrophage population revealed differential Ly6C expression, with 
populations of high, intermediate and low expressing cells evident. When Ly6C expression is 
plotted against side scatter (A) it can be seen that the Ly6Cint cells (green) have higher side 
scatter than Ly6Chi (red). Back gating onto a CD11B v F4/80 plot (B) it can be seen that 
these populations have differential expression of other macrophage markers too, with Ly6Cint 
cells being relatively CD11Blo F4/80hi and the Ly6Chi population relatively CD11Bhi F4/80lo. 
Back gating the macrophage populations onto the plot of all CD45+ leucocytes, emphasises 
that the Ly6Chi and Ly6Cint cells are distinct populations (C). Histograms from baseline (D) 
and 24 hours after liver injury (E) show the predominance of recruited Ly6Chi cells post-
injury. 
 
At baseline there were no statistically significant differences in intrahepatic neutrophil, 
macrophage or macrophage sub-populations within the livers of wild type and Slpi null mice 
(Figure 6.15).  There was a trend for a reduced proportion of neutrophils in the Slpi-/- group, 
with a mean neutrophil proportion of parent of 7%, compared with 13% in wild type mice.  
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Figure 6.15 Baseline intrahepatic neutrophils and macrophage populations in Slpi-/- 
and WTLM control mice. 
The proportion of intrahepatic neutrophils and macrophages was quantified by flow 
cytometry in wild type and Slpi null mice. In each group n=5. There were no statistically 
significant differences in (A) neutrophils, (B) all macrophage, (C) Ly6Cint macrophages or 
(D) Ly6Chi macrophages. Baseline neutrophil numbers varied between individuals, from in 
excess of 20% of parent in a WTLM (E) to less than 5% in a Slpi-/- mouse. 
 
103
104
105
0
CD
11
B-
AP
C 
64
0-
67
0/
14
-A
0 103 104 105
Ly6G- eFluor625 405- 605/ 12- A
R1 [T0KO4]
R1  98.94% Events:26407
103
104
105
0
CD
11
B-
AP
C 
64
0-
67
0/
14
-A
0 103 104 105
Ly6G- eFluor625 405- 605/ 12- A
R1 [TOWT4]
R1  98.98% Events:26798
%
 o
f p
ar
en
t
WT
LM
SL
PI
-/-
0
5
10
15
20
25
Neutrophils
Ly6Cint  macrophages
%
 o
f a
ll 
M
ac
s
WT
LM
SL
PI
-/-
30
40
50
60
70
80
All macrophages
%
 o
f p
ar
en
t
WT
LM
SL
PI
-/-
0
5
10
15
Ly6Chi  macrophages
%
 o
f a
ll 
M
ac
s
WT
LM
SL
PI
-/-
0
20
40
60
C
D
11
B
 
C
D
11
B
 
Ly G Ly6G 
A B 
C D 
E F 
 219 
Following the induction of liver injury with paracetamol, a massive increase in the proportion 
of macrophages in the liver was seen. Total macrophages as a proportion of parent peaked 
at 8 hours post-injury, declining thereafter until by 5 days post-injury the proportion of 
macrophages in the liver was similar to pre-injury levels, though not entirely normalised 
(Figure 6.16 panel A). The expansion of the total macrophage population was consistent 
between Slpi-/- and wild type mice.  
By dividing the macrophages into three populations based on Ly6C and side scatter 
properties, the relative proportions of these three cell types could be quantified. At baseline 
Ly6Cint cells predominated, accounting for approximately 60% of hepatic macrophages with 
Ly6Chi cells making up a further 35% and Ly6Clo cells the final 5% (Figure 6.16 panel B). This 
baseline pattern was preserved in Slpi null mice (Figure 6.16 panel C). Within 8 hours of 
hepatotoxic paracetamol exposure, the proportion of Ly6Chi cells increased markedly. In wild 
type mice the mean proportion of Ly6Chi macrophages was 82% at 8 hours post-paracetamol 
and 75% at 24 hours. In the Slpi-/- group the relative increase in the Ly6Chi population of 
macrophages was less pronounced at 64% and 65% of total macrophage numbers at 8 and 
24 hours respectively. Due to some variability between animals and small numbers in each 
group, these trends did not reach statistical significance (8hr Ly6Chi macrophages Slpi-/- v 
WTLM p=0.29 and 24hr Ly6Chi macrophages Slpi-/- v WTLM p=0.18).  
By 48 hours after paracetamol administration, the ratio of Ly6Chi and Ly6Clo macrophages 
had returned to baseline in WT mice, despite a persisting expansion of the total macrophage 
population.  A similar pattern was observed in the Slpi-/- mice, with Ly6Cint macrophages 
regaining their position as the predominant macrophage population between 24 and 48 hours 
post-injury. 
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Figure 6.16 Intrahepatic macrophage populations in Slpi-/- and WTLM controls after 
liver injury. 
(A) Total CD11B+ F4/80+ macrophage numbers as a percentage of parent at different time 
points after paracetamol in WTLM and Slpi-/- mice. (B) and (C) Proportion of Ly6Chi, Ly6Cint 
and Ly6Clo macrophages in the liver of WTLM controls and Slpi-/- mice respectively. 
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Hepatic neutrophils were identified by their expression of CD11B and Ly6G. The proportion 
of neutrophils was quantified in Slpi-/- and wild type mice and various stages of liver injury 
(Figure 6.17).  At peak injury, 24 hours after paracetamol, there was a significant decrease in 
the number of neutrophils in the Slpi-/- mice compared with their littermate controls. 
Neutrophils made up 41.4 +/- 10.3% of the parent population in WTLMs, but only 20.8+/- 
4.1% in Slpi-/- at 24 hours post injury (p=0.0003). The difference in neutrophils was only 
observed at the peak injury time point. There was a suggestion of a faster decline in 
neutrophils in the WTLM control group, though the differences at the later time points did not 
reach statistical significance. 
 
 
 
Figure 6.17 Hepatic neutrophils as a percentage of parent cells in Slpi-/- and WTLM 
control mice at different time points after liver injury. 
(A) At various time points after induction of liver injury, hepatic neutrophils were quantified by 
flow cytometry and characterised as CD45+ CD11B+ Ly6G+ cells. (B) At peak liver injury, 24 
hours after paracetamol, a significant reduction in intrahepatic neutrophil numbers was seen 
in Slpi-/- mice compared with WTLM controls (p=0.0003).  
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6.3.11 Carbon tetrachloride induced fibrosis 
Having noted the protective effect of an absence of SLPI at peak injury in an acute model, it 
was hypothesised that chronic liver injury may also be milder in the Slpi-/- mouse. Carbon 
tetrachloride is a potent hepatotoxin that, like paracetamol, is bioactivated by hepatic 
CYP450 enzymes. A high single dose of CCl4 can lead to centrilobular hepatocellular 
necrosis. Repeated exposure at lower doses causes the deposition of collagen fibres and 
development of hepatic fibrosis. Repeat exposure to carbon tetrachloride is the most widely 
used animal model of liver fibrosis. 
Following six weeks of twice-weekly CCl4, mice were sacrificed 72 hours after the last dose. 
One of the five mice in the Slpi-/- group died of complications of an intraperitoneal injection 
and did not complete the experiment, therefore analysis has been performed between four 
Slpi-/- mice and five WTLM controls. 
Example Sirius Red stained liver sections are shown in Figure 6.18 to demonstrate the 
induction of liver fibrosis in this model. Bands of fibrosis, dyed red by the collagen-specific 
stain are seen to encircle the central veins and extend into the lobule. There were frequent 
examples of fibrous bands bridging between central veins. Quantification of the collagen 
proportionate area (CPA) was conducted using image analysis software. In vehicle only 
treated controls the CPA for Slpi-/- was 0.71 +/- 0.38% and for WTLMs was 0.38 +/- 0.17%. In 
those mice that had received carbon tetrachloride there was a significantly higher CPA than 
vehicle only groups (vehicle only groups v treated groups, Mann-Whitney U test p=0.0004), 
proving that toxin exposure had induced fibrosis as intended. However, there was no 
significant difference between the degree of collagen deposition in WTLM and Slpi-/- mice 
(CPA of 3.42 +/- 0.66% v 3.38 +/- 0.54% respectively) Figure 6.18 C. 
ALT values were not significantly different 72 hours after completion of the CCL4 regimen, 
between the Slpi-/- and WTLM control mice (mean ALT 146+/-43 U/L v 169+/- 95U/L). 
Haemolysis of a number of the vehicle only control blood tests made these results unreliable, 
and hence they have not been shown.  
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Figure 6.18 Liver fibrosis and injury following chronic carbon tetrachloride 
administration to Slpi-/- and wild type littermate controls. 
Representative sections of Sirius Red-stained liver at x10 (A) and x40 (B) magnification 
show peri-portal collagen deposition with fibrous bands extending and at times bridging 
between portal tracts. Quantification of the collagen proportionate area showed no 
significant different between Slpi-/- and WTLM controls treated with vehicle only (mean 
0.71% and 0.38% respectively, n=3 per group) (C). In the CCL4 treated mice the CPA was 
significantly higher than in vehicle only treated mice, but there was no significant difference 
between Slpi-/- and WTLM controls (CPA 3.38% n=4 and 3.42% n=5, respectively). ALT 
values in the CCL4 dosed mice were not significantly different between WTLM controls and 
the Slpi-/-. 
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6.3.12 Immune infiltrate in CCl4 induced liver fibrosis 
In this same model, hepatic immune cells were isolated from liver and analysed using flow 
cytometry, to determine whether the absence of SLPI affected the recruitment of immune 
cells to the liver in chronic injury. Gating of flow cytometry data was performed according to 
Figure 6.13 to identify populations of CD45+ CD11B+ Ly6G+ neutrophils and CD45+ CD11B+ 
Ly6G- F4/80+ macrophages. Macrophages were then further defined into three subgroups 
depending on their expression of the cell surface marker Ly6C. The proportion of neutrophils, 
macrophages, and macrophage subgroups did not differ significantly between WTLM 
controls and Slpi-/- (Figure 6.19) 
 
Figure 6.19 Proportion of macrophages and neutrophils in chronic CCl4-induced liver 
injury in Slpi-/- and wild type littermate controls. 
Immune cells were isolated from liver 72 hours after the last CCl4 dose of a 6-week dosing 
regimen. Cells were analysed by flow cytometry. Neutrophils and macrophages as a 
percentage of parent (see Figure 6.13) were quantified. Following gating on all 
macrophages (CD45+ CD11B+, Ly6G- F4/80+), Ly6C high, low and intermediate 
macrophages were quantified as a proportion of the total macrophage number. The pattern 
of immune cell infiltrate was similar between Slpi-/- and WTLM controls, with no significant 
difference in the proportion of macrophages, neutrophils or macrophage subtypes. 
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6.4 Discussion 
It was hypothesised that a systemic absence of SLPI in the null mouse would lead to an 
exacerbation of paracetamol-induced liver injury due to enhanced NFκB activation and a 
persistence of pro-inflammatory macrophages in the liver. The data presented here 
unexpectedly show that the Slpi-/- mouse actually has a milder acute liver injury phenotype 
than control mice. The peak of liver injury post-paracetamol is at 24 hours in this time course 
model. At this point the Slpi-/- mice displayed a lower ALT and lesser degree of hepatic 
necrosis than wild type littermates. Examination of the hepatic inflammatory infiltrate also 
revealed a marked reduction in the proportion of neutrophils within the liver at this time, while 
no differences in the total macrophage proportion was observed. In the chronic model of liver 
injury, induced by repeated low-grade toxic insults to the liver with carbon tetrachloride, no 
difference was observed in liver injury, as determined by fibrosis and ALT between wild type 
or Slpi-/- mice. 
Examination of the Slpi-/- mice at baseline showed no differences from wild type mice, with 
respect to liver function tests, hepatic glutathione reserves or CYP2E1 expression. Of 
potential interest was the observation of occasional foci of inflammation in the liver of Slpi-/- 
mice. It was also shown that the Slpi null mice had higher basal circulating concentrations of 
IL-1β. These two features hint at an underlying pro-inflammatory state in the Slpi-/- mice, 
which is not unexpected given the known anti-inflammatory, immune-regulatory roles of 
SLPI. It is possible that this pro-inflammatory state might have a form of conditioning effect 
that acts to reduce the magnitude of an inflammatory response to a subsequent injurious 
stimulus. This conditioning could not occur through reduced expression of CYP2E1 or 
through enhanced cellular glutathione reserves as these were found to be equivalent in null 
and wild type mice. Indeed the mechanism by which this conditioning might occur is unclear 
and would seem to be contradicted by the robust cytokine response to paracetamol-induced 
liver injury seen in the Slpi-/- mice. 
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The reduced number of intrahepatic neutrophils in the livers of Slpi-/- mice at peak injury is 
intriguing. This might be a proportionate response to the reduced degree of liver damage, or 
could be the primary cause of the reduction in liver injury. As described in the introduction 
(section 1.5.4) there is controversy over the role of neutrophils in paracetamol-induced acute 
liver injury, with some data suggesting neutrophils recruited to the liver following the initial 
toxic insult have tissue destructive effects.  
Analysis of the baseline intrahepatic leucocytes showed that Slpi-/- mice had a mean 
neutrophil proportion of 7% of parent, whereas wild type littermates had a mean of 13%. 
Although this result in an n=5 v n=5 comparison did not reach statistical significance it may 
reflect a primary neutrophil defect in the Slpi-/- mice. A recent study on human neutrophil 
differentiation has elucidated a role for SLPI in the normal maturation and survival of bone 
marrow granulocytes (Klimenkova et al., 2014). This study showed that downregulation of 
SLPI in bone marrow myeloid progenitors caused defects in signalling cascades that regulate 
cell cycling. This resulted in decreased myeloid differentiation, cell cycle arrest and enhanced 
apoptosis in the neutrophil progenitors (Klimenkova et al., 2014). No effects on 
monocytopoiesis or erythropoiesis were demonstrated. In myeloid progenitors in which SLPI 
had been down regulated, the usual G-CSF induced phosphorylation of extra-cellular signal 
regulated kinases (ERK1/2) was abolished and downstream transcription factor activation 
was inhibited. This suggests in the absence of SLPI granulopoiesis is impaired, in particular 
in the ability of progenitors to respond to G-CSF produced during an inflammatory stimulus. 
This could explain the deficit in neutrophil numbers observed at peak injury in the Slpi-/- mice. 
The observation of equivalent liver injury and neutrophil numbers in Slpi-/- mice in the chronic 
model, with milder toxic injury on each occasion is interesting. It might suggest a threshold 
effect, in which the bone marrow can produce enough competent neutrophils to respond to 
low-grade inflammation. However, with a more severe inflammatory insult in which G-CSF 
stimulation of granulopoiesis is required to replenish neutrophil numbers, the absence of 
SLPI impacts negatively on tissue neutrophil numbers. This threshold effect might also 
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suggest why in the original description of the Slpi-/- mouse as a model of impaired wound 
healing, which is a relatively mild inflammatory stimulus compared with massive hepatocyte 
necrosis, a reduction in neutrophil numbers was not observed (Ashcroft et al., 2000). 
Interestingly a 2003 study by Nakamura et al reported that SLPI deficient mice were more 
susceptible to systemic sepsis as induced by caecal ligation and puncture (Nakamura et al., 
2003). The study assessed macrophage and B cell function in the knockout mice, and 
attributed the excess mortality from severe sepsis to an enhanced NFκB response in 
macrophages. In light of the recent discovery that SLPI is required for neutrophil maturation 
and survival these results might be open to reinterpretation. Susceptibility to severe sepsis in 
the Slpi-/- mice might be mediated by a lack of competent bone marrow-derived neutrophils. 
Further experimental work would be required to assess neutrophil function in Slpi-/- mice and 
define whether there is a primary deficit in number, or defect in function as suggested by 
human studies. If a primary neutrophil problem was identified in these mice, adoptive transfer 
studies of wild type neutrophils into Slpi null mice during the development of liver injury would 
be required to prove a causal role for neutrophils in the pathogenesis of liver injury. 
This study has a number of limitations. Firstly a desire to look at a number of time points 
through the development and resolution of tissue injury and practical considerations 
necessarily limited the number of mice that could be used at each time point. This meant that 
the study only had power to detect large differences between the Slpi null mice and controls. 
One of the original aims of the study was to examine the resolution of hepatic inflammation in 
the absence of SLPI.  This was specifically with the intention of determining whether the 
therapeutic blockade of SLPI to reverse immunoparesis in human acute liver failure would 
have deleterious intrahepatic effects (Possamai et al., 2014a). The unexpected finding of a 
significant difference between the level of peak injury in the control and null mice confounded 
the interpretation of the resolution phase data. Further experiments using small molecule 
inhibitors or gene silencing later in the genesis of liver injury will therefore be required to 
answer this question. 
 228 
In summary, the investigation of liver injury in a Slpi null mouse unexpectedly revealed a 
milder liver injury phenotype in these mice compared to controls. It is unclear what is the 
cause of attenuated liver necrosis, reduced ALT and reduced neutrophil infiltrate in the liver 
of these mice. A baseline pro-inflammatory state that produces a conditioning effect is a 
possibility, though seems unlikely in view of cytokine concentrations in the null mouse being 
elevated to a similar extent as wild type controls. A more likely cause is a primary neutrophil 
defect in Slpi-/- mice as has recently been described in human studies. This requires further 
investigation and may yield important insights into the role of neutrophils in acute liver injury, 
potentially highlighting early neutrophil recruitment as a therapeutic target. Useful 
characterisation of intrahepatic macrophage populations throughout a murine acute 
paracetamol-induced liver injury model was also achieved. 
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7 CONCLUSION 
7.1 Introduction 
Paracetamol-induced acute liver failure is a complex disorder that is initiated by hepatocyte 
toxicity and may ultimately progress to multi-organ failure and death. Though there is no 
mystery in the causation of this condition, the factors which render some individuals much 
more susceptible than others to hepatotoxicity and progression of acute liver failure, remain 
incompletely understood. The role of the innate immune system in the progression of 
paracetamol-induced acute liver injury is controversial, particularly the influence of infiltrating 
neutrophils and macrophages (Jaeschke et al., 2013, Jaeschke et al., 2011) (Possamai, 
2010, Holt et al., 2008). 
The aims of this thesis have been to identify novel genetic and environmental susceptibility 
factors in murine models of paracetamol hepatotoxicity and to investigate factors that 
influence outcome through their effect on the immune response to liver injury. 
 
7.2 Synthesis of findings 
The main findings of this thesis have been considered in detail in the discussion sections of 
experimental chapters 2 to 6. At first a non-hypothesis driven ‘forward genetics’ approach 
was pursued to identify novel loci that contributed to outcome in paracetamol-induced acute 
liver injury. This proved to be successful in identifying two loci in mice that associated with 
outcome. These loci contained a number of promising candidate genes, in particular 
Commd10, Ticam1 and Tnfaip8. Further experimental work in this area was confounded by 
an observation of marked inter-individual variation between genetically identical mice housed 
in the same environment. A number of hypotheses regarding the cause of this variation were 
tested and excluded. Differences in intestinal microbiota were hypothesised to be a source of 
variable response to paracetamol. It was established that in the absence of intestinal 
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microbiota a wide range of responses remained. However, these germ free animals 
demonstrated some changes in hepatic metabolism of paracetamol and in their secondary 
responses to acute liver injury. A group of mice with impaired TLR4 signalling were tested 
alongside the germ free mice and an additional protective effect from TLR4 impairment was 
noticed. This supports the widely accepted view that DAMP signalling through Toll-like 
receptors is a key event in the pathogenesis of acute liver failure (Kubes and Mehal, 2012). 
A different approach to the genotype-phenotype relationship was taken with a study of the 
effect of SLPI in murine paracetamol-induced acute liver failure. This yielded yet more 
evidence that the innate immune response to liver injury is key to determining the 
progression and outcome from paracetamol hepatotoxicity. The Slpi-/- mouse displayed 
reduced peak liver injury compared to wild type controls. Recent evidence from the literature 
suggests that SLPI may be essential for bone marrow neutrophil maturation and survival, 
particularly in response to G-CSF. If a primary neutrophil defect can be proved to be the 
cause of the protection from liver injury in the Slpi-/- mouse, this would be important evidence 
implicating neutrophils in tissue damage. This is an area of controversy and experimental 
techniques to deplete neutrophils have been criticised in the past for off-target effects 
(Jaeschke and Liu, 2007). A genetic model with intrinsic blunting of the neutrophil response 
could be a valuable experimental tool for investigating the role of neutrophils in acute liver 
injury.  
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Figure 7.1 A schematic diagram of the progression of paracetamol-induced acute liver 
injury, with environmental and genetic influences. 
The diagram has been reproduced from the thesis introduction and demonstrates how key 
findings of the thesis fit into the model of paracetamol as a complex trait. Gut microbiota 
have been shown to influence the metabolism of paracetamol and the development of 
secondary complications. Novel loci on murine chromosomes 17 and 18 associate 
significantly with response to paracetamol. The exploration of variability within genetically 
identical mice has raised the hypothesis that epigenetic variation may contribute to 
differential response to paracetamol. Finally neutrophil activation and recruitment to the 
inflamed liver may also contribute to outcome. This may be influenced by genetic and 
environmental factors. 
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7.3 Limitations of animal models 
Working with murine models offers great possibilities for experimental manipulations that 
would not be possible in humans. The classical genetics techniques such as QTL mapping 
and targeted genetic perturbations such as in the Slpi-/- mouse enable the investigation of 
gene-phenotype relationships. Studying the effects of environmental manipulation, such as 
the maintenance of germ free animals is also made possible by murine models. However 
despite the great advantages and possibilities of murine models of human diseases, there 
are also limitations that must be remembered. The external validity of results from murine 
studies can be questioned. Genes and pathways that influence disease outcome in mice 
may not be recapitulated in humans.  
In investigating paracetamol-induced liver failure in rodents it should be recognised that the 
full human clinical syndrome cannot be modelled. Assessment of hepatic encephalopathy is 
not possible and coagulopathy cannot be readily measured. The supportive care that is 
delivered to humans permits survival despite a degree of liver injury that causes marked 
haemodynamic disturbance and hypoglycaemia among other complications. In mice early 
endpoints or a reduction in the degree of liver injury to that which is compatible with 
spontaneous survival are necessary compromises. Larger animal models, such as porcine 
models, may be more suitable for use in small studies looking at the critical care aspects of 
managing patients with acute liver failure. However these animal models do not have many 
of the benefits of murine models. They are expensive to house, have long generational times 
and are less easy to manipulate genetically. It is therefore evident that a perfect animal 
model of paracetamol-induced acute liver failure does not exist. 
A number of other limitations were evident from my work and could be addressed in future 
research on this subject. The dosing of mice by the IP route rather than the oral route is 
widely used in experimental work on paracetamol-induced acute liver failure. Paracetamol is 
absorbed very rapidly from the proximal small bowel when taken orally and is available to the 
liver for first pass metabolism. It is therefore considered that IP dosing provides a suitable 
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approximation of drug delivery to the liver, while being easier technically and more 
reproducible. IP dosing is done using anatomical landmarks to standardise location of 
dosing. However there may be variability in which compartment the injection enters (eg 
bowel, omental fat) and this could impact on the pharmacokinetics of the drug. My attempts 
to quantify plasma paracetamol at 30 minutes post-dosing gave a single ‘snap shot’ in time. 
Further studies with testing of plasma paracetamol concentrations at multiple time points 
would be required to accurately determine the kinetics of IP versus oral dosing. 
 
7.4 Future directions 
The work described in this thesis has produced some promising leads for future research.  
7.4.1 Commd10 and candidate genes on chromosome 18 
The QTL mapping project described in Chapter 2 was not followed up with further classical 
genetics breeding experiments, such as the development of congenics. This strategy would 
have been extremely difficult given the inherent variability within each murine strain and 
would have required impractical numbers of animals. Congenics involves the selective 
breeding of mice selected for phenotype with another strain. Over many generations this 
isolates the locus, and even gene, of interest from one strain onto the genetic background of 
another. However it relies on the single locus having a large enough effect size to be 
apparent despite the loss of other interacting loci and to exceed natural population diversity 
of response. Multiple QTL modelling (Chapter 2) suggested that the locus on chromosome 
18, though robust, accounted for a small proportion of overall variability and thus would not 
have been suitable for further exploration using congenics. 
Despite this limitation, it is worth noting that the most significant area of association on 
Chromosome 18 was relatively gene-poor. A manageable number of candidate genes were 
discovered, although the mapped locus was large. The most promising of these candidate 
genes in my opinion, is Commd10. The protein product of this gene has a role in the 
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suppression of NFκB-dependent pro-inflammatory signalling. This pathway is vital in 
paracetamol-induced acute liver failure in the recognition of uncontrolled cell death, 
amplification of the alarm signal and production of chemokines and cytokines that recruit 
immune effector cells to the liver. Differing levels of inherent NFκB suppression is a plausible 
mechanism for the observed differences in susceptibility to acute liver failure between murine 
strains. Even more promising are recent reports of Commd10 polymorphisms being detected 
in human GWAS studies of an inflammatory airway disease and response to the drug 
fenofibrate (Smolonska et al,. 2014)(Aslibekyan et al., 2012).  
The first step in the investigation of this gene as a potential source of variability between the 
C57Bl/6 and C3H/HeH mice, would be to demonstrate differences in gene expression or 
protein function between the two strains. Further studies could investigate the role of 
targeted disruption of the gene utilising conditional knockouts, as the complete knockout is 
embryonic lethal.  
. 
7.4.2 Epigenetics as a ‘third factor’ 
Another fascinating area for future research would be to explore the hypothesis that non-
genetic, non-environmental variability in murine models of paracetamol is a result of 
epigenetic variation. This may be driven by an evolutionary imperative to ensure population 
diversity of response to toxins.  
This question was considered during the period of my research work. However, experimental 
technicalities and costs proved to be prohibitive. Epigenetic signatures are tissue specific. 
Sampling of liver tissue would be required in order to determine a gene expression or 
epigenetic profile with which to compare response to paracetamol. We would aim to identify 
an epigenetic profile that discriminated genetically identical ‘high responder’ with ‘low 
responder’ mice.  However, as epigenetic modifications are plastic they would alter in 
response to and with the degree of liver injury. Sampling of the liver would therefore need to 
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occur before a mouse was challenged with paracetamol and would involve surgical liver 
resection. This could prove to be technically challenging, though would be possible. 
With the development and wider application of genome-wide techniques for exploring DNA 
methylation signatures, the profiling of mice is now cheaper and more readily available. This 
avenue of experimental work is fascinating and over the coming decades it is anticipated that 
research into the epigenetic determinants of disease susceptibility will expand significantly. 
 
7.4.3 SLPI and neutrophil maturation 
It was unexpected to find a significant protective effect from peak liver injury in the Slpi-/- 
mice. With the known anti-inflammatory, immune-modulating effects of SLPI I had 
hypothesised that the Slpi-/- mice would be more susceptible to paracetamol-induced acute 
liver injury and would experience delayed recovery. This unexpected result has produced a 
potentially exciting experimental system in which the role of neutrophils in acute liver injury 
might be explored. Future research should aim to determine whether the reduction in 
neutrophil numbers in the livers of Slpi-/- mice is due to a primary defect, or is a secondary 
phenomenon due to lesser liver injury mediated by another mechanism. Adoptive transfer of 
competent wild type neutrophils into Slpi-/- mice after injury, with reversal of protection would 
be required to prove that a defect in neutrophil number or function was responsible for the 
protection from liver injury. If this were demonstrated, it would be very convincing evidence 
for neutrophil-mediated liver damage being an important and non-redundant mechanism of 
hepatic injury in paracetamol-induced liver injury. This is an area that is currently 
controversial, with previous experiments using in vivo neutrophil depletion having been 
criticised for off target effects.  
If the bone marrow production of neutrophils or their trafficking to the liver were shown to be 
important in driving liver injury, these would make attracted targets for therapeutic 
intervention. 
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Considering the previous study on Slpi-/- mice that showed them to be much more sensitive 
to systemic sepsis, and my results here in sterile inflammation, the Slpi-/- mouse presents an 
interesting experimental paradigm whereby an innate immune defect leaves an organism 
susceptible to infection but protected from sterile inflammation. This raises interesting 
questions about the evolution of the innate immune system and how a swift and effective 
response to pathogens might be better balanced with restraint in sterile inflammation. 
 
7.4.4 Microbiota 
The work contained in chapter 4 of this thesis, on the role of the intestinal microbiome in 
paracetamol-induced acute liver failure reveals a number of interesting avenues for future 
research. The study was limited by its short duration due to the severity of liver injury that 
was induced. Firstly, and most simply, it would be instructive to look at the differences 
between germ free and conventional mice through the whole 5-day recovery model 
described in chapter 5. The apparent divergence of metabolic outcomes at 8 hours and the 
hints at a worse ALF phenotype in conventional animals could then be interrogated more 
fully. Rather than using germ free animals raised in a colony from birth, it might be instructive 
to use animals in whom bowel sterility has been achieved just prior to the experiment, with 
antibiotics. This would have some advantages, in that the physiological alterations that occur 
as a result of development in a germ free environment would not confound the study. 
However, induction of ‘sterility’ in mice using antibiotics may in itself have unwanted and 
confounding effects on paracetamol metabolism.  
If particular bacterial species were of interest, a more subtle manipulation of bowel 
microbiota would be possible using gnotobiotic animals in whom only known bacterial 
species are permitted to colonise the intestine (Smith et al., 2007).  
This field also lends itself to clinical studies. Selective decontamination of the GI tract with 
antibiotics is a practice sometimes used in intensive care departments. Liver patients are 
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also sometimes administered non-absorbable, gut-clearing antibiotics for the treatment of 
hepatic encephalopathy. A clinical study of selective bowel decontamination in acute liver 
failure might be warranted given the promising experimental results and that this it is a safe 
and established intervention. 
 
 
7.5 Summary 
Paracetamol-induced acute liver failure should be thought of as a complex trait. The outcome 
for any individual taking a paracetamol overdose is reliant on interacting host genetic, 
epigenetic and environmental influences, including an effect from the gut microbiota (Figure 
7.1). The initial toxic insult to the liver is followed by a period of massive immune cell 
activation, which can have both beneficial and deleterious effects on liver cell survival and 
outcome. The involvement of the innate immune system in the pathogenesis of acute liver 
failure yields opportunities for targeted immunotherapy.  This thesis has highlighted the gut 
microbiota, DAMP signalling through TLR4 and neutrophil recruitment as areas that may 
offer promising targets for therapeutic intervention. 
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9  APPENDICES 
 
Appendix A: Summary of heterologous SNP markers for QTL mapping 
Chromosome 
Mapped 
length (cM) 
total 
estimated 
size Mbp 
markers per 
chromosome 
1 112 197 8 
2 114 182 6 
3 95 160 5 
4 84 156 6 
5 92 153 5 
6 75 150 3 
7 74 153 4 
8 82 132 3 
9 79 124 4 
10 82 130 5 
11 104 122 4 
12 66 121 5 
13 80 120 3 
14 69 125 4 
15 75 103 4 
16 72 98 4 
17 58 95 3 
18 59 91 4 
19 57 61 3 
  Average 4.35 
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Appendix B: List of 83 heterologous SNP markers for initial QTL mapping 
JAX SNP ID 
(chromosome
-position-
source)  
RS 
 
New Chr 
pos (bp) 
Build 30 
Allel
e 
C3H/
HeH 
Allel
e 
C57
BL/6 
Sequence 
01-004147733-M rs3658242 4,147,733 T A GCATTACCTCTCATG[A/T]GCCTTCCTCTGCGAT 
01-041992138-M rs3706173 41,901,606 A G AGGTTTGTTGTTGTT[A/G]TCCTGTTTGTGTGAG 
01-073702240-N rs3022818 73,704,829 T A GGTAAATGCCAGTCG[A/T]GACGAAATTCGGAAT 
01-080181487-M rs3677697 80,071,474 A T TTTGGTTGCCATAAC[A/T]CTCCAACTCCTTCCA 
01-093273478-N rs3022828 93,044,874 C T GTCCAGTGGGACAGG[C/T]CGGCTCCTACTGCCC 
01-119969798-M rs3689749 119,445,345 C T CCAGTGCCCCACTTA[C/T]CCTCCCATAACATCC 
01-157000923-M rs3724524 156,626,018 A G AAGGATTATATATAG[A/G]ACATGATTTTGGTAA 
01-194803746-N rs4222922 193,831,793 T G AGTGAAGCTATACGT[G/T]CTGGGCAGTGTGCTG 
02-020414303-M rs3677975 20,549,059 C G GAGATTTGATGCACA[C/G]GGTTGGGGATATGGA 
02-043953410-M rs3678765 44,241,087 T C TTAAAATTATCATTT[C/T]CAAAACAAAACAAAA 
02-094964773-M rs3682381 95,285,458 T G ACCCAGCCGATCCCA[G/T]CAGGCTGGGCCAGCG 
02-131136658-M rs3662211 131,793,573 A C CGCCCTGCAGGGTCC[A/C]GGAAGGAGAGGCAGG 
02-149438298-N rs4223557 150,107,206 A C AGAACACAAGCAAAG[A/C]CTTTGCTTATGACGT 
02-172943830-M rs3710327 173,661,211 A G CCTTTGAGCAACACT[A/G]TAATAGTAAACCTGA 
03-005501855-M rs3661884 5,518,547 T G AACAGCTAACATTTG[G/T]TTTTTTGTGCCTGAC 
03-043110442-M rs3725852 42,937,822 A G AACTCTTCACAGTAG[A/G]GAAGTATACATTTTT 
03-110268748-M rs3712218 110,183,711 T C CTCCATCTCAGGCAG[C/T]AGCAGCATTACTCTC 
03-132149973-M rs3689296 132,284,456 T A TGTCTAGCTTCCCCA[A/T]TGTTCATATTTCAAG 
03-157197990-M rs3697892 157,308,271 A G GTGGGTTTTTCCTTA[A/G]AAGGAATGGTAAAGC 
04-003163167-M rs3694594 3,163,293 T G TCCTGCGTGAACTGT[G/T]AATATTGCAGAGGTT 
04-039199957-M rs3723778 39,330,757 G C TCCTAAAGTGAGCCA[C/G]TGTGTTTAAATGACT 
04-068252469-M rs3654162 68,347,160 T C TATCCCACAAGGAAA[C/T]CCAGACCTCTGAACT 
04-096975786-M rs3691775 97,146,866 C T ACGTTGGAGTATTTT[C/T]TGTGTTTGCGTTCTC 
04-124081318-M rs3692521 124,736,861 G A CACGTCTGTGAAGGC[A/G]TGAGAACAGCCCAGA 
04-151168886-M rs3680364 152,370,035 T G GTGTTTAAGGTTGTA[G/T]CGTGCCTGTGGCCTG 
05-021194830-M rs3726629 20,886,343 T C GTTATTCTGGGATGC[C/T]GGGTCCCTTTGTGCA 
05-054736743-M rs3714098 54,585,598 C T TGGAGAAACCATGTG[C/T]GTCCTAAATTTAAAT 
05-085931742-M rs3688741 85,593,361 C T GATTCTTTTTTTTCT[C/T]GAACAATGTATCATG 
05-117214009-M rs3723083 116,482,336 G T AGGGCTACTGAGACA[G/T]AACAGTAATGATTAT 
05-149044358-M rs3722801 147,758,431 A C CTCTCAGCTACCTGG[A/C]AAACCAATGGAGTGA 
06-003167392-M rs3661828 3,165,742 T C CAAGAAAATAATCTT[C/T]CAAGGATATATGTCA 
06-074130696-M rs3713062 73,719,242 T C CCTCAGCGTTTGTCA[C/T]GGCTTTTCCTGGGCG 
06-149052281-M rs3711088 148,689,545 G C CACTTCTCTGTCAAT[C/G]CACTTAGGAAGTAAA 
07-004201219-N rs4226386 4,237,211 G A ACTTTTCCTTCATCC[A/G]TGGATCCCAAGAGTG 
07-036014647-M rs4137562 35,081,477 A G TTGGTCCTTCTGAGG[A/G]CAGAGAAGCCAGAGG 
07-069074251-M rs3686423 67,915,042 T C TCCAGCTGGGAAAAC[C/T]GAGGGCCGGGAAAGG 
07-102009856-M rs3681072 100,650,744 T C CACTGTGTTTGCCTG[C/T]TCCAGCTTCCACGGC 
08-017931675-M rs3664394 17,977,301 C A GAAGGTCTCTTCATG[A/C]TACTCTTAATGGCAT 
08-055226913-M rs3717220 54,922,086 A T GATCAATTATATAAA[A/T]TTCCCAGGAGTCATT 
08-125070695-M rs3709824 124,681,350 T C CAGCCGAGAGGCCTT[C/T]AGCTGGCTTTTAGGC 
09-013396060-N rs3023202 13,253,350 A G AAAATAAGTAGTATT[A/G]CTTTTCTCATTTAAT 
09-049820222-M rs3688870 49,609,241 A C AAAGCTACTACAGCT[A/C]TATCAGTTTATATAC 
09-086008489-M rs3673117 85,460,183 C A TTTCATGCTGAGGCA[A/C]ACATTTATTTGCTCT 
09-123708875-M rs3713370 122,571,070 A G TCTATGGAAAGCCAG[A/G]CCACCAGGATCAGGT 
10-005282123-M rs3660611 5,282,123 C T AATAATCTATTGCAG[C/T]TGGATAATCTAATTT 
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10-028554348-N rs3023233 28,316,427 G A TCAGTTTCTGTGACT[A/G]TATGAGAGCATCCAC 
10-066453624-M rs3723140 66,088,952 T C CAGTCTGTGTTCTTG[C/T]TGACTCTAGCAGAGG 
10-100345477-M rs3710293 99,641,926 C T TCTTGTTGGTTGTTT[C/T]TCCTCAAATGTTCTA 
10-129117100-M rs3719409 128,477,779 A G GCAAGTTCAAGGCCA[A/G]CCTAGCTGCATAGTG 
11-004367508-M rs3659787 4,383,867 A G GCACGAACTTACTAA[A/G]CAAACCCACTGAGCA 
11-033040833-M rs3723833 33,409,549 C T AGAGAAATGCTTTCC[C/T]CAAGCAGGTGTGAAC 
11-063538723-N rs3024185 63,756,728 G A ATTCTTCCTCAGCTC[A/G]GGTTCTTAAGAAGAG 
11-121181118-M rs3726373 121,130,566 C A GGGGTTACATAGACA[A/C]TGGTCCGCTTGGCAG 
12-003567042-M rs3675632 3,567,742 T G AACCTCAGTGGCTTA[G/T]GAGCTTCCAGATATT 
12-031214248-M rs3658204 31,246,893 A C TTAAACTTACGCTTA[A/C]ACCTTTCCCTCAACA 
12-059204373-M rs3712499 59,022,301 G T CAACATAAATAGAAT[G/T]ACTTTACTTTTCTGG 
12-084289638-M rs3707414 84,101,707 A C AAGGCGCATGTGGAA[A/C]TTATTGTCTGATGCT 
12-113315003-M rs3696039 113,523,670 G C CATCTATAGGAACTG[C/G]AATAGTTATACTAAA 
13-015609597-M rs3701757 15,605,056 G A ATAAGACAGTCAAAA[A/G]CTGAACTCAATTGGC 
13-089524884-N rs3090591 88,554,097 C T AATGGAGTGTAAAGG[C/T]CTCAATTTTCCTAGG 
13-117094028-M rs3710370 116,221,605 A G GCTGAGAAGGGCGNC[A/G]TAGCCAGGCATGGGA 
14-005055006-M rs3689508 5,057,217 A T CTCTGTACCAATTGC[A/T]CACATGATTCCAAGC 
14-042965786-N rs3023408 42,485,449 T G AGAACACTGGTTCCA[G/T]CGTTCATTGTCAGGG 
14-080955404-M rs3699634 80,452,831 C A GTTTAACTTTGTGTA[A/C]ATATATAATTGTTAT 
14-112544301-N rs4230609 112,375,370 G A CGTAGTCCCAGCCCC[A/G]GTGATTGGCCCCAAT 
15-005994001-M rs3715343 6,003,109 C A GTGTGAGAGGGAACA[A/C]GTTTGTTCAGTTCAA 
15-039906196-M rs3683812 39,661,063 A G CAACGAGTTGTAAGA[A/G]CAGGGCCCTGTGTTT 
15-070911071-M rs3703015 70,655,901 A C CCATACTTGTTTGGA[A/C]GGCACTTTACCAATA 
15-103221933-M rs3665905 102,699,389 G C ACCTAGGCGGAATGT[C/G]ACAGTGCGTGGAGAG 
16-005053446-C rs4153115 5,057,146 T G TCTTGTCAGGTGGAC[G/T]ATGAAGATTAGGCAT 
16-034014165-C rs3681905 34,002,457 T G AGAAGGCAGCTCTCA[G/T]TGGGGAAACATGCCA 
16-064069423-N rs4151935 64,162,302 T C ATTCTTCACTGTAAA[C/T]GGGCACTTTTTGAAG 
16-093066825-C rs4219612 93,016,203 T C CCATTTGTATACACA[C/T]ATGCCCAGGTGCTGC 
17-007230139-M rs3660203 6,958,021 G C TGGTATCTGTGGACC[C/G]GTCTAGTCACTAGGC 
17-035364626-M rs3712621 34,890,520 T A AACAGTTGGCATTCA[A/T]CATATTTGCGTGTAT 
17-065545592-M rs3718630 64,865,659 C T ATGAGCCCCGTTCAG[C/T]TATCTCCCAGTCACA 
18-006845916-M rs3664664 6,960,532 A G CTGACTGGACCAGAG[A/G]AAGCTGGTTTTATCC 
18-034779074-M rs3701931 34,866,134 A C CAAAGAAAGGAAGAA[A/C]ACATGAGTGAGTTGC 
18-065309421-N rs4231907 65,386,550 C T AACCaCGATTAAACA[C/T]TCATATACTATTTTT 
18-086980249-M rs3670234 86,838,611 A G CATTTCTGACAATTA[A/G]ATGGGAATAATCAAT 
19-005091208-M rs3705162 4,941,258 T C AGCCACCATGCCCGG[C/T]GAAACAAACCTTTTC 
19-030086739-M rs3704503 29,710,292 G A GGTGTGATAGATCAT[A/G]GACTCAAGTTGTAGA 
19-060030696-N rs3023517 59,767,603 G A TGATCTTTGCTTGCC[A/G]TAACTTCCTTGAGTG 
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Appendix C: List of additional 9 heterologous SNP markers on chromosomes 17 and 
18 for QTL mapping 
JAX SNP ID 
(chromosome-
position-source)  
RS 
 
New Chr 
pos (bp) 
Build 30 
Allele 
C3H/H
eH 
Allele 
C57B
L/6 Sequence 
17-050794277-N rs3023778 50,023,076 A C GTTTTACTGTGTTTT[A/C]CAAAACTGCTTGGCA 
17-080241937-M rs3676709 79,603,774 G A CCAGTTGGTCCTCAC[A/G]ANCCTTATGAGGGTG 
17-089136255-M rs3659009 88,501,268 C T GAAGATAGAGGAGGC[C/T]AAATGTAACAGGTTT 
18-011819268-M rs3710602 11,945,554 C T TTTAATTTTCAAACA[C/T]CTACTCATAAAATCA 
18-024982833-M rs3660676 25,094,230 T C AAATGCTGGATGGGT[C/T]CTTGTCTGGAGATGG 
18-029963387-M rs3714233 30,071,607 C T CAACTGAGACTTTTG[C/T]TTCTCACAGAAAAAC 
18-039129483-M rs3695510 39,216,821 C A GCACCTTAATTTACA[A/C]TAGGGCATAACCTTA 
18-043868444-M rs3708056 43,956,481 C A TCCCTGACCAATTAC[A/C]ATGGAAGTATCTAAT 
18-055728214-N rs3089229 55,816,819 C G CGTTCACGATCACAT[C/G]CACCATCAAAATCAT 
 
Appendix D: Full results of Haley-Knott regression on 24hr ALT vales (92 marker 
panel) 
Chromosome Position LOD Significance threshold 
0.05 0.01 
1 4.15  0.137 2.56 3.27 
2 20.55  0.224 2.56 3.27 
3 45.52  0.363 2.56 3.27 
4 39.33  0.761 2.56 3.27 
5 94.89  0.391 2.56 3.27 
6 3.17  0.590 2.56 3.27 
7 33.24  0.210 2.56 3.27 
8 124.68  1.048 2.56 3.27 
9 49.61  0.342 2.56 3.27 
10 66.09  0.607 2.56 3.27 
11 4.38  1.296 2.56 3.27 
12 35.57  0.397 2.56 3.27 
13 48.61  0.921 2.56 3.27 
14 5.06  0.277 2.56 3.27 
15 102.70  0.256 2.56 3.27 
16 5.06  1.404 2.56 3.27 
17 50.02  2.956* 2.56 3.27 
18 46.96  3.304** 2.56 3.27 
19 57.94  0.318 2.56 3.27 
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Appendix E: Full results of Bayesian interval mapping, showing Bayesian factors and 
standard errors for single loci. In order, with chromosomes with highest level of 
evidence at the top. 
  
Chromosome Posterior     Prior Bayesian 
Factor (BF) 
BF standard 
error 
18  0.1720 0.0365 11.70 0.469 
17     0.1270  0.0373   8.50 0.406 
5      0.0891  0.0580   3.82 0.223 
3      0.0956  0.0694   3.43 0.192 
8      0.0474  0.0488   2.42 0.198 
10     0.0530  0.0563   2.34 0.181 
13     0.0416  0.0460   2.25 0.197 
12     0.0357  0.0503   1.77 0.168 
16     0.0270  0.0402   1.67 0.183 
6      0.0440  0.0665   1.64 0.140 
15     0.0285  0.0442 1.60 0.171 
11     0.0320  0.0534   1.49 0.150 
4      0.0405  0.0682 1.48 0.131 
1      0.0486  0.0867 1.39 0.113 
9      0.0274  0.0500 1.37 0.148 
14     0.0269  0.0491 1.36 0.150 
7      0.0226  0.0441   1.27 0.153 
19     0.0123  0.0251   1.23 0.200 
2      0.0281  0.0700   1.00 0.107 
 
Appendix F: Full results of Bayesian interval mapping, showing Bayesian factors and 
standard errors for interactiong (epistatic) chromosomal pairs.  
 
Chromosome 
pair 
Posterior     Prior Bayesian 
Factor (BF) 
BF standard 
error 
3:5       0.4030  0.00762 19.60 0.435 
6:18      0.0640  0.00460 5.15 0.360 
16:17     0.0280  0.00284 3.65 0.393 
1:10      0.0807  0.00925 3.23 0.199 
10:13     0.0393  0.00490 2.97 0.268 
10:12     0.0370  0.00536 2.56 0.238 
12:15     0.0263  0.00421 2.32 0.257 
4:17      0.0290  0.00481 2.23 0.236 
7:18      0.0167  0.00305 2.03 0.284 
2:17      0.0253  0.00494 1.90 0.215 
8:14      0.0187  0.00453 1.53 0.202 
9:15      0.0167  0.00418 1.48 0.207 
4:15      0.0207  0.00571 1.34 0.168 
3:18      0.0173  0.00480 1.34 0.184 
6:9       0.0170  0.00629 1.00 0.139 
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Appendix G: Table of all genes between 41-54Mbp on murine chromosome 18 (from 
NCBI Map Viewer Mouse genome overview page (Annotation Release 104) 
 
Region Symbol Gene Name 
41
-4
2M
bp
 Gm18530 crumbs homolog 1 pseudogene 
LOC102633556 uncharacterized LOC102633556 
Gm18371 cyclin-dependent kinase 1 pseudogene 
Prelid2 PRELI domain containing 2 
Grxcr2 glutaredoxin, cysteine rich 2 
42
-4
3M
bp
 
Sh3rf2 SH3 domain containing ring finger 2 
Gm5689 stefin A pseudogene 
Gm18086 ribosomal protein SA pseudogene 
Plac8l1 PLAC8-like 1 
Gm5504 high mobility group box 1-like pseudogene 
Lars leucyl-tRNA synthetase 
Rps19-ps4 ribosomal protein S19, pseudogene 4 
Gm4013 predicted gene 4013 
Rbm27 RNA binding motif protein 27 
Pou4f3 POU domain, class 4, transcription factor 3 
LOC102633668 uncharacterized LOC102633668 
Gm16415 ribosomal protein L21 pseudogene 
LOC102633749 uncharacterized LOC102633749 
Gm3631 ribosomal protein S2 pseudogene 
Tcerg1 transcription elongation regulator 1 (CA150) 
Gpr151 G protein-coupled receptor 151 
C030004G16Rik RIKEN cDNA C030004G16 gene 
  
43
-4
4M
bp
 
Ppp2r2b protein phosphatase 2, regulatory subunit B, beta 
Gm8181 predicted gene 8181 
LOC102633948 uncharacterized LOC102633948 
Stk32a serine/threonine kinase 32A 
Dpysl3 dihydropyrimidinase-like 3 
Gm3650 predicted gene 3650 
Eif3j2 eukaryotic translation initiation factor 3, subunit J2 
Jakmip2 janus kinase and microtubule interacting protein 2 
Spink3 serine peptidase inhibitor, Kazal type 3 
Scgb3a2 secretoglobin, family 3A, member 2 
Gm94 predicted gene 94 
44
-4
5M
bp
 
Spink5 serine peptidase inhibitor, Kazal type 5 
Spink14 serine peptidase inhibitor, Kazal type 14 
Gm8390 high mobility group box 2 pseudogene 
Spink6 serine peptidase inhibitor, Kazal type 6 
Spink12 serine peptidase inhibitor, Kazal type 12 
Gm10267 predicted gene 10267 
Spinkl serine protease inhibitor, Kazal type-like 
Spink11 serine peptidase inhibitor, Kazal type 11 
Npy6r neuropeptide Y receptor Y6 
Myot myotilin 
Dcp2 DCP2 decapping enzyme homolog (S. cerevisiae) 
Mcc mutated in colorectal cancers 
A930012L18Rik RIKEN cDNA A930012L18 gene 
Ythdc2 YTH domain containing 2 
45
-
46
M
bp
 Gm6663 mortality factor 4 like 1 pseudogene 
LOC102634020 uncharacterized LOC102634020 
Gm4839 DnaJ (Hsp40) homolog, subfamily C, member 30 pseudogene 
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LOC102634097 small ubiquitin-related modifier 2-like 
Gm18652 coiled-coil domain containing 53 pseudogene 
LOC102634214 uncharacterized LOC102634214 
LOC102634286 uncharacterized LOC102634286 
LOC102634440 uncharacterized LOC102634440 
LOC102634598 uncharacterized LOC102634598 
Kcnn2 potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 2 
LOC102634515 uncharacterized LOC102634515 
A330093E20Rik RIKEN cDNA A330093E20 gene 
46
-4
7M
bp
 
A330093E20Rik RIKEN cDNA A330093E20 gene 
LOC102639325 filaggrin-2-like 
Trim36 tripartite motif-containing 36 
LOC102634682 uncharacterized LOC102634682 
Pggt1b protein geranylgeranyltransferase type I, beta subunit 
Ccdc112 coiled-coil domain containing 112 
Gm4840 symplekin pseudogene 
LOC102634855 uncharacterized LOC102634855 
LOC102634787 uncharacterized LOC102634787 
Mospd4 motile sperm domain containing 4 
LOC102634956 60S ribosomal protein L7a-like 
Fem1c fem-1 homolog c (C.elegans) 
Ticam2 toll-like receptor adaptor molecule 2 
Gm18606 RAD51 homolog c pseudogene 
Tmed7 transmembrane emp24 protein transport domain containing 7 
Eif1a eukaryotic translation initiation factor 1A 
Cdo1 cysteine dioxygenase 1, cytosolic 
Atg12 autophagy related 12 
Ap3s1 adaptor-related protein complex 3, sigma 1 subunit 
Gm8295 predicted gene 8295 
4833403I15Rik RIKEN cDNA 4833403I15 gene 
Arl14epl ADP-ribosylation factor-like 14 effector protein-like 
Gm3744 predicted gene 3744 
Commd10 COMM domain containing 10 
47
-4
8M
bp
 
Hspe1-rs1 heat shock protein 1 (chaperonin 10), related sequence 1 
Gm8468 ADP-ribosylation factor interacting protein 1 pseudogene 
Sema6a sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6A 
Gm6883 ribosomal protein L6 pseudogene 
9130209A04Rik RIKEN cDNA 9130209A04 gene 
LOC102635279 uncharacterized LOC102635279 
Gm5095 predicted gene 5095 
Gm5236 ribosomal protein large PO subunit pseudogene 
Gm4146 predicted gene 4146 
G630055G22Rik RIKEN cDNA G630055G22 gene 
48
-
49
M
bp
 Eno1b enolase 1B, retrotransposed 
G630055G22Rik RIKEN cDNA G630055G22 gene 
Gm5237 predicted gene 5237 
Gm5839 glyceraldehyde-3-phosphate dehydrogenase pseudogene 
49
-5
0M
bp
 
Gm18993 cyclin-dependent kinase 9 (CDC2-related kinase) pseudogene 
LOC102635576 uncharacterized LOC102635576 
Gm18837 developmental pluripotency associated 4 pseudogene 
1700044K03Rik RIKEN cDNA 1700044K03 gene 
LOC102635683 uncharacterized LOC102635683 
Dtwd2 DTW domain containing 2 
LOC102635853 uncharacterized LOC102635853 
1700065O20Rik RIKEN cDNA 1700065O20 gene 
Dmxl1 Dmx-like 1 
 263 
Tnfaip8 tumor necrosis factor, alpha-induced protein 8 
50
-5
1M
bp
 LOC102635912 uncharacterized LOC102635912 
Cd63-ps CD63 antigen, pseudogene 
Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 
LOC102636260 uncharacterized LOC102636260 
Gm8529 glyceraldehyde-3-phosphate dehydrogenase pseudogene 
Fam170a family with sequence similarity 170, member A 
51
-
52
M
bp
 Gm3815 polymerase (RNA) II (DNA directed) polypeptide C pseudogene 
Prr16 proline rich 16 
Gm4950 proteasome (prosome, macropain) subunit, beta type 3 
pseudogene 
52
-5
3M
bp
 
Ftmt ferritin mitochondrial 
Srfbp1 serum response factor binding protein 1 
Lox lysyl oxidase 
Gm18151 ribosomal protein S3A pseudogene 
Zfp474 zinc finger protein 474 
1700034E13Rik RIKEN cDNA 1700034E13 gene 
Gykl1 glycerol kinase-like 1 
Sncaip synuclein, alpha interacting protein (synphilin) 
Gm8572 RAN guanine nucleotide release factor pseudogene 
53
-5
4M
bp
 
Snx2 sorting nexin 2 
Gm1859 Rac GTPase-activating protein 1 pseudogene 
Gm18887 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 pseudogene 
Snx24 sorting nexing 24 
LOC102636345 uncharacterized LOC102636345 
LOC102636449 uncharacterized LOC102636449 
Ppic peptidylprolyl isomerase C 
Prdm6 PR domain containing 6 
Gm19466 predicted gene, 19466 
Cep120 centrosomal protein 120 
LOC102636605 uncharacterized LOC102636605 
Csnk1g3 casein kinase 1, gamma 3 
Gm5507 glyceraldehyde-3-phosphate dehydrogenase pseudogene 
54
-5
5M
bp
 
Gm8594 high mobility group box 2 pseudogene 
LOC102636672 uncharacterized LOC102636672 
Gm20567 heat shock protein 1 (chaperonin) pseudogene 
Redrum Redrum, erythroid developmental long intergenic non-protein coding transcript 
9330117O12Rik RIKEN cDNA 9330117O12 gene 
Gm5821 high mobility group box 2 pseudogene 
LOC102636743 uncharacterized LOC102636743 
Zfp608 zinc finger protein 608 
Gm4221 predicted gene 4221 
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Appendix H: Amino acid sequence of the Commd10 protein with methionine/threonine 
substitution at position 98 highlighted. (A) the amino acid sequence as in C57BL/6 (B) 
amino acid sequence in C3H  
 (A) 
1  maasaalilp espsmkkavp linaidtgrf prllsrilqk lhlkaessfs eeeeeklqaa 
61  fslekqelhl vletisfvle qavyhnvkpa alqqqlemih lrkdkaeafa sawsamgqet 
121  vekfrqrilg phkletvgwq lnlqmahsaq aklqspqavl qlgvskedak nvekvlvefn 
181  hkelfdfynk letiqaqlds lt 
 
(B) 
1  maasaalilp espsmkkavp linaidtgrf prllsrilqk lhlkaessfs eeeeeklqaa 
61  fslekqelhl vletisfvle qavyhnvkpa alqqqletih lrkdkaeafa sawsamgqet 
121  vekfrqrilg phkletvgwq lnlqmahsaq aklqspqavl qlgvskedak nvekvlvefn 
181  hkelfdfynk letiqaqlds lt 
 
Appendix I: COMMD10 predicted protein structure with (A) methionine at position 98 
and (B) threonine at position 98. Note the additional protein binding domain (red 
diamond) and polynucleotide binding region (yellow circle) at positions 127 and 147 in 
protein variant B. 
 
(A) 
 
 
(B) 
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Appendix J: Table of all genes between 40-55Mbp on murine chromosome 17 (from 
NCBI Map Viewer Mouse genome overview page (Annotation Release 104) 
 
Region Symbol Gene Name 
40
-4
2M
bp
 
Gm21666 protein 
Gm7148 TGFB-induced factor homeobox 2 pseudogene 
Pgk2 phosphoglycerate kinase 2 
Crisp3 cysteine-rich secretory protein 3 
Crisp1 cysteine-rich secretory protein 1 
LOC102637463 ADP/ATP translocase 2-like 
C330004N01Rik RIKEN cDNA C330004N01 gene 
Esp8 exocrine gland secreted peptide 8 
LOC101055941 anaphase-promoting complex subunit CDC26-like 
Esp6 exocrine gland secreted peptide 6 
Esp6Esp5 Esp6-Esp5 readthrough transcript 
Esp5 exocrine gland secreted peptide 5 
Esp4 exocrine gland secreted peptide 4 
Esp3 exocrine gland secreted peptide 3 
Esp1 exocrine gland secreted peptide 1 
Crisp2 cysteine-rich secretory protein 2 
Rhag Rhesus blood group-associated A glycoprotein 
Gm20574 cytochrome P450, family 2, subfamily ac, polypeptide 1, pseudogene 
9130008F23Rik RIKEN cDNA 9130008F23 gene 
Glyatl3 glycine-N-acyltransferase-like 3 
Cenpq centromere protein Q 
Mut methylmalonyl-Coenzyme A mutase 
Ldha-ps3 lactate dehydrogenase A, pseudogene 3 
Gm6771 glyceraldehyde-3-phosphate dehydrogenase pseudogene 
42
-4
4M
bp
 
LOC102637637 serine palmitoyltransferase small subunit A-like 
Ptchd4 patched domain containing 4 
Opn5 opsin 5 
Gpr115 G protein-coupled receptor 115 
Gpr111 G protein-coupled receptor 111 
LOC102637749 40S ribosomal protein S2-like 
Cd2ap CD2-associated protein 
Tnfrsf21 tumor necrosis factor receptor superfamily, member 21 
LOC102637939 uncharacterized LOC102637939 
LOC102638048 uncharacterized LOC102638048 
E130008D07Rik RIKEN cDNA E130008D07 gene 
Gpr110 G protein-coupled receptor 110 
Gpr116 G protein-coupled receptor 116 
Mep1a meprin 1 alpha 
Ankrd66 ankyrin repeat domain 66 
1700071M16Rik RIKEN cDNA 1700071M16 gene 
Pla2g7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) 
Tdrd6 tudor domain containing 6 
Slc25a27 solute carrier family 25, member 27 
Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 
LOC102638137 uncharacterized LOC102638137 
Rcan2 regulator of calcineurin 2 
44
-
46
M
bp
 Rcan2 regulator of calcineurin 2 
Enpp5 ectonucleotide pyrophosphatase/phosphodiesterase 5 
Enpp4 ectonucleotide pyrophosphatase/phosphodiesterase 4 
 266 
Clic5 chloride intracellular channel 5 
Runx2 runt related transcription factor 2 
Runx2os2 runt related transcription factor 2, opposite strand 2 
4930564C03Rik RIKEN cDNA 4930564C03 gene 
Supt3 suppressor of Ty 3 
Gm4766 coiled-coil domain containing 94 pseudogene 
Cdc5l cell division cycle 5-like (S. pombe) 
Spats1 spermatogenesis associated, serine-rich 1 
Gm9104 ribosomal protein L21 pseudogene 
Aars2 alanyl-tRNA synthetase 2, mitochondrial (putative) 
Tcte1 t-complex-associated testis expressed 1 
Tmem151b transmembrane protein 151B 
Nfkbie nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, epsilon 
Slc35b2 solute carrier family 35, member B2 
Hsp90ab1 heat shock protein 90 alpha (cytosolic), class B member 1 
Slc29a1 solute carrier family 29 (nucleoside transporters), member 1 
Gm7325 predicted gene 7325 
Capn11 OTTMUSP00000041130 
Tmem63b transmembrane protein 63b 
Mrpl14 mitochondrial ribosomal protein L14 
BE949265 cDNA sequence BE949265 
1600014C23Rik RIKEN cDNA 1600014C23 gene 
LOC102639512 uncharacterized LOC102639512 
F630040K05Rik RIKEN cDNA F630040K05 gene 
LOC102639361 uncharacterized LOC102639361 
4930542M03Rik RIKEN cDNA 4930542M03 gene 
LOC102639924 uncharacterized LOC102639924 
46
-4
8M
bp
 
Vegfa vascular endothelial growth factor A 
Polh polymerase (DNA directed), eta (RAD 30 related) 
Xpo5 exportin 5 
Polr1c polymerase (RNA) I polypeptide C 
Abcc10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 
Zfp318 zinc finger protein 318 
Slc22a7 solute carrier family 22 (organic anion transporter), member 7 
Cul9 cullin 9 
Srf serum response factor 
Ptk7 PTK7 protein tyrosine kinase 7 
Cul7 cullin 7 
Mea1 male enhanced antigen 1 
Ppp2r5d protein phosphatase 2, regulatory subunit B', delta 
Pex6 peroxisomal biogenesis factor 6 
Gnmt glycine N-methyltransferase 
Cnpy3 canopy 3 homolog (zebrafish) 
Ptcra pre T cell antigen receptor alpha 
Prph2 peripherin 2 
Ubr2 ubiquitin protein ligase E3 component n-recognin 2 
Trerf1 transcriptional regulating factor 1 
Guca1b guanylate cyclase activator 1B 
Guca1a guanylate cyclase activator 1a (retina) 
Taf8 TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factorq 
Ccnd3 cyclin D3 
Bysl bystin-like 
Frs3 fibroblast growth factor receptor substrate 3 
Pgc progastricsin (pepsinogen C) 
Tfeb transcription factor EB 
Mdfi MyoD family inhibitor 
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Foxp4 forkhead box P4 
48
-5
0M
bp
 
1700122O11Rik RIKEN cDNA 1700122O11 gene 
Gm20596 heat shock protein 1 (chaperonin) pseudogene 22 
A730006G06Rik RIKEN cDNA A730006G06 gene 
1700067P10Rik RIKEN cDNA 1700067P10 gene 
9830107B12Rik RIKEN cDNA 9830107B12 gene 
A530064D06Rik RIKEN cDNA A530064D06 gene 
Trem1 triggering receptor expressed on myeloid cells 1 
Gm18679 Ewing sarcoma breakpoint region 1 pseudogene 
Trem3 triggering receptor expressed on myeloid cells 3 
Treml4 triggering receptor expressed on myeloid cells-like 4 
Treml2 triggering receptor expressed on myeloid cells-like 2 
B430306N03Rik RIKEN cDNA B430306N03 gene 
Trem2 triggering receptor expressed on myeloid cells 2 
Treml1 triggering receptor expressed on myeloid cells-like 1 
Nfya nuclear transcription factor-Y alpha 
Oard1 O-acyl-ADP-ribose deacylase 1 
Apobec2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2 
Tspo2 translocator protein 2 
Unc5cl unc-5 homolog C (C. elegans)-like 
Lrfn2 leucine rich repeat and fibronectin type III domain containing 2 
1700008K24Rik RIKEN cDNA 1700008K24 gene 
Gm9586 antigenic determinant of rec-A protein pseudogene 
Gm17830 predicted gene, 17830 
Gm18067 ribosomal protein L5 pseudogene 
Mocs1 molybdenum cofactor synthesis 1 
Daam2 dishevelled associated activator of morphogenesis 2 
Kif6 kinesin family member 6 
LOC102632654 uncharacterized LOC102632654 
Gm19465 potassium channel subfamily K member 16-like 
Rftn1 raftlin lipid raft linker 1 
50
-5
2M
bp
 
Gm9191 cell division cycle 20 homolog pseudogene 
Gm18735 mitochondrial ribosomal protein L45 pseudogene 
AY702103 cDNA sequence AY702103 
Gm4669 predicted gene 4669 
Dazl deleted in azoospermia-like 
LOC102633037 uncharacterized LOC102633037 
LOC102633107 uncharacterized LOC102633107 
Plcl2 phospholipase C-like 2 
Gm7334 B-cell translocation gene 3 pseudogene 
LOC102633195 uncharacterized LOC102633195 
Tbc1d5 TBC1 domain family, member 5 
C330011F03Rik RIKEN cDNA C330011F03 gene 
LOC102633281 uncharacterized LOC102633281 
Satb1 special AT-rich sequence binding protein 1 
LOC102633357 uncharacterized LOC102633357 
Gm20098 predicted gene, 20098 
53
-5
5M
bp
 
Gm19585 predicted gene, 19585 
Kcnh8 potassium voltage-gated channel, subfamily H (eag-related), member 8 
Gm9210 3-phosphoglycerate dehydrogenase pseudogene 
Gm9214 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 pseudogene 
Efhb EF hand domain family, member B 
Tpt1-ps7 tumor protein, translationally-controlled, pseudogene 7 
Rab5a RAB5A, member RAS oncogene family 
Pp2d1 protein phosphatase 2C-like domain containing 1 
Kat2b K(lysine) acetyltransferase 2B 
Sgol1 shugoshin-like 1 (S. pombe) 
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LOC102633791 protein phosphatase 2C-like domain-containing protein 1-like 
Gm18680 RAB5A, member RAS oncogene family pseudogene 
4932415M13Rik RIKEN cDNA 4932415M13 gene 
Ck-ps1 creatine kinase pseudogene 1 
LOC102637912 sperm motility kinase W-like 
Sult1c2 sulfotransferase family, cytosolic, 1C, member 2 
Mrps36-ps1 mitichondrial ribosomal protein S36, pseudogene 1 
Gm4458 predicted gene 4458 
Gm9221 predicted gene 9221 
Gm19674 creatine kinase, brain pseudogene 
Gm6949 brain creatine kinase pseudogene 
Gm324 predicted gene 324 
Sult1c1 sulfotransferase family, cytosolic, 1C, member 1 
Gm5684 erythrocyte protein band 4.1-like 4b pseudogene 
Slc5a7 solute carrier family 5 (choline transporter), member 7 
1700025K24Rik RIKEN cDNA 1700025K24 gene 
Trp53-ps transformation related protein 53, pseudogene 
Gm4946 myo-inositol 1-phosphate synthase A1 pseudogene 
LOC102634480 uncharacterized LOC102634480 
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Appendix J: Table of all genes between 11-31Mbp on murine chromosome 5 (from 
NCBI Map Viewer Mouse genome overview page (Annotation Release 104). 
Heterologous coding non-synonymous or locus region SNPs between C57BL/6 and 
C3H/HeJ are noted 
 
Region Symbol Gene Name 
 
Heterologous SNP 
11
-1
6M
b 
Sema3a sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A  
Sema3e sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E  
Pclo piccolo (presynaptic cytomatrix protein)  
Speer4d spermatogenesis associated glutamate (E)-rich protein 4d  
Speer4c spermatogenesis associated glutamate (E)-rich protein 4c  
16
-2
1M
b 
Cacna2d1 calcium channel, voltage-dependent, alpha2/delta subunit 1  
Hgf hepatocyte growth factor  
Speer4f spermatogenesis associated glutamate (E)-rich protein 4f  
Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C  
Cd36 CD36 antigen  
Gnat3 guanine nucleotide binding protein, alpha transducing 3  
Gnai1 guanine nucleotide binding protein (G protein), alpha inhibiting 1  
Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2  
Phtf2 putative homeodomain transcription factor 2  
Tmem60 transmembrane protein 60  
Rsbn1l round spermatid basic protein 1-like  
21
-2
6M
b 
Ptpn12 protein tyrosine phosphatase, non-receptor type 12  
Fgl2 fibrinogen-like protein 2  
Fbxl13 F-box and leucine-rich repeat protein 13 Locus region (4) 
Napepld N-acyl phosphatidylethanolamine phospholipase D Locus region 
Dnajc2 DnaJ (Hsp40) homolog, subfamily C, member 2  
Psmc2 proteasome (prosome, macropain) 26S subunit, ATPase 2 Locus region 
Slc26a5 solute carrier family 26, member 5  
Reln reelin Coding non-synonymous 
Lhfpl3 lipoma HMGIC fusion partner-like 3 Locus region (5) 
Kmt2e lysine (K)-specific methyltransferase 2E  
Srpk2 serine/arginine-rich protein specific kinase 2  
Fam126a family with sequence similarity 126, member A  
Kcnh2 potassium voltage-gated channel, subfamily H (eag-related), member 2  
Nos3 nitric oxide synthase 3, endothelial cell  
Abcb8 ATP-binding cassette, sub-family B (MDR/TAP), member 8  
Cdk5 cyclin-dependent kinase 5  
Asic3 acid-sensing (proton-gated) ion channel 3  
Slc4a2 solute carrier family 4 (anion exchanger), member  
 270 
2 
Fastk Fas-activated serine/threonine kinase  
Tmub1 transmembrane and ubiquitin-like domain containing 1  
Gbx1 gastrulation brain homeobox 1  
Abcf2 ATP-binding cassette, sub-family F (GCN20), member 2  
Smarcd3 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily d, 
member 3 
 
Nub1 negative regulator of ubiquitin-like proteins 1  
Wdr86 WD repeat domain 86  
Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit  
Kmt2c lysine (K)-specific methyltransferase 2C 
Coding-non-
synonymous (3) 
Locus region 
Xrcc2 X-ray repair complementing defective repair in Chinese hamster cells 2  
26
-3
1M
b 
Actr3b ARP3 actin-related protein 3B  
Dpp6 dipeptidylpeptidase 6 Coding-non-synonymous 
Paxip1 PAX interacting (with transcription-activation domain) protein 1  
Htr5a 5-hydroxytryptamine (serotonin) receptor 5A  
Insig1 insulin induced gene 1  
En2 engrailed 2  
Cnpy1 canopy 1 homolog (zebrafish)  
Rbm33 RNA binding motif protein 33  
Shh sonic hedgehog  
Lmbr1 limb region 1  
Nom1 nucleolar protein with MIF4G domain 1  
Mnx1 motor neuron and pancreas homeobox 1  
Ube3c ubiquitin protein ligase E3C  
Dnajb6 DnaJ (Hsp40) homolog, subfamily B, member 6  
Il6 interleukin 6  
Tyms thymidylate synthase  
Hadha 
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
hydratase (trifunctional protein), alpha subunit 
 
Hadhb 
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
hydratase (trifunctional protein), beta subunit 
 
Otof otoferlin  
Kcnk3 potassium channel, subfamily K, member 3  
Slc35f6 solute carrier family 35, member F6  
Cenpa centromere protein A  
Dpysl5 dihydropyrimidinase-like 5  
Mapre3 microtubule-associated protein, RP/EB family, member 3  
Agbl5 ATP/GTP binding protein-like 5  
Emilin1 elastin microfibril interfacer 1  
Khk ketohexokinase  
Cgref1 cell growth regulator with EF hand domain 1  
Preb prolactin regulatory element binding  
Tcf23 transcription factor 23  
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Appendix K: Table of all genes between 43-73Mbp on murine chromosome 3 (from 
NCBI Map Viewer Mouse genome overview page (Annotation Release 104). 
Heterologous coding non-synonymous or locus region SNPs between C57BL/6 and 
C3H/HeJ are noted 
 
Regi
on 
Symbol Gene Name 
 
Heterologous SNP 
43
-4
8 
M
bp
 
Pcdh10 protocadherin 10 
 
48
-5
3M
b 
Pabpc4l poly(A) binding protein, cytoplasmic 4-like  
Pcdh18 protocadherin 18 Coding-non-synonymous 
Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 
 
Ccrn4l CCR4 carbon catabolite repression 4-like (S. cerevisiae) 
Locus region 
Elf2 E74-like factor 2  
Mgarp mitochondria localized glutamic acid rich protein  
Ndufc1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 
 
Naa15 N(alpha)-acetyltransferase 15, NatA auxiliary subunit  
Rab33b RAB33B, member RAS oncogene family  
Setd7 SET domain containing (lysine methyltransferase) 7  
Mgst2 microsomal glutathione S-transferase 2  
Maml3 mastermind like 3 (Drosophila)  
Foxo1 forkhead box O1  
LOC1026
37513 cytochrome c oxidase subunit 7B, mitochondrial-like 
 
-5
8M
bp
53
 
Cog6 component of oligomeric golgi complex 6 Locus region 
Lhfp lipoma HMGIC fusion partner  
Nhlrc3 NHL repeat containing 3  
Proser1 proline and serine rich 1  
Stoml3 stomatin (Epb7.2)-like 3  
Frem2 Fras1 related extracellular matrix protein 2  
Ufm1 ubiquitin-fold modifier 1  
Trpc4 transient receptor potential cation channel, subfamily C, member 4 
 
Postn periostin, osteoblast specific factor  
Supt20 suppressor of Ty 20  
Exosc8 exosome component 8  
Alg5 asparagine-linked glycosylation 5 (dolichyl-phosphate beta-glucosyltransferase) 
 
Smad9 OTTMUSP00000023428  
Rfxap regulatory factor X-associated protein  
Sertm1 serine rich and transmembrane domain containing 1  
Ccna1 cyclin A1  
Spg20 spastic paraplegia 20, spartin (Troyer syndrome) homolog (human) 
 
Ccdc169 coiled-coil domain containing 169  
Sohlh2 spermatogenesis and oogenesis specific basic helix-loop-helix 2 
 
LOC1010
56032 uncharacterized LOC101056032 
 
Dclk1 doublecortin-like kinase 1 Locus region (2) 
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Mab21l1 mab-21-like 1 (C. elegans)  
Nbea neurobeachin  
Tm4sf1 transmembrane 4 superfamily member 1  
Tm4sf4 transmembrane 4 superfamily member 4  
Wwtr1 WW domain containing transcription regulator 1  
Commd2 COMM domain containing 2  
Ankub1 ankrin repeat and ubiquitin domain containing 1  
Rnf13 ring finger protein 13  
58
-6
3M
b 
Pfn2 profilin 2  
Serp1 stress-associated endoplasmic reticulum protein 1  
Eif2a OTTMUSP00000037517  
Selt OTTMUSP00000023471|selenoprotein T  
Erich6 glutamate rich 6  
Siah2 seven in absentia 2  
Fam188b
2 family with sequence similarity 188, member B2 
 
Clrn1 clarin 1 Locus region (3) 
Gpr171 G protein-coupled receptor 171  
P2ry14 purinergic receptor P2Y, G-protein coupled, 14  
Med12l mediator complex subunit 12-like  
Gpr87 G protein-coupled receptor 87  
P2ry13 purinergic receptor P2Y, G-protein coupled 13  
P2ry12 purinergic receptor P2Y, G-protein coupled 12 Locus region (3) 
Igsf10 immunoglobulin superfamily, member 10  
Aadacl2 arylacetamide deacetylase-like 2 Locus region (2) 
Aadac arylacetamide deacetylase (esterase)  
Sucnr1 succinate receptor 1 Locus region (5) 
Mbnl1 muscleblind-like 1 (Drosophila)  
P2ry1 purinergic receptor P2Y, G-protein coupled 1  
Rap2b RAP2B, member of RAS oncogene family  
Arhgef26 Rho guanine nucleotide exchange factor (GEF) 26 Locus region  
Dhx36 DEAH (Asp-Glu-Ala-His) box polypeptide 36  
63
-6
8M
b 
Gpr149 G protein-coupled receptor 149  
Plch1 phospholipase C, eta 1  
Slc33a1 solute carrier family 33 (acetyl-CoA transporter), member 1 
 
Gmps GMP synthase [glutamine-hydrolyzing]  
Vmn2r1 vomeronasal 2, receptor 1  
Vmn2r2 vomeronasal 2, receptor 2  
Vmn2r3 vomeronasal 2, receptor 3  
Vmn2r4 vomeronasal 2, receptor 4  
Vmn2r5 vomeronasal 2, receptor 5  
Vmn2r6 vomeronasal 2, receptor 6  
Vmn2r7 vomeronasal 2, receptor 7  
Kcnab1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 
 
Ssr3 signal sequence receptor, gamma  
Tiparp TCDD-inducible poly(ADP-ribose) polymerase  
Lekr1 leucine, glutamate and lysine rich 1  
Ccnl1 cyclin L1  
Ptx3 pentraxin related gene  
Shox2 short stature homeobox 2  
Rsrc1 arginine/serine-rich coiled-coil 1  
Mlf1 myeloid leukemia factor 1  
Gfm1 G elongation factor, mitochondrial 1  
Lxn latexin  
Mfsd1 major facilitator superfamily domain containing 1  
6 8 - 7 3 M b Iqcj IQ motif containing J  
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Schip1 schwannomin interacting protein 1  
Il12a interleukin 12a  
Ift80 intraflagellar transport 80 homolog  
Smc4 structural maintenance of chromosomes 4  
Trim59 tripartite motif-containing 59  
Kpna4 karyopherin (importin) alpha 4 Locus region 
Arl14 ADP-ribosylation factor-like 14  
Ppm1l protein phosphatase 1 (formerly 2C)-like  
B3galnt1 UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, polypeptide 1 
 
Rpl32-ps ribosomal protein L32, pseudogene  
Nmd3 NMD3 homolog (S. cerevisiae) Locus region 
Sptssb serine palmitoyltransferase, small subunit B  
Otol1 otolin 1 homolog (zebrafish)  
Sis sucrase isomaltase (alpha-glucosidase) 
Coding non-
synonymous 
Locus region 
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Appendix L: Table of all genes between 20-40Mbp on murine chromosome 2 (from 
NCBI Map Viewer Mouse genome overview page (Annotation Release 104). 
Heterologous coding non-synonymous or locus region SNPs between C57BL/6 and 
C3H/HeJ are noted 
 
Regi
on 
Symbol Gene Name 
 
Heterologous SNP 
20
-2
4M
bp
 
Etl4 enhancer trap locus 4  
Arhgap21 Rho GTPase activating protein 21  
Enkur enkurin, TRPC channel interacting protein  
Thnsl1 threonine synthase-like 1 (bacterial)  
Gpr158 G protein-coupled receptor 158  
Myo3a myosin IIIA  
LOC1026375
66 
guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-5-like 
 
Myo3a myosin IIIA  
Gad2 glutamic acid decarboxylase 2  
Apbb1ip amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 
 
Pdss1 prenyl (solanesyl) diphosphate synthase, subunit 1  
Abi1 abl-interactor 1  
Acbd5 acyl-Coenzyme A binding domain containing 5  
Mastl microtubule associated serine/threonine kinase-like  
Yme1l1 YME1-like 1 (S. cerevisiae)  
Nxph2 neurexophilin 2  
Spopl speckle-type POZ protein-like  
25
-3
0M
bp
 
Fut7 fucosyltransferase 7  
Abca2 ATP-binding cassette, sub-family A (ABC1), member 2 
 
Ptgds prostaglandin D2 synthase (brain)  
Traf2 TNF receptor-associated factor 2  
Lcn5 lipocalin 5  
Lhx3 LIM homeobox protein 3  
Card9 caspase recruitment domain family, member 9  
Notch1 p300  
Egfl7 EGF-like domain 7  
Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta) 
 
Surf1 surfeit gene 1  
Adamts13 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 13 
 
Dbh dopamine beta-hydroxylase  
Vav2 vav 2 oncogene  
Wdr5 WD repeat domain 5  
Rxra retinoid X receptor alpha  
Col5a1 collagen, type V, alpha 1  
Olfm1 olfactomedin 1  
Ralgds ral guanine nucleotide dissociation stimulator  
Cel carboxyl ester lipase  
Gfi1b growth factor independent 1B  
Tsc1 tuberous sclerosis 1  
Barhl1 BarH-like 1 (Drosophila)  
Ttf1 transcription termination factor, RNA polymerase I  
Rapgef1 Rap guanine nucleotide exchange factor (GEF) 1  
Slc27a4 solute carrier family 27 (fatty acid transporter),  
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member 4 
Odf2 outer dense fiber of sperm tails 2  
Sptan1 spectrin alpha, non-erythrocytic 1  
30
-3
4M
bp
 
Set SET nuclear oncogene  
Endog endonuclease G  
Crat carnitine acetyltransferase  
Prrx2 paired related homeobox 2  
Ptges prostaglandin E synthase  
Tor1a torsin family 1, member A (torsin A)  
Ncs1 neuronal calcium sensor 1  
Ass1 argininosuccinate synthetase 1  
Abl1 c-abl oncogene 1, non-receptor tyrosine kinase  
Lamc3 laminin gamma 3  
Golga2 golgi autoantigen, golgin subfamily a, 2  
Dnm1 dynamin 1  
Ciz1 CDKN1A interacting zinc finger protein 1  
Lcn2 lipocalin 2  
Ptges2 prostaglandin E synthase 2  
Ak1 adenylate kinase 1  
Eng endoglin  
Fpgs folylpolyglutamyl synthetase  
Cdk9 cyclin-dependent kinase 9 (CDC2-related kinase)  
Sh2d3c SH2 domain containing 3C  
Stxbp1 syntaxin binding protein 1  
Slc2a8 solute carrier family 2, (facilitated glucose transporter), member 8 
 
Angptl2 angiopoietin-like 2  
Lmx1b LIM homeobox transcription factor 1 beta  
Pbx3 pre B cell leukemia homeobox 3  
Mapkap1 mitogen-activated protein kinase associated protein 1 
 
Hspa5 heat shock protein 5  
Traf1 TNF receptor-associated factor 1  
Hc hemolytic complement  
35
-4
0M
bp
 
AI182371 expressed sequence AI182371  
Cntrl 110 kDa centrosomal protein|antigen identified by monoclonal antibody 2A8|centriolin 
 
Rab14 RAB14, member RAS oncogene family  
Gsn gelsolin  
Stom stomatin  
Ggta1 glycoprotein galactosyltransferase alpha 1, 3  
Dab2ip disabled 2 interacting protein  
Ttll11 tubulin tyrosine ligase-like family, member 11  
Ndufa8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8 
 
Lhx6 LIM homeobox protein 6  
Ptgs1 prostaglandin-endoperoxide synthase 1  
Pdcl phosducin-like  
Rc3h2 ring finger and CCCH-type zinc finger domains 2  
Zbtb6 zinc finger and BTB domain containing 6 Coding-non-synomyous 
Zbtb26 zinc finger and BTB domain containing 26  
Rabgap1 RAB GTPase activating protein 1  
Strbp spermatid perinuclear RNA binding protein  
Crb2 crumbs homolog 2 (Drosophila)  
Dennd1a DENN/MADD domain containing 1A  
Lhx2 LIM homeobox protein 2  
Nek6 NIMA (never in mitosis gene a)-related expressed Locus region 
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kinase 6 
Psmb7 proteasome (prosome, macropain) subunit, beta type 7 
Locus region 
Nr5a1 nuclear receptor subfamily 5, group A, member 1  
Nr6a1 nuclear receptor subfamily 6, group A, member 1  
Olfml2a olfactomedin-like 2A  
Arpc5l actin related protein 2/3 complex, subunit 5-like  
Golga1 golgi autoantigen, golgin subfamily a, 1  
Scai suppressor of cancer cell invasion  
Ppp6c protein phosphatase 6, catalytic subunit  
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Appendix N: Example data from Bradford Assay 
 
(A) Raw data from plate reader, optical density read at 595nm with standards and 
samples (liver homogenates diluted 1 in 20) run in duplicate. (B) Calculation of 
standard curve by averaging duplicates for each standard and subtracting OD from 
‘blank’ well. (C) Standard curve in range 0.1-1.4mg/ml. (D) Interpolated values for the 
10 unknown samples and calculation of the dilution factor for the original 
homogenate stock to normalise total protein content to 1mg/ml. 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A 0.436 0.4309 0.7098 0.7018 0.7344 0.705 0.0455 0.05 0.05 0 0 0
B 0.44 0.4444 0.6715 0.7637 0.8082 0.7829 0.0456 0.05 0.05 0 0 0
C 0.4622 0.4752 1.0089 0.8525 0.0459 0.0455 0.046 0.05 0.05 0 0 0
D 0.4964 0.5079 0.648 0.7574 0.0458 0.0455 0.0458 0.05 0.05 0 0 0
E 0.6075 0.6203 0.6708 0.6111 0.0453 0.0453 0.0457 0.05 0.05 0 0 0
F 0.6579 0.6974 0.6969 0.8639 0.0461 0.0461 0.0461 0.05 0.05 0 0 0
G 0.7698 0.7944 0.6881 0.7345 0.0471 0.047 0.0455 0.05 0.05 0 0 0
H 0.0465 0.0471 0.6681 0.6563 0.0475 0.0473 0.0456 0.05 0.05 0 0 0
standard
Optical 
density at 
595 nm 
dupl 1
Optical 
density at 
595 nm 
dupl 2
Average 
OD
Minus 
Blank
blank 0.436 0.4309 0.43345
0.1 0.44 0.4444 0.4422 0.00875
0.2 0.4622 0.4752 0.4687 0.03525
0.4 0.4964 0.5079 0.50215 0.0687
0.8 0.6075 0.6203 0.6139 0.18045
1 0.6579 0.6974 0.67765 0.2442
1.4 0.7698 0.7944 0.7821 0.34865
sample
Optical 
density at 
595 nm 
dupl 1
Optical 
density at 
595 nm 
dupl 2
Average 
OD
Minus 
Blank
Interpolat
ed Conc 
in mg/ml
Dilution of 
stock to 
give 
1mg/ml
KO1 0.7098 0.7018 0.7058 0.27235 1.12 22.46
WT1 0.6715 0.7637 0.7176 0.28415 1.17 23.35
KO2 1.0089 0.8525 0.9307 0.49725 1.98 39.52
WT2 0.648 0.7574 0.7027 0.26925 1.11 22.22
KO3 0.6708 0.6111 0.64095 0.2075 0.88 17.54
WT3 0.6969 0.8639 0.7804 0.34695 1.41 28.12
KO4 0.6881 0.7345 0.7113 0.27785 1.14 22.87
WT4 0.6681 0.6563 0.6622 0.22875 0.96 19.15
KO5 0.7344 0.705 0.7197 0.28625 1.18 23.51
WT5 0.8082 0.7829 0.79555 0.3621 1.46 29.27
standards Samples
96 well plate - raw data
0.0 0.5 1.0 1.5
0.0
0.1
0.2
0.3
0.4
Assay
MG/ML
O
pt
ic
al
 D
en
si
ty
A 
B C 
D 
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Appendix O:  Murine (A) and Human (B) SLPI protein primary structure.  The eight 
conserved cysteine residues of the two WAP domains in each protein are highlighted 
 
(A) 
1  mkscgllpft vllalgilap wtveggknda ikigacpakk paqclklekp qcrtdwecpg 
61  kqrccqdacg skcvnpvpir kpvwrkpgrc vktqarcmml nppnvcqrdg qcdgkykcce 
121  gicgkvclpp m 
 
(B)  
1  mkssglfpfl vllalgtlap wavegsgksf kagvcppkks aqclrykkpe cqsdwqcpgk 
61  krccpdtcgi kcldpvdtpn ptrrkpgkcp vtygqclmln ppnfcemdgq ckrdlkccmg 
121  mcgkscvspv ka 
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Appendix P: Example data from RT-PCR 
 
CT mean for each individual calculated from three technical replicates and compared with 
reference gene expression to give ΔCT. Mean ΔCT for each time point was calculated from 
the five biological replicates. ΔΔCT was calculated by using the control ΔCT as a reference 
value. 
Sample' Target'Name Cт'Mean Target'Name Cт'Mean ΔCT
MTC'CA SLPI 35.52215195 B2M 29.08200264 6.44014931
MTC'CB SLPI 35.01742172 B2M 27.24634361 7.77107811
MTC'CC SLPI 34.46815872 B2M 27.6213131 6.84684563
MTC'CD SLPI 34.99484253 B2M 28.74978065 6.24506187
MTC'CE SLPI 33.28039932 B2M 27.89877892 5.38162041
MTC'1 SLPI 34.86082077 B2M 29.48786736 5.37295341
MTC'2 SLPI 36.45904922 B2M 30.98898125 5.47006798
MTC'3 SLPI 34.04378128 B2M 30.36197853 3.68180275
MTC'4 SLPI 30.05930328 B2M 28.08408546 1.97521782
MTC'5 SLPI 32.77799225 B2M 28.02483559 4.75315666
MTC11 SLPI 31.17146873 B2M 25.48587036 5.68559837
MTC12 SLPI 32.16491699 B2M 26.46949959 5.6954174
MTC13 SLPI 32.43540573 B2M 25.55131721 6.88408852
MTC14 SLPI 31.90223694 B2M 25.2978878 6.60434914
MTC15 SLPI 32.8174324 B2M 25.29792595 7.51950645
MTC26 SLPI 33.70654678 B2M 25.94291687 7.76362991
MTC27 SLPI 32.15930557 B2M 25.01763344 7.14167213
MTC28 SLPI 30.35320473 B2M 24.35015106 6.00305367
MTC29 SLPI 33.9029808 B2M 26.21465492 7.68832588
MTC30 SLPI 31.47241211 B2M 25.56389427 5.90851784
ΔCT'controls ΔCT'8hrs ΔCT'24hrs ΔCT'48hrs
6.440149307 5.372953415 5.685598373 7.763629913
7.77107811 5.470067978 5.695417404 7.141672134
6.846845627 3.68180275 6.884088516 6.003053665
6.245061874 1.975217819 6.604349136 7.688325882
5.381620407 4.753156662 7.519506454 5.908517838
6.536951065 4.250639725 6.477791977 6.901039886
2.28631134 0.059159088 H0.364088821
1 4.878072974 1.04185831 0.776959433
co
nt
ro
l
8'
hr
s
24
'h
rs
48
'h
rs
Fold'change'(2ΔΔCT)'
relative'to'control
ΔΔCT
Mean'
Time post-APAP
Fo
ld
 c
ha
ng
e 
in
 S
LP
I 
ex
pr
es
si
on
 (a
rb
itr
ar
y 
un
its
)
co
ntr
ol
8h
rs
24
hrs
48
hrs
0
2
4
6
p=0.016 p=0.008
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Appendix Q:  Power Calculation for SLPI KO v wild type experiment 
Sample size calculation for comparing two means 
 
  N in each group = ƒ (α,β) x 2 x σ2 
                     (µ2-µ1)2 
 
Where: 
α = significance level 
β = probability of type II error 
σ = Standard deviation of response (assumed to be the same in both groups) 
µ1 = mean value in control group 
µ2 = mean value in transgenic group 
µ2-µ1 = minimum difference to detect 
 
For this experiment: 
α = 0.05 
β = 0.05 
σ = 1500 (standard deviation of peak (24hr) ALT from chapter 5) 
µ1 = 9,000 (peak (24hr) ALT) 
µ2 = 12,600 – estimated from a 40% increase in peak ALT compared with  control 
µ2-µ1 = 3,600 
 
 
N in each group = 13.00 x   2 x 15002 
          (12,600-9,000)2 
 
N in each group = 4.51 
 
Therefore to detect a 40% increase in mean peak ALT to a power of 95% and 
significance of 0.05, I will require 5 mice in each group. 
 
 
